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Summary 
 
Title: Adherence to Antidepressants in Psychiatry:  A Descriptive Survey of Outpatients in 
Johannesburg, Gauteng. 
By: Lian Taljaard 
Degree: Master of Arts in Social Science 
Subject: Psychology  
Supervisor: Mrs. Henderson 
Summary:  Pharmacological treatment is often required in the management of psychiatric 
disorders.  Non-adherence to medication represents a significant health concern that 
prevents patients from fully benefitting from their treatment, and can lead to negative 
consequences for individuals, their families and the healthcare system. The adherence rates 
to antidepressant medications in a sample of psychiatric outpatients in the Johannesburg 
Metropolitan district of Gauteng Province were examined. A descriptive survey method was 
employed to systematically collect data from n=377 patients using a structured, non-clinical 
questionnaire and the 8-item Morisky Medication Adherence Questionnaire. Variables were 
analysed using descriptive and correlational statistical methods. Antidepressant adherence 
rates were reported as 47.7% (low), 31.3% (medium) and 21% (high). These high rates 
represent a concern in antidepressant treatment, and health care practitioners and health 
systems must take this into consideration when planning and developing interventions to 
improve adherence in this area. The current study found significant correlations between 
antidepressant adherence rates and some medication-, health system- and moderating 
variables. Based on these findings, interventions that provide appropriate health-related 
education about treatment and improved social support systems may be effective in 
addressing antidepressant non-adherence in psychiatric outpatients in this region.  
 
Key terms: 
Adherence; Non-adherence; Medication; Antidepressant(s); Psychiatry; Psychiatric 
outpatient(s); Johannesburg; Survey;  Questionnaire; Morisky Medication Adherence 
Questionnaire. 
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CHAPTER 1 
STUDY BACKGROUND 
1.1. Introduction 
Up to one in three South Africans could experience a psychiatric disorder at some point 
during their lives, and 16.5% have experienced one in the past 12 months (Williams,  
Herman, Stein, Heeringa, Jackson, Moomal & Kessler, 2008; Khasakhala, Sorsdahl, Harder, 
Williams, Stein, & Ndetei, 2011). Nearly one in ten (9.8%) could experience Major 
Depressive Disorder during their lives, and this rate goes up to nearly half (43.7%) for South 
Africans living with HIV/AIDS (Freeman, Nkomo, Kafaar, & Kelly, 2007; Herman, Stein, 
Seedat, Heeringa, Moomal & Williams 2009). Due to the chronic nature of many psychiatric 
disorders, prolonged treatment is often required (Nolen-Hoeksema, 2011), and psychotropic 
medication such as antidepressants, antipsychotics, anxiolytics, mood stabilisers and 
sedative hypnotics are commonly prescribed in the treatment of these conditions (Bulloch & 
Patten, 2010; Panksepp, 2004). Antidepressant medication has become the most common 
treatment used in Major Depressive Disorder (MDD), but is also prescribed in the treatment 
of Bipolar I Mood Disorder (BMD-I), as well as Obsessive-Compulsive Disorder (OCD) and 
Generalised Anxiety Disorder (GAD) (Centers for Medicare and Medicaid Services, 2015; 
Linde, Kriston & Rücker, 2015). A public hospital-based study (Janse van Rensburg, 
Taljaard, & Wilson, 2014) from a sample of n=91 psychiatric outpatients in Gauteng Province 
found that nearly all patients were prescribed more than one psychotropic medication (89%), 
and of those more than half (57%) were prescribed antidepressants. 
To support the successful management of these psychiatric conditions the treatment relies 
heavily on the patient’s continued commitment to the prescribed treatment regimen, and 
herein lies one of the major contributors to less than desired treatment outcomes - non-
adherence to the treatment regimen. There are many reasons why patients who have been 
prescribed antidepressants may cease taking their medication (Brown & Bussell, 2011; 
Gumnick & Nemeroff, 2000; Lanouette, Folsom, Sciolla, & Jeste, 2009; Moret, Isaac, & 
Briley, 2009; Procyshyn, Barr, Brickell, & Honer, 2010; Sajatovic et al., 2011; Venturini, 
Sung, Nichol, & Sellner, 1999). According to the US Surgeon General Regina Benjamin, 
"Doctors, nurses, pharmacists and other health care professionals can help prevent many 
serious health complications by initiating conversations with their patients about the 
importance of taking medication as directed" (Benjamin, Press statement. November 2, 
2011). This is especially important for people with chronic health conditions, who may have a 
number of medications to take each day. Adherence to antidepressant medications in 
psychiatric populations therefore becomes a significant public health issue.  
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The terms compliance and adherence have been used interchangeably across different 
settings around the world. It is important to recognise that adherence suggests a patient-
centred approach, whereas compliance implies a health care provider-centred approach, 
and that the different subtext of each concept is also an important aspect (Salvo & Cannon-
Breland, 2015). "Compliant patients submit to the prescriptions of doctors and take their 
medicine, or follow their advice, a phrase that also means accepting punishment", 
suggesting that compliance is considered to have negative associations and suggests 
yielding or submission (Vermeire, Hearnshaw, Van Royen, & Denekens, 2001, p. 332). In 
contrast, adherence incorporates the broader notions of concordance (agreement and 
harmony), cooperation and partnership. The World Health Organization (WHO) has thus 
defined adherence as "the extent to which a person's behaviour - taking medication, 
following a diet, and/or executing lifestyle changes - corresponds with agreed 
recommendations from a health care provider" (World Health Organization, 2003, p. 3). The 
current study accepts the definition of the term adherence provided by the WHO (World 
Health Organization, 2003), and will be referring to this description throughout the text. 
Non-adherence may be deliberate (e.g., due to adverse side effects) or accidental (e.g., due 
to forgetting), and can manifest in various ways, such as: forgetting to take one's medication; 
incomplete or incorrect dosage taken; medication taken at the wrong time; stopping 
medication altogether; non-participation in recommending health programmes; breaking of 
appointments or not renewing prescriptions (Ho, Bryson, & Rumsfeld, 2009; Jamaluddin 
Moloo, 2014). Furthermore, non-adherence may refer to several distinct aspects of 
medication-taking behaviours, i.e., failure to attend an initial appointment, failure to have the 
prescription filled, having the prescription filled, but failing to take the medication, not 
following the frequency or dose instructions on the prescription, deliberate errors or use of 
inadvertent combinations (Hovstadius & Petersson, 2011; Kronish, Rieckmann, Halm, 
Shimbo, Vorchheimer, Haas & Davidson, 2006).  
Non-adherence to medication is a universal issue in medicine that has been extensively 
researched (Blackwell, 1996; Cramer & Rosenheck, 1998; Cramer, 1995). Due to the 
difficulties in measuring adherence, care should be taken in generalising estimates, but non-
adherence can be expected in approximately 30-50% of all patients, irrespective of disease, 
prognosis or setting (Hohmann, Neumann-Haefelin, Klotz, Freidank, & Radziwill, 2014; 
Acosta, Hernández, Pereira, Herrera, & Rodríguez, 2012; Brown & Bussell, 2011; Tacchi, & 
Scott, 2005;Donovan, 1995; Morris & Schulz, 1992; Sacket & Snow, 1979). Patients with 
psychiatric diagnosis were also found to have higher rates of non-adherence in comparison 
to those with organic illness (Kardas, 2011). A profile of psychiatric patients admitted to a 
general public hospital in Gauteng revealed that nearly half (47%) of patients admitted for 
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any psychiatric disorder were non-adherent to their respective medications at the time 
(Janse van Rensburg, 2007). In terms of specific psychiatric disorders, non-adherence rates 
were estimated to be: 51-69% depression, 57% for Anxiety Disorders, 30-60% in 
Schizophrenia , 21-50% for Bipolar Mood Disorder; 35% for Alcohol Use Disorder  and13% 
in HIV/AIDS related psychiatric conditions (Buckley, Foster & Patel, 2009). In terms of 
different medication categories, Bulloch and Patten (2010) analysed data from the Canadian 
Community Health Survey and found that non-adherence rates of 34.7% of users of 
antipsychotics, 38.1% in patients taking sedative-hypnotics, 44.9% in mood stabilisers and 
45.9% of users of antidepressants. 
Adherence is viewed as a primary determinant of treatment effectiveness, and poor 
adherence attenuates optimum clinical benefit (World Health Organization, 2003). Non-
adherence to medication in psychiatry is associated with a worse prognosis, greater 
probability of relapse, rehospitalisation and increased resource consumption (Erwin & 
Peters, 1999; Siegel, Karus, & Schrimshaw, 2000). Poor treatment adherence in psychiatry 
is associated with decreased likelihood of achieving a reduction in symptoms and recovery, 
as well as increased risk of relapse and hospitalization and suicide attempts. In addition, the 
World Health Organization reports that the financial costs incurred by non-adherent patients 
are significantly higher due to increased treatment costs (World Health Organization, 2003). 
High levels of adherence have been positively correlated with treatment outcomes in 
depression, independent of the type of antidepressant drugs used (Thompson, Peveler, 
Stephenson, & McKendrick, 2000). Furthermore, higher rates of medication adherence may 
translate into economic benefits. This is seen in the form of direct savings by decreased use 
of expensive health services caused by disease exacerbation, crisis, relapses or 
rehospitalisation of patients. Indirect savings can be attributed to the improvement of the 
quality of life and a patient's social and work roles (Agh, 2012; World Health Organization, 
2003).  
Leo, Jassal and Bakhai (2005) identified: (1) medication factors (complex regimens, adverse 
effects, costs, availability); (2) illness factors (cognition/memory, reasoning interference); (3) 
concurrent substance abuse or dependence; (4) patient factors (denial, beliefs and attitudes, 
stigma); (5) physician factors (inadequate information provided, inadequate follow-up of 
response to treatment); (6) patient-physician factors (poor alliance/communication); and (7) 
social and environmental factors (supportive network, financial resources, inaccessibility and 
unavailability of treatment resources) as reasons for non-adherence to psychiatric treatment. 
In addition to patient attitudes and beliefs, literature indicates community attitudes and 
beliefs  as being associated with adherence levels (Botha, Koen, & Niehaus, 2006; Fung, 
Tsang, & Chan, 2010; Hugo, Boshoff, Traut, Zungu-Dirwayi, & Stein, 2003; Weiss, Chang, 
 4 
 
Rauch, Smallwood, Schechter, Kosowsky et al., 2012). Although non-adherence to 
medication in psychiatry has long been identified as problematic in the international 
community (DiMatteo, 2004; Gillis, Trollip, Jakoet, & Holden, 1987; Leo et al., 2005; 
Vermeire et al., 2001), there is currently a scarcity of evidence of rates and contributing 
factors of non-adherence to antidepressant treatment in the local South African psychiatric 
setting(Mahaye, Mayime, Nkosi, Mahomed, Pramlal, Setlhabana & Oosthuizen, 2012).  
The South African Depression and Anxiety Group (SADAG) recognise the important role of 
adherence to treatment in psychiatry, and seek to address the issue of non-adherence in the 
mental health context of South Africa. SADAG is a non-profit organisation (NPO), Section 21 
company that was established in 1994 to provide mental health care advocacy to users 
across South Africa (NPO Registration number: 013-085-NPO), (see Appendix VI for 
Certificate of Registration). SADAG is currently the country's largest and most recognised 
mental health advocacy initiative. SADAG routinely provides its members with different free 
telephonic counselling initiatives, such as: Suicide Crisis-; Trauma-; Bipolar-; Sleeping 
Disorder-; Substance Abuse-; Mental Health- and the Support Group Helplines (SADAG, 
2015). SADAG aims to increase public awareness of anxiety and mood disorders, 
disseminate information and provide continuous support to mental health care users. 
SADAG works closely with various mental health patients with various psychiatric conditions 
on an on-going basis by providing a variety of services to support patients on their journey to 
recovery and, to help patients manage their mental health treatment and care. These 
services include, but are not limited to, regular follow-up telephone calls and lay counselling, 
on-site outpatient support, SMS communications, distribution of printed and electronic 
resources and on-line information. Through their regular and close contact with patients, 
SADAG has become increasingly aware of non-adherence to taking medication and 
recognises the importance of investigating this issue.  
 
1.2. Research problem 
1.2.1. Statement of the Research Problem 
Non-adherence to prescribed antidepressant medications is a remarkably common human 
experience. This behaviour and its impact on disease management are magnified in chronic 
illnesses in psychiatric patients. For people with chronic mental illnesses, non-adherence to 
treatment substantially adds to the burden of disease and leads to poorer long‐term 
outcomes in these conditions. Firstly, it is associated with decreased likelihood of achieving 
a reduction in symptoms and recovery. Secondly, non-adherence increases the risk of 
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relapse and hospitalisation and suicide attempts. Finally, the direct or indirect financial costs 
incurred by non-adherent patients, as well as health care systems, are significantly higher 
due to increased treatment costs (Leo et al., 2005). Non-adherence to psychiatric 
medication, therefore, has a profound impact on the psychiatric disease course and 
recovery. In addition, it can have detrimental effects on the patient's long-term functioning, 
including social adjustment and academic or vocational productivity and performance (Agh, 
2012; Pareek & Kalia, 2013; Robinson, Long, Chang, Able, Baser, Obernchain & Swindle, 
2006; Wang, Simon, & Kessler, 2003).  
Evidence suggests that non-adherence to treatment can be expected in approximately half 
of all patients in psychiatric settings (Tacchi, & Scott, 2005; Brown & Bussell, 2011b; 
Hohmann et al., 2014). These rates increase when specific conditions such as depression 
(51 % - 69%) or other Anxiety Disorders (57%) are considered (Buckley, Foster & Patel, 
2009). In antidepressant medication specifically, Bulloch and Patten (2010) reported non-
adherence rates of 45.9%. Adherence to pharmacological treatment in chronic conditions 
can be influenced by several interacting factors such as age, gender, race, beliefs about 
illness and treatment, stigma, type of medication, complexity of treatment regiment, 
medication related adverse effects, costs, availability, type and severity of illness, concurrent 
substance abuse or dependence, inadequate information and follow-up, poor social support 
structures, as well as inaccessibility and unavailability of treatment resources (Barbui & 
Conti, 2014; Hung, 2014; Kane, Kishimoto, & Correll, 2013; Przemyslaw Kardas, Lewek, & 
Matyjaszczyk, 2013; Leo et al., 2005; Pampallona, Bollini, Tibaldi, Kupelnick, & Munizza, 
2002; Procyshyn et al., 2010; World Health Organization, 2003). Considering the multi-
faceted problems to which non-adherence to antidepressants may contribute to, it becomes 
critically important to determine these adherence rates and, with reference to the current 
research specifically, the contributing factors of these rates in order to address the issue of 
non-adherence to antidepressant medication in the South African psychiatric population.  
 
1.2.2. Research questions and study hypotheses 
Studies measuring non-adherence rates and identifying factors that contribute to non-
adherence varies widely in study design, assessment instruments, populations and sampling 
selection methods (Leo et al., 2005; Procyshyn, et al., 2010; Kardas et al., 2013; Perestelo-
perez & Serrano-aguilar, 2013; Brown & Bussell, 2011). It is also apparent there is a great 
deal of variability across these studies as to which of these factors are statistically 
significantly correlated with treatment adherence rates.  With this in mind, two main research 
questions have been identified in the current study:  
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(1) What are the rates of non-adherence to antidepressant medication in a sample of 
psychiatric outpatients living in Johannesburg, Gauteng? (2) Which variables have a 
significant correlation with antidepressant treatment adherence in this sample of psychiatric 
outpatients? The second main research question has been divided into five specific sub-
questions; 2a) Which patient-related variables significantly correlate with antidepressant 
treatment adherence rates in this sample? 2b) Which illness-related variables significantly 
correlate with antidepressant treatment adherence rates in this sample of psychiatric 
outpatients? 2c) Which medication-related variables significantly correlate with 
antidepressant treatment adherence rates in this sample of psychiatric outpatients? 2d) 
Which health system-related variables significantly correlate with antidepressant treatment 
adherence rates in this sample of psychiatric outpatients? 2e) Which moderating factor-
related variables significantly correlate with antidepressant treatment adherence rates in this 
sample of psychiatric outpatients? 
Informed by the literature cited above and further discussed in Chapter 2, it is clear that 
adherence rates vary greatly across psychiatric conditions, treatment settings and treatment 
regiments themselves, and a number of factors that could have a negative impact on 
treatment adherence that have been identified by the literature (Pampallona et al., 2002; 
WHO, 2003; Kane et al., 2013; Hung, 2014). The hypotheses of the current study are based 
on the assumptions that the study design, the adherence-measuring instrument, participant 
selection methods and adherence rates would not have a significant influence on the 
adherence rates observed. This is due to the multiple confounding factors in this study, such 
as the heterogeneity of previous study designs, definitions, settings, samples, conditions, 
instruments and results. Therefore, it is expected that the antidepressant medication 
adherence rates observed in the current study would be similar to previous studies using 
different research methods, instruments and conceptual definitions.In addition, although an 
indirect measurement (self-report questionnaire) of adherence rates were used, it is 
assumed that this may not necessarily imply significantly over- or under-reporting of 
adherence rates observed in the current study sample (Bauer Parker, Schillinger, Katon, 
Adler, Adams, Karter et al., 2014; Bulloch & Patten, 2010; Leo et al., 2005; Morisky Malotte, 
Choi, Davidson, Rigler, Sugland, & Langer, 1990; Morisky & Dimatteo, 2011; Perestelo-
perez & Serrano-aguilar, 2013). The literature referenced here also informed the formulation 
of the current study’s hypotheses which will discussed in detail in Chapter 3.  
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1.3. Purpose of the study 
Non-adherence to pharmacological treatment in psychiatry poses a serious problem and 
significant public health issue in mental health care. Adherence in psychiatry is also 
influenced by a myriad of factors that are still not clearly understood. Relevant, local 
evidence on the rates of non-adherence and identifying factors that may contribute to these 
rates is essential in any attempts to address this issue.  
Based on the literature cited in the previous section of this chapter, the current study set out 
to determine the rates of non-adherence and possible contributing factors that influence 
antidepressant medication adherence rates in a sample of psychiatric outpatients in 
Johannesburg, Gauteng. To date, there have been no large-scale studies that aim to 
objectively determine the rate of antidepressant medication adherence in Gauteng, 
suggesting a shortage of local evidence measuring and describing non-adherent behaviours 
of psychiatric outpatients. It is important to ascertain the scope of this problem, as well as 
gain an understanding of the mechanisms and dynamics of its functioning, if health care 
providers and health systems wish to address the problem more effectively. The purpose of 
the current investigation was to identify and describe the scope of non-adherence to 
antidepressant medication in psychiatric outpatient in this particular region, and to provide 
evidence of contributing factors that influence these rates to gain a better understanding of 
its underlying causes. 
 
1.3.1. Aim of the study 
Overall, the goal of this particular investigation was to contribute to the body of knowledge 
regarding antidepressant adherence of outpatients, with various psychiatric diagnoses, in the 
Gauteng Province of South Africa, with a specific focus on antidepressant medications. In 
this study, the researcher sought to examine the rates of non-adherence to antidepressant 
medications by psychiatric outpatients in a previously unstudied population and to identify 
possible factors that may contribute to non-adherence in this sample. To achieve this, data 
was systematically collected and variables were analysed using descriptive and correlational 
statistical methods.  
 
1.3.2. Study objectives 
The following specific objectives have been identified in the study: 
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i. Distribute a structured, non-clinical (i.e., non-clinician administered) questionnaire 
relating to information about mental health care users' socio-demographical- and 
illness- and treatment profile, supplemented with a self-report adherence measuring 
questionnaire  to a sample of psychiatric outpatients residing in Johannesburg, 
Gauteng. 
ii. Describe the socio-demographic profile (i.e., age, gender, race, home language), 
clinical profile (i.e., type of DSM-IV-TR diagnosis, comorbid conditions, duration of 
illness), and medication profile (i.e., type of antidepressant prescribed, the number of 
antidepressants prescribed, perceived adverse reactions from medication), and 
medication profile of this sample of psychiatric outpatients from the data collected by 
the research instrument.  
iii. Determine the rates for non-adherence to antidepressant medications in a sample of 
psychiatric outpatients in Johannesburg, Gauteng.  
iv. Identify and discuss the variables that significantly correlate with antidepressant 
medication adherence rates in this sample of psychiatric outpatients.  
 
1.4. Significance of the study 
Non-adherence to medication for psychiatric disorders is a significant public health concern 
that prevents patients from realising the full benefits of their treatment and negatively 
impacts on individuals, their families and the health care system (Agh, 2012; Leo et al., 
2005; Pareek & Kalia, 2013; R. Robinson et al., 2006; Wang et al., 2003). Understanding 
non-adherence and determining its rates and influencing factors are therefore a key 
challenge to address in order to enhance the quality of care for patients with psychiatric 
disorders.  At the very least, health care providers are required to take on the responsibility 
of gaining a better understanding of non-adherence behaviour in order to provide 
appropriate care to patients. New evaluation data and information from this specific sample 
can inform patient care and planning by providing indices of the extent to which patients 
adhere to their prescribed antidepressant medication regime, as well as identifying factors 
that may contribute to these adherence levels.  The information gathered from this study 
could be used by patients, health care practitioners and health care systems to identify 
possible areas for greater understanding, as well as targeted intervention in these patients.  
The findings reported here may also be used as an information source for those wishing to 
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inform any interventions that patient-, illness-, medication- as well as structural or health-
system factors to increase antidepressant treatment adherence in psychiatric outpatients. 
 
1.5. Definition of concepts 
For the purposes of the current study, adherence was determined by the application of the 
Morisky 8-item Medication Adherence Questionnaire (MMAQ-8), ( Morisky, Green, & Levine, 
1986), and indicated by a total score that ranges from zero (low adherence) to eight (high 
adherence).  Instead of dichotomously categorising patients as adherent or non-adherent, 
three levels of adherence were applied to the current study results (low, medium and high), 
in accordance with the guidelines of the MMAQ-8 (Morisky, Ang, Krousel-Wood, & Ward, 
2008). Low adherence was indicated by a total score ranging between zero and less than 
six, a total score ranging between six and less than eight indicates medium adherence, and 
a total score of eight on the MMAQ-8 indicated high adherence. However, adherence has 
been defined by studies differently across various settings and illnesses. There are also 
various methods for measuring medication adherence, and currently there is no universally 
accepted "gold standard" measuring these rates (Lee Ahn, Kim, Hong, Hong, Kim & Morisky, 
2013; Vik, Maxwell, & Hogan, 2004). Each adherence measurement approach has strengths 
and weaknesses and each rests on specific assumptions (O’Brien, Petrie, & Raeburn, 1992). 
Regardless, at the very least, one can assume that patients who admit to non-adherence to 
their medication are most likely being honest about it. Therefore, by the mere virtue of asking 
patients to report about their adherence to their antidepressant treatment can be a relatively 
accurate, efficient and cost-effective method for determining rates of antidepressant 
medication adherence.  
 
1.6. Conceptual framework 
Like most health-promoting behaviours, having to take medication regularly for a long period 
of time involves a conscious commitment to a new healthy behaviour and requires a change 
in daily habits. The World Health Organization identifies several psychological approaches 
that may be helpful in intervening with non-adherent patients (World Health Organization, 
2003). These theories as discussed below can offer an interesting and innovative conceptual 
framework for investigating antidepressant medication adherence behaviours in psychiatric 
outpatients in this particular region of South Africa. Despite decades of research undertaken 
to understand the psychology of non-adherence (DiMatteo, 2004), these rates have not 
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improved much, and the situation is especially difficult in the case of medications used to 
control chronic illnesses such as psychiatric diagnoses (Bosworth, Granger, Mendys, 
Brindis, Burkholder, Czajkowski, Granger et al., 2011).  
Leventhal & Cameron (1987) provided a very useful overview of the history of adherence 
research. They outlined five general theoretical perspectives on adherence: biomedical 
perspective, behavioural perspective, communication perspective, cognitive perspective, and 
self-regulatory perspective. These perspectives are discussed in greater detail in the 
following chapter. Although these theories and models can provide a conceptual framework 
for organising thoughts about adherence and other health behaviours, each perspective 
encompasses several theories with its own advantages and disadvantages, and no single 
approach may be readily translated into a comprehensive understanding of adherence.  
Recent approaches that are more specific to health behaviours may provide more helpful 
frameworks. This includes stage perspectives, such as the transtheoretical model and 
cognitive perspectives (Brawley & Culos-Reed, 2000; Munro, Lewin, Swart, & Volmink, 
2007a; Ozmete & Hira, 2011; Redding, Rossi, & Rossi, 2000; World Health Organization, 
2003). These approaches are also included in a broader discussion of the relevant 
theoretical perspectives in the following chapter. These theories are specifically located 
within the realm of adherence to long-term medication (defined as medication treatment of 
three months or more), describing their key characteristics and examining their relevance 
with regard to adherence to treatment for tuberculosis (TB) and human immune virus/ 
acquired immunodeficiency syndrome (HIV/AIDS) (Munro et al., 2007). These theoretical 
models focus on understanding, predicting and improving adherence. Their common 
components involve health professional–patient communication, patients' cognitive and 
social processes (e.g., beliefs, norms) and patients' resources (e.g., financial, psychological 
and social support), (World Health Organization, 2003).  
Studies vary widely in methodologies, and operational definitions of adherence are as varied 
as the diseases, regimens and patients examined (Rahman, Dignan, & Shelton, 2005; Unni, 
2008). Informed by these previous theories, the information–motivation–behavioural skills 
model (IMB), Fisher and Fisher (1992) borrows elements from earlier work to construct a 
conceptually-based, generalisable and simple model to guide thinking about complex health 
behaviours.  According to this dynamic model, a patient will adhere to his or her treatment if 
he or she is physically and mentally able to (patient’s capability to follow the medication 
regime), has the information (patient’s knowledge and understanding of his or her condition 
and treatment) and motivation (patient’s attitude and beliefs about the condition and 
treatment) to behave adherently (Fisher, Fisher, Misovich, Kimble, & Malloy, 1996). The IMB 
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constructs, and how they pertain to patient adherence, are discussed in further detail in 
Chapter 2.   
Interventions based on Fisher and Fisher’s (1992) IMB model have been effective in 
influencing behavioural change across a variety of clinical applications, such as simple drug 
use, medication switching or duplication (American Pharmacists Association, 2013; Martin 
Wiley-Exley, Richards, Domino, Carey & Sleath, 2009; Mayberry & Osborn, 2014). In both 
prospective and correlational studies, the information, motivation and behavioural skills 
constructs have accounted for between 30% - 40% of the variance in behaviour change 
(Munro, Lewin, Swart, & Volmink, 2007b). 
 
1.7. Design of the study 
1.7.1. Research paradigm 
According to Weaver and Olson (2006, p. 460), investigations are guided by a certain 
paradigm, which they describe as "patterns of beliefs and practices that regulate enquiry 
within a discipline by providing lenses, frames and processes through which an investigation 
is accomplished”. In the positivist tradition, social scientists support the idea that the social 
sciences should match the methodology of the natural sciences (Babbie & Mouton, 2011). 
Therefore, they often use experiments, surveys and statistics in an effort to ensure rigorous 
measures and allow for the testing of hypotheses (Neuman, 2011). This positivist, 
quantitative approach is best suited to answer the research questions in this particular study 
by systematically gathering information from a large number of people and generate 
quantifiable data to determine the strength of the relationship between variables through 
statistical tests. 
 
1.7.2. Research design 
A research design is usually highly detailed and structured, which allows for easy collation 
and statistical presentation of results (Shaughnessy, Zechmeister & Jeanne, 2011). 
Bhattachejee (2012) explains that descriptive research can be used to identify and count the 
frequency of a particular response among participants. This definition was applied to the 
current study as a systematic collection of data from a sample population of psychiatric 
patients using a survey questionnaire. The research design of the current study focused on 
measuring the rate and frequency of specific variables, and to determine the antidepressant 
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medication adherence rates and, identify possible reasons for non-adherence among 
psychiatric outpatients in the Gauteng Province of South Africa. A descriptive, multi-mode 
survey design was employed by the current study.  
 
1.8. Research method 
The current study employed a mixed-mode survey, i.e. collecting data using  different ways 
in which the assessment instruments were presented to the participants. This entailed using 
the same questionnaire, but allowing the participants to choose the most convenient mode of 
completion, namely the pen-and-paper questionnaire, a telephonically administered 
questionnaire or completing the questionnaire online (internet). Mixed-mode surveys provide 
the benefit of increasing the response rate of respondents, as well as limiting the exclusion 
of participants (Tobin, Thomson, Radhakrishna, & LaBorde, 2012). The research method 
utilised by the current study is discussed in Greater detail in Chapter 3. 
 
1.8.1. Research setting and population 
Pavlichev (2004) defined the target population for a survey as the entire set of units for 
which the survey data are to be used and, for which the findings are meant to be 
generalisable to the entire population. In the current investigation, the target population was 
defined as all individuals 18 years or older who were prescribed at least one antidepressant 
medication (as classified by the Monthly Index of Medication Specialities (MIMS, November 
2014), at the time of the study, and resided in the Gauteng Province of South Africa. 
 
1.8.2. Sample and sampling procedures 
Howitt and Cramer (2011, p. 432) describes purposive sampling as sampling “with a 
particular purpose in mind, such as when a particular sort of respondent is sought” rather 
than a representative sample." A non-probabilistic, purposive sampling method is often used 
because the procedures used to collect data from a sample are more efficient and cost-
effective in comparison with probability sampling techniques (Howitt & Cramer, 2011). Given 
the objectives of the current study, the nature of the research project, availability of financial 
resources and the population and the sample size, a non-probability sample design, namely 
purposive sampling, was selected for the current investigation. 
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1.8.3. Data collection 
Data collection commenced in October 2014 after ethical approval was obtained from the 
Ethics Committee of the Department of Psychology from the University of South Africa 
(UNISA), refer to Appendix IV, and SADAG, (Appendix V referred). A database containing 
information on psychiatric outpatients from SADAG was accessed to invite potential 
participants to the study. As part of routine database updating and follow-up procedures, 
patients were informed of the study and invited to participate if they expressed an interest in 
doing so. Once informed consent was received (Appendix II), participants were assigned a 
coded participant number and was requested to complete a structured, non-clinical 
questionnaire, accompanied by a well-established medication adherence rating scale 
(Appendix I). Patients were provided with the option of completing the survey through any 
one of three formats that were deemed most convenient for them (via telephone interview, 
self-completed paper-and-pen based or electronic/ on-line). Participants' responses were 
captured and coded according to the structured datasheet (Appendix III) in a designated 
database using Statistical Package for the Social Sciences® (SPSS) computer software 
version 22. Data from a total of n=377 eligible patients were included in the final analysis of 
the results. 
 
1.8.4. Research instrument 
A structured non-clinical questionnaire was developed that comprised four sections to elicit 
specific information: 1) socio-demographic information, 2) clinical information and 3) 
medication information. This was supplemented with 4) the well-established self-report 8-
item Morisky medication adherence questionnaire (MMAQ-8), (Morisky et al., 1986).  
Adherence to antidepressant medication (as measured by the MMAQ-8), was determined by 
the summated score (ranging from 0 to 8) of “positive” or correct responses. A total score 
ranging between zero and less than six indicated low adherence, medium adherence by a 
score between six and less than eight, and high adherence indicated by a score of eight 
(Morisky et al., 2008).  
 
1.8.4.1. Validity and reliability of the MMAQ-8 
The MMAQ-8 was found to have a moderate level of reliability (Cronbach's alpha is 0.83) 
and high levels of concurrent and predictive validity (De Las Cuevas, Peñate, & Sanz, 2014; 
Oliveira-Filho, Barreto-Filho, Neves, & Lyra Junior, 2012), and, was also validated by a study 
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in which a chemical marker was used for measuring actual medication-taking behaviour 
(Morisky et al., 1990). 
 
1.8.5. Data analysis 
Responses to the structured questionnaire and MMAQ-8 were coded according to the 
structured datasheet (Appendix III). Variables were analysed and described using standard 
descriptive and where indicated, correlational statistical tests. Descriptive results were 
expressed as frequencies (n=), and percentages (%) of the sample. Between-group tests 
were conducted using the Chi-square χ2 test to assess the relationships between 
categorical variables. Fisher’s exact test was used for 2 x 2 tables or where the requirements 
for the χ2 test could not be met. The relationship between continuous and categorical 
variables was assessed by the t-test or analysis of variance (ANOVA) for more than two 
categories. The relationship between two continuous variables was assessed by Pearson’s 
correlation coefficient. The accepted level of significance (alpha level and p-value) was < .05 
for the appropriate statistical tests, and 2-tailed level of significance was reported on. 
 
1.9. Ethical considerations 
The current study was conducted according to the ethical guidelines and principles of the 
international Declaration of Helsinki (World Medical Association, 2013). Participants were 
protected by informing them of the nature and purpose of the research, their rights and that 
their participation was on a voluntary basis. In the current study, the researcher 
acknowledged the rights of the respondents to choose to participate in the study by 
explaining the purpose and informing them of their rights regarding their participation and 
withdrawal during the process. Potential participants were given the opportunity to decide 
voluntarily whether to take part in the study or not. Other than the possibility that participants 
may potentially feel inconvenienced by the survey, no additional expected risks were 
anticipated by taking part in this research survey. This possible inconvenience was likely to 
be minimal as the survey was kept brief and took approximately ten to fifteen minutes to 
complete. Furthermore the questionnaire could be completed at any convenient time, place 
and in one of three modes that was convenient for potential respondents. Additionally, 
participants could possibly experience slight psychological discomfort by divulging personal 
information for research purposes. Emphasis was placed on the anonymous and confidential 
nature of the information during the introduction of the study and informed consent form. The 
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SADAG 24-hour emergency helpline number was also provided to all participants if they felt 
they needed support. Confidentiality of participant information was maintained by using a 
unique coded identifier for participants during the entire research process. No names were 
linked to the information at any point, and all results were reported anonymously.  
 
1.10. Study limitations 
Self-report measures offer easy-to-use, inexpensive and convenient tools for measuring 
adherence rates, especially in certain study designs, such as the current descriptive study. 
However, this kind of measurement is also subject to biases, such as social desirability, 
recall bias and response bias (Shi, Lui, Koleva, Fonseca, Kalsekar & Pawaskar, 2010). 
Participants were selected based on their accessibility and by the personal judgement of the 
researcher, and all potential participants did not have an equal opportunity to take part in the 
survey. However, Daniels (2012) noted that non-probability sampling techniques, such as 
purposive sampling used in this particular study, may be more appropriate in study designs 
that are descriptive in nature, when the target population under investigation is difficult to 
access, an accurate sampling frame does not exist and, it is not within the scope of the study 
to generalise its findings to the broader population. The current study meets the above 
criteria which motivated the researcher’s choice of the sampling method used. As outlined in 
Chapter 3, steps were taken to minimise the potential impact of the study limitations on data 
quality and were taken into consideration during the discussion of the results.  In spite of 
these limitations discussed, the current study still constitutes novel research in this particular 
area, thus providing meaningful conclusions and recommendations for health care users, 
providers and health care systems.  
Chapter 2 introduces the reader to the literature review on the research topic, and provides a 
descriptive overview of previous studies investigating treatment. This is followed by Chapter 
3, which describes the approach, methods and instruments used in the current study. 
Chapter 4 reports on the results of the study after statistical analysis of the data were 
performed, and briefly discuss these results in the context of the current study. The final 
chapter (Chapter 5) provides a more detailed discussion of the results relating to research 
findings in the literature. In addition, Chapter 5 also provides recommendations for patients 
and health care providers on potential targets for improving antidepressant adherence and, 
suggests possible directions for improvement in future studies.  
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1.11.    Chapter summary 
In this chapter the reader was introduced to the current research study by providing a 
background to the study and identifying the area of concern. The purpose of the study was 
subsequently formulated and supplemented by eliciting the significance of this particular 
investigation. Specific concepts used in the study were also defined, and a background of 
the theoretical framework that guided the study was provided. In addition to this, an overview 
of the study design, methods, context, sample, instrument and analysis procedures utilised 
was provided. Individuals with psychiatric disorders are considered a minority and a 
vulnerable population, and ethical considerations regarding these aspects were also 
mentioned. This chapter concluded with a brief overview of the limitations of this 
investigation. 
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CHAPTER 2 
LITERATURE REVIEW 
2.1. Introduction 
Non-adherence to medication use is a global challenge in psychiatry that has been 
extensively researched over the past decades (Vermeire, et al., 2001; Blackwell, 1996, as 
cited in Bulloch, et al., 2010, p. 47; World Health Organization, 2003). The scope of the 
problem has reached endemic proportions. Nearly half of all patients given pharmacological 
treatment for chronic conditions do not take sufficient doses to achieve a positive therapeutic 
effect (Sacket & Snow 1979; Haynes, McKibbon & Kanani, 1997 as cited in Joyce, 2002; 
Keller, Hirschfeld, Demyttenaere & Baldwin 2002; Sherbourne, Schoenbaum, Wells & 
Croghan, 2004; Gopinath, Katon, Russo & Ludman, 2006; Åkerblad, 2007). 
In this chapter, the researcher first defines the term adherence, followed by a background 
discussion of adherence in psychiatry, and the pharmacological treatments identified in the 
study. A subsequent discussion on the measurement of adherence follows. The researcher 
describes the types of non-adherence based on the existing literature. Factors which 
influence non-adherence and the consequences of this behaviour are also discussed in 
greater detail in the subsequent sections. This is followed by a brief overview of the types of 
psychotropic medication that were identified in the study. In the final section, the researcher 
discusses the behavioural theories that explain non-adherence. Lastly, the conceptual 
framework of the study is presented and discussed. 
 
2.2. Definition of adherence 
The World Health Organization (WHO) has defined adherence as “the extent to which a 
person's health behavior - taking medication, following a diet, and/or executing lifestyle 
changes -  corresponds with agreed recommendations from a health care provider” (WHO, 
2003, p. 3). Non-adherence may be deliberate or unintentional, and it is accepted that non-
adherence refers to various aspects of medication-taking behaviours. The medical domain 
has traditionally accepted the term compliance, which is associated too closely with blame. 
This perspective would typically prefer objective measurements as biomarkers or its 
metabolites in serum or urine samples of psychiatric patients.  
Although this is a reliable method for assessing adherence, it is also more intrusive, 
inconvenient and expensive compared to other indirect methods of measurement (Shi et al., 
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2010). Strong emphasis must be placed on the need to differentiate adherence from 
compliance. The key distinction is that adherence requires the patient’s agreement to the 
recommendations and is a better way of describing the dynamic and complex interactions 
required over various domains over extended periods to sustain optimal health in people 
with mental illnesses.  
In the current study, the adherence rates of patients were defined by the application of the 8-
item Morisky Medication Adherence Questionnaire (MMAQ-8), a reliable and validated 8-
item, self-report measure of medication-taking behaviour (Morisky et al., 1986;  Morisky et 
al., 2008). The MMAQ scores range from zero to eight and have been classified into three 
adherence levels: high adherence (8 points), medium adherence (6 to < 8 points) and low 
adherence (< 6 points). 
 
2.3. Background to adherence 
Non-adherence is a universal issue in medicine, and has been extensively researched 
(Blackwell, 1996; Nichol, Venturini & Sung, 1999; Cramer, 2004; Bulloch & Patten, 2010; 
Chong, Aslani, & Chen, 2011; Kardas, Lewek, & Matyjaszczyk, 2013). These studies 
attempted to determine rates of adherence using different methods in a variety of diseases 
and patient samples, and research focused on the extent, determinants and strategies to 
improve adherence (Vermeire et al., 2001; Julius, Novitsky & Dubin, 2009). The question of 
how to measure adherence has perplexed researchers, and the difficulty of the problem has 
hindered the development of a gold standard method of measurement (Lee et al., 2013). 
This is a challenge for medication adherence research and measurement in itself, as it 
presents a key obstacle to the generalisability of study findings. Despite these challenges, it 
is estimated that between 25%-50% of all patients, irrespective of disease, prognosis or 
setting, are non-adherent to their treatment (Morris & Schulz, 1992; Sacket & Snow, 1979; 
Donovan, 1995, as cited in Vermeire et al., 2001, p. 334; Vergouwen, Bakker, Katon, Verheij 
& Koerselman, 2003; Bambauer, Adams, Zhang, Minkoff, Grande, Weisblatt et al., 2006; 
Olfson, Marcus, Tedeschi & Wan 2006). These high rates make it crucial to investigate this 
phenomenon in order to gain a better understanding of its key elements and processes and 
would allow for the development of more effective intervention strategies that can be 
employed.  However, it is not within the scope of this study to provide in-depth 
recommendations for potential intervention methods to address non-adherence in 
psychiatry, but simply to describe the rates and potential contributing factors of non-
adherence to antidepressant medications in this specific sample in sufficient detail. 
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2.3.1. Adherence in psychiatry 
Kardas (2011) conducted a multi-centre study and found that psychiatric patients had 
significantly higher rates of non-adherence in comparison to those with organic illnesses (p < 
.05). According to Cramer and Rosenheck (1998), patients with psychiatric disorders also 
show a greater degree of non-adherence to treatment than those with physical disorders. 
The observed mean adherence rate for patients with physical disorders was 76%, whereas 
psychiatric patients on antipsychotics had a mean adherence rate of 58%, and patients on 
antidepressants had a mean adherence rate of 65%. A profile of psychiatric patients 
admitted to a general public hospital in Gauteng revealed that nearly half (47%) of patients 
admitted for any psychiatric disorder were non-adherent to their respective medications at 
the time (Janse van Rensburg, 2007).  However, it is unclear from this paper which definition 
of non-adherence was used. Venturini, Sung, Nicho and Sellner (1999) also found that 
roughly 30% of all patients with psychiatric disorders discontinue their medication in the first 
month and 44% stop taking it within the first 3 months of initiation (Lin, Von Korff, Katon, 
Bush, Simon, Walker, & Robinson, 1995, as cited in Moosa, 2007). However, the reasons for 
non-adherence in these patients could not be observed.  
In terms of different psychiatric disorders, non-adherence rates were estimated for the 
following: depression 51-69%, Anxiety Disorders 57%, Schizophrenia  30-60%, Bipolar 
Mood Disorder 21-50%; Alcohol Use Disorders  35%; and HIV/AIDS-related psychiatric 
conditions 13% (Buckley et al., 2009). A review by Julius et al., (2009) showed that non-
adherence ranges between 28% - 52% for Major Depressive Disorder, 20%-50% for Bipolar 
Bood Disorder, and 20% - 72% in Schizophrenia. 
 
2.3.2. Adherence in depression 
Major Depressive Disorder is associated with enormous personal suffering for affected 
patients, great distress to their family and friends and contributes to major economic and 
societal costs (Wells, Stewart, & Hays, 1989; Greenberg, Stiglin, Finkelstein, & Berndt, 1993; 
Wang, Simon, & Kessler, 2003, as cited in Aikens, Nease, Nau, Klinkman, & Schwenk, 
2005). The South African Stress and Health Study, the first nationally representative 
epidemiological study undertaken in the country to determine the prevalence of psychiatric 
disorders, estimated that 9.8% of South Africans have been diagnosed with a mood disorder 
(Herman et al., 2009). A South African investigation into the association between mental 
disorders and lost income through simulations by Lund, Myer, Stein, Williams and Flisher 
(2013) found that the mean estimated lost income due to severe depression and anxiety 
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disorders was USD $4,798 per adult per year, after adjusting for age, gender, education, 
marital status, and household size. To put this into perspective, Lund et al.(2013) further 
explained that projections of the total annual cost in lost earnings for South Africans with 
severe depression and anxiety ($4,798 per person), extrapolated from the sample, was USD 
$3,626,666,995, at the initial observed 12-month prevalence rate of 3.25% (Herman et al., 
2009). However, their calculations relied upon outdated statistics of the South African adult 
population (20-64 years) of 23,257,556 based on the 2001 South African census (Statistics 
South Africa, 2003). This amount could be significantly higher by current measures.  
Myers and Branthwaite (1992) found that the relapse rates in unipolar mood disorders are as 
high as 80% one year after patients stop taking their prescribed antidepressant medication, 
and 60% of patients stop their treatment within 3 months of beginning their treatment.  
However, the reasons for this could not be observed. Nevertheless, in support of the 
previous finding, it was observed that between 30% and 83% of patients who begin 
antidepressants discontinue treatment prematurely (Melfi, Chawla & Croghan, 1998; 
Peveler, Grorge, Kinmonth, Campbell, & Thompson, 1999). A review of quantitative 
evidence of factors associated with non-adherence reported rates for medication adherence 
in depression ranging between 30.0% and 97.0% (Pampallona et al., 2002).  The wide range 
in adherence rates reported here may be due to the fact that their review of 32 observational 
studies conducted between 1973 and 1999 reported on adherence measured by various 
methods, such as appointments kept, direct pill count of pills actually taken, plasma levels, 
as well as ad hoc composite measures of medication intake.  
Although some of these studies did not report on the factors associated with non-adherence 
in patients with depression, other studies have suggested that improved adherence was 
associated with the use of Fluoxetine, imipramine rather than any other antidepressant, high 
education level, married status and good social adjustment, no adverse reactions, female 
gender, referral or prescription by a psychiatrist, and no personality or Substance Use 
Disorders (Croghan, Lair, Engelhart, Crown, Copley-Merriman, Melfi, Buesching et al., 1997; 
Last, Thase, Hersen, Bellack, & Himmelhoch, 1985; Matas, Staley, & Griffin, 1992; 
Robinson, Gilbertson, & Litwack 1986; Simon, VonKorff, Wagner, & Barlow, 1993). 
 
2.3.3. Adherence to medication 
Due to the chronic nature of many psychiatric disorders, prolonged treatment of these 
conditions is often required (Nolen-Hoeksema, 2011). Psychotropic medication, such as 
antidepressants, antipsychotics, anxiolytics, mood stabilizers and sedative hypnotics are 
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used in the treatment of psychiatric conditions (Panksepp, 2004; Bulloch & Patten, 2010). In 
psychiatry, antidepressants play a pivotal role in the treatment and management of various 
psychiatric conditions, such as Major Depressive Disorder, Generalised Anxiety Disorder, 
Social Phobia and Specific), Obsessive-Compulsive Disorder, Eating Disorders, 
Posttraumatic Stress Disorder and the psychological effects of living with chronic pain (Royal 
College of Psychiatrists, 2012).  
Over the past 50 years, antidepressants have become the main treatment modality for 
depressive disorders. According to Ban (2014), prior to this, the treatment of depression 
(formerly known as melancholia) was in line with contemporary beliefs about the condition at 
that time, and until the 19th century there was little documentation of the results of these 
treatments. Historically, the treatment approach to depression included the use of warm 
baths, psychotherapy and bodily exercise treatments, and this approach continued until the 
1960’s when antidepressants replaced these methods (Ban, 1981; Hunter & Macalpine, 
1964). More recently, the British National Clinical Practice Guidelines (NICE) published 
international guidelines recommending that newer selective serotonin reuptake inhibitors 
(SSRI’s) should be the first-line treatment for depression (NICE, 2004). In general, SSRIs, 
selective noradrenaline reuptake inhibitors (SNRIs), noradrenaline and dopamine reuptake 
inhibitors (NDRIs) and mirtazapine, a tetracyclic agent, were encouraged over the use of 
tricyclic antidepressants and monoamine oxidase inhibitors (MAOI’s). Newer melatonergic 
agents may also be employed. These antidepressant classes were recommended in view of 
their increased tolerability and safety in patients. This is supported by other international 
societies, such as the American Psychiatric Association (APA), (Silverman, Galanter, 
Jackson-Triche, Jacobs, Lomax, Riba, Yager et al., 2015; Gelenberg, Freeman, Markowitz, 
Rosenbaum, Thase, Trivedi, Silbersweig et al., 2010), the Canadian Network for Mood and 
Anxiety Treatments (CANMAT)  (Kennedy, Lam,  Parikh, Patten, & Ravindran, 2009) and the 
British Association of Pharmacology (BAP) (Cleare, Pariante, & Young, 2015).  
These recommendations by the international societies are similar to treatment guidelines 
adopted in the local South African context. The South African Society of Psychiatrists 
(SASOP) provided guidelines that apply to the current private health care settings (Emsley, 
Colin, Flisher, Grobler, Hawkridge, Potocnik, et al., 2013) and the National Department of 
Health (The South African National Department of Health, 2012) provides treatment 
guidelines for psychiatric disorders in the published Standard Treatment Guidelines and 
Essential Medicines List for South Africa, which typically apply to public health care settings 
in South Africa. These documents recommend the use of an SSRI above older tricyclic or 
MAOI’s as the first-line treatment for moderate to severe depression, while psychotherapy or 
cognitive-behavioural therapy (CBT) is recommended in patients with mild depression. A 
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particular reference by SASOP is made to Fluoxetine or switched to an alternative 
mirtazapine and bupropion, for example, in patients who experience SSRI-induced sexual 
dysfunction adverse reactions (Emsley et al., 2013). The NDoH Primary Health Care level 
(PHC) - typically used by outpatients in the public sector - (The South African National 
Department of Health, 2014), also makes reference to Fluoxetine or amitriptyline (a tricyclic) 
if a sedating antidepressant is required.  
Earlier work by Johnson (1973) in primary care settings in the United Kingdom indicated that 
up to two-thirds of patients being treated with tricyclic-type antidepressant medication for 
depression stopped taking them within a month of starting treatment. Katon, von Korff and 
Lin (1992) assessed the extent to which patients receiving prescriptions for antidepressant 
drugs actually obtained supplies of medication. It was found that only 20% of patients 
prescribed antidepressants of the tricyclic type filled four or more prescriptions within 6 
months, while 34% of patients who had been prescribed newer antidepressants did so 
(Katon et al., 1992). This indicated that patients receiving tricyclic antidepressants were 
adhering less to their treatment regime when compared with patients taking newer 
antidepressants, but both groups displayed low levels of adherence to medication treatment. 
Both these studies (Johnson, 1973; Katon et al., 1992) reported on the efficacy of an 
intervention that was implemented, but did not include the reasons for non-adherence to 
treatment reported by patients. Reasons for non-adherence by psychiatric patients are 
discussed in greater details in the following section of this chapter.  
Gasquet, Bloch, Cazeneuve, Perrin and Bouhassira (2001) conducted a large national 
survey of a representative sample of the general French population in order to assess 
antidepressant non-compliance frequency and the factors that influence it. Data was 
collected by telephone interview to assess two types of non-adherent behaviours: 1) 
premature interruption of treatment and 2) omitting doses. Their results reported that 36.9% 
of people taking antidepressants were non-adherent (15.4% by treatment interruption and 
21.5% by dosage modification). They reported that 15% of the subjects admitted to early 
termination of their treatment, and 22% admitted to reducing their dose without discussing it 
with their doctor (Gasquet et al., 2001).  
In terms of different psychotropic medication classes, a study by Bulloch and Patten (2010), 
used data from the Canadian Community Health Survey, and reported non-adherence of 
34.7% for patients on antipsychotics, 38.1% on sedative-hypnotics, 44.9% on mood-
stabilisers and 45.9% for patients on antidepressants, respectively. Although an abstract 
from the publication by Gasquet et al., (2001) was available in English, the full-text was only 
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available in French language. This made drawing any comparisons between studies 
challenging due to the language barriers. 
 
2.3.4. Adherence in the local context 
Although there are South African studies that investigated non-adherence to antiretroviral 
(ARV) treatment (Goudge  & Ngoma, 2011; Catz, Kelly, Bogart, Benotsch, McAuliffe, 2000; 
Kagee, 2008; Kagee, Nothling & Coetzee, 2012), very few recent studies have focused on 
the adherence rates to antidepressants in the local psychiatric outpatient setting. Local ARV 
medication adherence rates among n=272 HIV positive men and women with alcohol 
problems were reported on (Catz et al., 2000). Adherence to ARV therapy was measured 
using a 14-day timeline interview to recall day by day all medication doses taken and missed 
during the past two weeks. They (Catz et al., 2000) reported a 43% adherence rate to HIV 
medication, and noted that depression and anxiety (as measured by the Center for 
Epidemiologic Studies-Depression Scale (CES-D) and Beck- Symptom Inventory), were not 
significantly associated with HIV medication adherence (p = .595). This figure of 43% non-
adherence to ARV therapy falls within the range of non-adherence rates to psychotropic 
medications and psychiatric conditions previously noted. Kagee, Nothling and Coetzee 
(2012) specifically reported on the barriers (poverty-related, institution-related and social 
barriers to clinic attendance and pill-taking) to ARV treatment and noted that food insecurity, 
stigma and discrimination were the main barriers to treatment adherence experienced by a 
sample of 10 patients at a public hospital.  
One local study by Sharif, Ogunbanjo and Malete (2003), did investigate non-adherence 
amongst psychiatric patients in the Mpumalanga Province. However, this was a qualitative 
study, and no objective measurement was used to determine the rate of non-adherence to 
their medication. Nevertheless, the following themes indicating reasons for non-adherence to 
treatment by patients with any psychiatric illness were identified: patients’ religious and 
spiritual beliefs; adverse reactions to medication; perceived non-response to treatment; fear 
and denial; lack of family and health care systems support, as well as social stigma.  
Mahaye, et al. (2012) assessed the medication adherence in a sample of 92 psychiatric 
outpatients in the KwaZulu-Natal Province using the same adherence measuring instrument 
as the current study (MMAQ-8), but instead focused only on antipsychotic medication in a 
smaller sample of Schizophrenia patients (n=95). Their (Mahaye, et al., 2012) observational 
study measured high adherence levels amongst 12.6% of the study sample, moderate 
adherence levels amongst 50.8%, and low adherence levels amongst 37% of participants. 
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Mahaye, et al., (2012) noted that significant predictors of adherence to antipsychotic 
medication were age (p = .045) and race (p = .055). The impact of variables such as the type 
of condition (Schizophrenia  only), employment status, educational level and medication 
related variables such as the number, formulation, and frequency of intake were however 
insignificantly associated with adherence levels.   
One study (Janse van Rensburg et al., 2014) did, however, investigate medication 
adherence and clinic attendance in a sample of n=91 psychiatric outpatients with various 
psychiatric diagnoses at a regional public hospital in Johannesburg, Gauteng.  They (Janse 
van Rensburg et al., 2014) conducted a 3-month pilot-intervention in 2012 to assess its 
effectiveness in improving adherence. The pilot-intervention programme included: weekly 
phone calls, free telephonic counselling, reminder SMS-messages, printed and electronic 
psycho-educational information on conditions and treatment and, access to free support 
groups (Janse van Rensburg et al., 2014).  Although the adherence scale component of this 
questionnaire was based on the MMAQ-8, this was a pilot study, and therefore the reliability 
and validity of the tool could not be established.  
In their study Janse van Rensburg, Taljaard and Wilson (2014) observed that the majority of 
patients were female (76%) with White (35%) and Black (34%) ethnicity.  The average age 
of patients was 41.9 years, while nearly two-thirds (58.2%) were older than 40 years. More 
than two-thirds (64.8%) of patients spoke English, with Afrikaans being the second most 
common spoken language (19.8%). More than two thirds of patients (61.5%) were not in a 
relationship with a partner at the time (single, divorced or widowed).  The majority of these 
participants (75%) were unemployed, and from the quarter of those who were employed, 
69.6% were working full-time and 30.4% part-time. Participants’ most common DSM IV-TR 
axis I diagnoses were Major Depressive Episode or Disorder (22%); Bipolar Mood Disorder 
(n = 12; 13.2%); Anxiety Disorders (n = 8; 9%) and Psychosis due to General  Medical 
Conditions (n = 8; 9%). The most common medication categories prescribed to these 
patients were antidepressants (57%), antipsychotics (56%), mood stabilisers (38.5%), 
anxiolytics/sedative medication (31.8%) and other general medical treatment (17.6%). For 
most participants (89%), more than one medication was prescribed. Prior to the pilot-
intervention, roughly 80% of the patients reported that they were adherent by taking their 
medication as suggested by their doctor.  However, 60 of the 74 patients who indicated that 
they were adherent to their medication gave reasons for non-adherence in a subsequent 
follow-up question. Therefore, a non-adherence rate of 15.4% prior to the pilot-intervention 
was defined as a more accurate estimate of non-adherence rates (Janse van Rensburg et 
al., 2014).  
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After the pilot-intervention (3 months), only 11.4% of participants reported that they skipped 
doses of their medication during the intervention. The majority (88.6%) indicated that they 
took their medication as prescribed by their doctor and none of the patients indicated that 
they stopped taking their medication completely (Janse van Rensburg et al., 2014). The 
most common reasons for non-adherence to medication prior to the pilot-intervention were 
forgetfulness, lack of reminder support, perceived adverse reactions, unavailability of 
medication at pharmacies, beliefs about medication and stigma, as well as lack of 
knowledge (Janse van Rensburg et al., 2014). Although it is possible that patients who took 
part in this pilot- intervention to increase medication adherence may have also participated in 
the current investigation, it is unlikely that the effect of the pilot-intervention had any 
significant impact on the adherence rates observed in the current study. The pilot-
intervention took place over a relatively short period (3 months), and concluded in 2012, two 
years after the current study took place.  To the best of the researcher’s knowledge, this 
local study by Janse van Rensburg, Taljaard and Wilson (2014) provided the only 
description of medication adherence behaviours in a sample of psychiatric outpatients that 
took place in the same geographical area as the current study (Johannesburg, Gauteng).  
Although it provides valuable socio-demographical-, clinical- and treatment information, as 
well as adherence behaviours in this sample, there are several limitations to this study. 
Firstly, it did not measure adherence rates using a validated instrument, and although their 
instrument was based on the MMAQ-8, the reliability and validity of the tool could not be 
established as this was a pilot-study. Secondly, adherence rates were dichotomously 
grouped as adherent and non-adherent based on patients’ self-reported response to a single 
item on a questionnaire that was being pilot-tested. This leaves the study limited as it does 
not allow one to create a profile for partial-adherence behaviours. Thirdly, their study sample 
included a relatively small sample (n=91), and did not perform statistical calculations to 
determine which variables were significantly correlated with adherence rates.  To date, no 
large-scale studies that aim to objectively determine the rate of adherence to antidepressant 
medications in Gauteng have been conducted, suggesting a shortage of local evidence 
measuring and describing non-adherent behaviours of psychiatric outpatients. It is important 
to ascertain the scope of this problem, as well as gain an understanding of the mechanisms 
and dynamics of its functioning if health care providers and health systems wish to address 
the problem more effectively. 
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2.4. Types of medication 
The medications identified in this study were listed according to their pharmacological 
classification from the Monthly Index of Medical Specialities (MIMS, September, 2014). The 
following categories have been identified under the Central Nervous System (CSN) class: 
central nervous system stimulants (CSNS); sedative hypnotics (SH); anxiolytics (ANX); 
antidepressants (AD); antipsychotics (ANTIP) and; Anti-epileptics (ANEPIL), (MIMS, 
September, 2014). It is not within the scope of this study to provide a detailed discussion of 
the mechanisms of action or neurophysiological effects of these medications, but and serves 
as a general guide instead, and should not be used for clinical reference or to inform 
pharmacological treatment of patients. Proprietary names of the medications are not 
provided, but grouped according to their active ingredients only.   
Table 1 identifies the antidepressant medications prescribed to psychiatric outpatients who 
participated in this observational study, and lists the common indications and mechanisms of 
action of these medications. This information was obtained from the electronic Medicines 
Compendium (eMC), (Datapharm, 2015). The eMC contains up to date, easily accessible 
information about medicines licensed for use in the UK, all of which have been checked and 
approved by either the UK or European government agencies which license medicines such 
as the UK Medicines and Healthcare Products Regulatory Agency (MHRA) and the 
European Medicines Agency (EMA), (Datapharm Communications Limited, 2015). The eMC 
contains: 1) Summaries of Product Characteristics (SPC), which provide health care 
professionals such as doctors, pharmacists and nurses information on how to prescribe and 
use the medicine correctly, and is based on clinical trials and gives information about dose, 
use and possible side effects and; 2) Patient Information Leaflets (PIL), which is written by 
pharmaceutical companies and is a patient-friendly version of the SPC, and typically 
contains information on what the medication is used for, what to do before taking the 
medication, how to take and store the medication, and possible adverse reactions  
(Datapharm Communications Limited, 2015). It is worth noting that the information reported 
in Table 1 only serve to provide a general guide.  
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Table 1: Mechanisms of action, active ingredients and indications of antidepressants recorded in the current study 
Antidepressant 
medication 
classification 
 
Mechanisms of action 
Active 
ingredient 
Indication in adults 
Tricyclic 
 
Thought to increase the synaptic 
concentration of noradrenaline and 
serotonin in the CNS by inhibiting their re-
uptake by the pre-synaptic neuronal 
membrane. 
Amitriptyline 
Symptoms of depression (especially where sedation is 
required). 
 
Nocturnal enuresis where organic pathology is excluded. 
Believed to be inhibition of the neuronal 
re-uptake of noradrenaline and serotonin 
5HT to about the same extent 
Imipramine Treatment of symptoms of depressive illness. 
Blocks alpha-adrenergic, histamine H1, 
and some types of serotonin receptors. 
Mianserin 
For the treatment of Major Depression. 
 
Mono-Amine Oxidase 
inhibitors  
Non-hydrazine monoamine oxidase 
inhibitor 
Tranylcypromine 
Treatment of symptoms of depressive illness especially 
where phobic symptoms are present or where treatment 
with other types of antidepressants has failed. It is not 
recommended for mild depressive states resulting from 
temporary situational difficulties. 
Involves the selective, reversible inhibition 
of MAO-A. This inhibition leads to a 
decrease in the metabolism and 
destruction of monoamines in the 
neurotransmitters. This results in an 
increase in the monoamines, relieving 
depressive symptoms. 
Moclobemide 
For the treatment of Major Depression. 
 
Selective serotonin re-
uptake inhibitors 
 (5-HT) re-uptake inhibitor with high affinity 
for the primary binding site. It also binds to 
an allosteric site on the serotonin 
transporter. Has no or low affinity for a 
number of receptors including 5-HT1A, 5-
HT2, DA D1 and D2 receptors, α1-, α2-, β-
adrenoceptors, histamine H1, muscarine 
cholinergic, benzodiazepine, and opioid 
receptors 
Escitalopram 
Treatment of Major Depressive Episodes. 
 
Treatment of Panic Disorder With or Without Agoraphobia. 
 
Treatment of Social Anxiety Disorder (Social Phobia). 
 
Treatment of Generalised Anxiety Disorder . 
 
Treatment of Obsessive-Compulsive Disorder. 
Selective inhibitor of serotonin reuptake, 
and this probably accounts for the 
mechanism of action. Fluoxetine has 
practically no affinity to other receptors 
such as α1-, α2-, and β-adrenergic; 
serotonergic; dopaminergic; 
histaminergic1; muscarinic; and GABA 
receptors 
Fluoxetine 
Treatment of the symptoms of major depressive illness, 
with or without associated anxiety symptoms, especially 
where sedation is not required. 
 
Treatment of Obsessive-Compulsive Disorder. 
 
Complement of psychotherapy for the reduction of binge-
eating and purging activity. 
Potent inhibitor of the serotonin (5-HT)-
uptake. Tolerance to the inhibition of 5-HT-
uptake is not induced by long-term 
treatment with citalopram. With no, or 
minimal, effect on noradrenaline (NA), 
dopamine (DA) and gamma aminobutyric 
acid (GABA) uptake. 
Citalopram 
Treatment of depressive illness in the initial phase and as 
maintenance against potential relapse/recurrence. 
 
Treatment of Panic Disorder With or Without Agoraphobia 
Inhibitor of neuronal serotonin (5-HT) 
uptake in vitro and in vivo, but is without 
affinity for muscarinic, serotonergic, 
dopaminergic, adrenergic, histaminergic, 
GABA or benzodiazepine receptors 
Sertraline 
Treatment and prevention of symptoms of depressive 
illness, or reoccurrence of further episodes including 
accompanying symptoms of anxiety. 
 
 
Potent and selective inhibitor of 5-
hydroxytryptamine (5-HT, serotonin) 
uptake 
Paroxetine 
Treatment of Major Depressive Episode 
 
Treatment of Obsessive Compulsive Disorder 
 
Treatment of Panic Disorder With and Without Agoraphobia 
 
Treatment of Social Anxiety Disorders/Social phobia 
 
Treatment of Generalised Anxiety Disorder 
 
Treatment of Post-raumatic Stress Disorder 
 
Serotonin & 
noradrenaline re-
uptake inhibitors 
Inhibitor of serotonin and noradrenaline 
reuptake ODV, and reduce β-adrenergic 
responsiveness after both acute (single 
dose) and chronic administration 
Venlafaxine 
Treatment of Major Depressive Episode. 
 
For prevention of recurrence of Major Depressive 
Episodes. 
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Antidepressant medication 
classification 
 
Mechanisms of action Active ingredient Indication in adults 
Serotonin & noradrenaline re-
uptake inhibitors 
 
It weakly inhibits dopamine  and 
noradrenaline reuptake, with no 
significant affinity for histaminergic, 
dopaminergic, cholinergic, and 
adrenergic receptors. 
Duloxetine 
Treatment of Major Depressive 
Disorder. 
 
Treatment of diabetic peripheral 
neuropathic pain. 
 
Treatment of Generalised Anxiety 
Disorder . 
 
Non-clinical data suggests a 5-HT3, 
5-HT7, and 5-HT1D receptor 
antagonist, 5-HT1B receptor partial 
agonist, 5-HT1A receptor agonist 
and inhibitor of the 5-HT 
transporter, leading to modulation 
of serotonin , norepinephrine, 
dopamine, histamine, acetylcholine, 
GABA and glutamate 
neurotransmission 
Vortioxetine 
Treatment of Major Depressive 
Episodes 
Noradrenaline & dopamine re-
uptake inhibitors 
Selective inhibitor of the neuronal 
re-uptake of catecholamines 
(noradrenaline and dopamine) with 
minimal effect on the re-uptake of 
indolamines (serotonin) and does 
not inhibit either monoamine 
oxidase 
Bupropion 
An aid to smoking cessation in 
combination with motivational 
support in nicotine-dependent 
patients. 
Potent inhibitor of noradrenaline 
reuptake. It has only a weak effect 
on the 5-HT reuptake and does not 
affect the uptake of dopamine 
Reboxetine 
Acute treatment of depressive 
illness/ and for maintaining the 
clinical improvement in patients 
initially responding to treatment 
Tetracyclic  
Use- and voltage-dependent 
blocker of voltage gated sodium 
channels. It inhibits sustained 
repetitive firing of neurones and 
inhibits release of glutamate 
Lamotrigine 
Prevention of depressive episodes 
in patients with bipolar I disorder 
who experience predominantly 
depressive episodes 
Centrally active presynaptic α2-
antagonist, which increases central 
noradrenergic and serotonergic 
neurotransmission. The 
enhancement of serotonergic 
neurotransmission is specifically 
mediated via 5-HT1 receptors, 
because 5-HT2 and 5-HT3 receptors 
are blocked 
Mirtazapine 
Treatment of episodes of 
depression 
Melatonergic Specific 
MT1 and MT2 receptors agonist and 
5-HT2C antagonist. Has no effect on 
monoamine uptake and no affinity 
for α, β adrenergic, histaminergic, 
cholinergic, dopaminergic and 
benzodiazepine receptors 
Agomelatine 
Treatment of Major Depressive 
Episodes. 
Lithium  
Related to inhibition of 
neurotransmitter receptor mediated 
processes involving beta-
adrenoceptors 
Lithium Carbonate 
Treatment of acute episodes of 
mania or hypomania and for the 
prophylaxis of recurrent manic-
depressive illness. 
Others 
Triazolopyridine derivative 
chemically unrelated to known 
tricyclic, tetracyclic and other 
antidepressant agents. It has 
negligible effect on noradrenaline 
re-uptake mechanisms. May 
concern noradrenergic potentiation 
by mechanisms other than uptake 
blockade 
Trazodone 
Anxiety, depression, mixed anxiety 
and depression. 
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2.5. Measurement of adherence 
Researchers and clinicians have used various methods in an attempt to accurately and 
reliably assess patient adherence to medication, as well as to identify non-adherent patients 
(World Health Organization, 2003).  Although a number of methods are available for the 
measurement of adherence to medications, accurate assessment continues to be a 
challenge, and there remains a debate as to which approach is the most reliable and valid. 
This is because, currently, there is no universally accepted "gold Standard" for measuring 
adherence (Vik, Maxwell, & Hogan, 2004).  Adherence to pharmacological treatment in 
psychiatry may be measured using biological measurements, clinician ratings, pill count, 
health professional reports and patient self-reporting (Moosa, 2007). The majority of 
medication adherence studies used indirect measures such as pill counts and self-reported 
questionnaires. This is because direct methods such as biological samples are not always 
possible, feasible, appropriate or cost effective (Vik Maxwell, & Hogan, 2004). 
 
2.5.1.  Biological measurements 
This approach implies a direct method of measuring medication adherence through the use 
of biomarkers or its metabolites in serum or urine samples of psychiatric patients. This is a 
reliable method for assessing adherence, but it is also more inconvenient and expensive 
(Evans & Spelman, 1983, as cited in Moosa, 2007). Some patients may object to giving 
blood specimens, regarding these as unnecessary and intrusive. Additionally, results may be 
influenced by other drug or food interactions, physiological variability, change in dosing 
schedules and the half-life of the medication (Smith, Psaty, Heckbert, Tracy & Cornell, 
1999). 
 
2.5.2.  Clinician ratings 
Health care provider ratings and the clinician’s subjective rating of the patient’s response to 
treatment are other methods of measuring medication adherence (Moosa, 2007).  An 
alternative, more direct surveillance method by clinicians may be the clinical observation of 
the medication being taken. Despite being inexpensive and comprehensive, it was noted that 
clinician ratings may not be the most accurate method for measuring the rates of medication 
adherence (Gordis, 1979; Stewart, 1987). Limitations of this method include the tendency to 
overestimate adherence, assessment of global perceptions rather than the frequency of 
behaviour (e.g., “Did you take all your medications yesterday?” vs. “How many medications 
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did you take yesterday?”), treatments may be shared by several health providers from whom 
the data must also be collected (Quittner, Modi, Lemanek, Ievers-Landis, & Rapoff, 2008). 
 
2.5.3.  Pill counts 
Moosa (2007, p. 42) stated that this method of measuring medication adherence “... involves 
either a standard pill count or use of drug packs with a built-in counting system.” The former 
requires that patients bring their medication to the appointment with the health care provider. 
The latter system records when the container is opened. However, this only measures the 
bottle opening, and not whether the medication was actually ingested by the patient. 
Additionally, both approaches also require that patients do not give out or share their 
medication (Moosa, 2007). Multiple variables need to be considered in this deceptively 
simple approach. If patients are required to bring their medication to the health care provider 
for counting, missing data will result, particularly from the least adherent patients. Some 
patients may throw away their medication to appear more adherent (Sajatovic, Velligan, 
Weiden, Valenstein & Ogedegbe, 2010). 
 
2.5.4.  Self-reporting 
Self-reporting medication adherence scales or surveys are simple and economical methods 
to detect non-adherence. According to (Lavsa, Holzworth & Asnani, 2011), the “first 
published and most commonly used adherence scale is the Morisky Medication Adherence 
Questionnaire (MMAQ),” (Morisky, et al., 1986). Overall, MMAQ is found to be simple to 
administer and score, and is validated in many populations, in different languages and 
different disease conditions, making it a good tool to measure adherence across patient 
populations (Toll, McKee, Martin, Jatlow & O’Malley, 2007; Tan, Patel  & Chang, 2014; 
Suárez, Pérez, Valentín, Palomo, Cepeda & Aguiar,  2011; Mahaye et al., 2012; Lavsa, 
Holzworth & Asnani, 2011). Morisky et al., (2008), stated that the advantages of utilising the 
MMAQ-8 lie in the 8 simple questions that are asked, and the ease of scoring these items 
(each yes answer = 1 point and; no = 0 points), For these reasons, the MMAQ-8 was used to 
measure the adherence rates of antidepressant medication in the current study, and will be 
discussed in greater detail in Chapter 3. 
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2.6. Types of non-adherence 
2.6.1. Primary non-adherence 
Primary non-adherence typically involves scenarios where health care practitioners provide 
prescriptions, but the medication is never filled or collected. This can also include non-
participation in health programmes or the breaking of appointments (Morris & Schulz, 1992). 
There is a direct failure to follow doctors’ instructions regarding the prescription. (Gellad, 
Grenard & McGlynn, 2009, as cited in Jimmy & Jose, 2011). Over the past 20 years studies 
have shown that this type of non-adherence is motivated by patient's beliefs about their 
treatment, illness and prognosis, as well as their experiences with medications (Benson, 
2002). Patients can exhibit different medication-taking behaviours for different medications 
because they weigh the perceived risks and benefits for each medication separately. This 
suggests that adherence interventions should be modifiable to patients' beliefs about 
different medications (Gadkari & McHorney, 2012). Several studies of various designs, 
populations and illnesses assessing primary non-adherence found between 1% and 21% of 
prescriptions unfilled or unclaimed within pharmacies (Jackevicius, Paterson, & Naglie, 
2007; Jones & Britten, 1998; Kirking, Zaleon, & Kirking, 1995; Skutnik & Katsanis, 2011). A 
survey of adults with chronic cardiovascular diseases (asthma, hypertension, diabetes, 
hyperlipidaemia, osteoporosis) reported that adherent patients were more likely to show 
higher perceived need, fewer adverse reaction concerns, and better knowledge about their 
condition and their medication when compared to non-adherent patients (McHorney & 
Gadkari, 2010).  
 
2.6.2. Secondary non-adherence 
Secondary non-adherence relates to patients who stop taking their medication after starting 
it without the recommendation of their health practitioner, take an incorrect dose or at wrong 
times, may forget one or more doses of the medication, or by failing to obtain a repeat 
prescription due to unavailability or inaccessibility to their medication (Morris & Schulz, 
(1992). Jimmy and Jose (2011) stated that this form of non-adherence is rarely intentional, 
but arises from patients' ability and resource limitations that inhibit patients to follow their 
prescribed treatment recommendations. A general secondary non-adherence rate of 50% for 
various types of drug therapies was observed by Hovstadius and Petersson (2011) using 
patient registry data in the Swedish general population. They noted that higher rates of 
secondary non-adherence contribute significantly to unnecessary medical spending, and 
efforts are needed to improve secondary adherence. 
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2.7 Factors influencing adherence 
Several publications (World Health Organization, 2003; Leo et al., 2005; Kane, Kishimoto & 
Correll, 2013) have reported on the factors that could have a negative impact on treatment 
adherence across various settings. The World Health Organization categorised the 
determinants of non-adherence into five dimensions: (1) social and economic (e.g., unstable 
living conditions, medication cost, lack of financial resources, burdensome work schedules 
and low health literacy); (2) health system-related (e.g., provider communication skills, 
provider-patient relationship and no continuity of care); (3) treatment-related, (e.g., 
complexity of medication use, medications with social stigma associated, duration of 
therapy, negative side effects); (4) condition-related (e.g., chronic conditions, psychiatric 
disorders, lack of symptoms); and (5) patient-related (e.g., negative beliefs about treatment, 
cognitive impairment, visual impairment), (World Health Organization, 2003). However, Leo, 
Jassal & Bakhai (2005), described the following six factors why psychiatric patients do not 
adhere to their medication: (1) medication factors (complex regimen (i.e. polypharmacy, 
adverse effects, duration and dosage, availability); (2) illness factors (cognition/memory, 
concentration interference and hopelessness); (3) patient factors (denial, beliefs and 
attitudes, stigma); (4) physician factors (inadequate information provided, inadequate follow-
up of response to treatment); (5) patient-physician factors (poor alliance/communication); 
and (6) social and environmental factors (supportive network, financial resources, 
inaccessibility and unavailability of treatment resources). More recently, Kane, Kishimoto 
and Correll (2013) identified the following five factors associated with non-adherence in 
patients with psychotic disorders: (1) patient characteristics such as sex, age, race and 
education; (2) illness characteristics such as duration, phase, severity or comorbidity, 
substance use cognitive function; (3) provider/ system characteristics include access to 
treatment, reimbursement or psycho-education; (4) family/ caregiver characteristics, 
including perceived need for treatment and support, stigma and availability of other support 
systems. They also noted (5) other characteristics such as financial constraints or transport 
related problems that may influence adherence to treatment.  
It is clear from the literature above that, although there is some overlap, the grouping of 
these factors is not universally agreed upon. For this reason, an adapted model was 
developed that could best describe non-adherent behaviours relevant to the current study 
sample, and was informed by the literature cited here and the data that was collected with 
the research instrument. The following factors were subsequentlyidentified in the current 
study: patient factors; treatment factors; illness factors; health system factors and; 
moderating factors.  
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2.7.1. Patient factors 
According to (Moosa, 2007), these include factors such as age, sex, and social conditions. 
Non-adherent patients are more likely to be younger, of lower socio-economic status and to 
have a lower level of education (Davis, 1968; Allan, 1988). Other factors include 
forgetfulness, inadequate knowledge, lack of insight, fear of being stigmatised, lack of 
financial resources, and co-morbid conditions, which have been found to negatively affect 
adherence rates (Owen, Fischer, Booth & Cuffel, 1996; Perkins, 2002; Löffler, Kilian, Toumi 
& Angermeyer, 2003).  
A systematic literature review on the psychosocial and behavioural factors associated with 
medication non-adherence in both chronic physical and mental disorders noted patient 
characteristics such as age, gender and race  were only significantly associated with 
adherence in a very small number of the twenty-four studies (published between 1966 and 
2011),  (12, 5  and 3 respectively), (Zeber,  Manias, Williams, Hutchins, Udezi, Roberts & 
Peterson, 2013). In South Africa, antipsychotic medication adherence was measured in a 
psychiatric outpatient setting in KwaZulu-Natal Province using the MMAQ-8, and also 
observed an insignificant association between gender and adherence (Mahaye et al., 2012). 
However, they (Mahaye et al., 2012) found that only age (p = .045) and race (p = .055) were 
significantly correlated with medication adherence. However, from the thirty-two studies 
included in a systematic review of observational studies measuring antidepressant 
adherence in Depressive Disorders (Perestelo-perez & Serrano-aguilar, 2013), only a very 
small number of studies indicated that patient factors such as gender and race were 
predictive of adherence (1 and 1, respectively). In general, the literature seems to indicate 
that all these factors are not highly correlated with treatment adherence in the majority of the 
studies.  
On the other hand, patient beliefs about medication and treatment efficacy were reported to 
be highly influential in treatment adherence in a qualitative study investigating reasons for 
non-adherence to treatment in psychiatry (Sharif, et al., 2003). Furthermore, Janse van 
Rensburg e. al., (2014) also reported that one of the common reasons psychiatric 
outpatients gave for not adhering to their medication regime was patient beliefs about 
medication. However, they did not report whether it had a significant correlation with 
medication adherence. To minimise the impact of outlying variables on the current study 
results, those who indicated they spoke languages other than Afrikaans or English 
comprised only a small percentage of the study sample (11.4%), and were grouped into the 
“other official SA languages” category (i.e., Northern Sotho: n=6; Sotho: n=10; Swazi: n=3; 
Tswana: n=8; Venda: n=1; Xhosa: n5; and Zulu: n=10). Similarly, patients who indicated 
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they were Coloured (n=23), Indian (n=7) or Mixed race (n=2) were also grouped into the 
“other SA populations” 
In the current study, the following five patient-related variables were identified:   
 Age: Age was calculated in years from patients’ date of birth until December, 2014, 
upon conclusion of the study. The following age categories were also defined; 18-29, 
30-39, 40-49, 50-59 and, 60 and older. 
 Gender: Biologicalsex was dichotomously grouped as male or female. 
 Race: Racial distribution of patients was grouped into the following categories; Black, 
White and, any other race 
 Language: The main languages spoken by patients were grouped into the following 
categories; English, Afrikaans and, other official South African languages. 
 Treatment beliefs: Perceived need for pharmacological treatment was dichotomously 
categorised as “yes” or “no”. 
 
2.7.2. Illness factors 
Potential illness-related factors for non-adherence in psychiatry may also be influenced by 
issues such as  illness severity, unique characteristics and symptoms associated with 
various psychiatric conditions, comorbid illnesses, previous history of episodes, cognitive 
impairment or lack of illness insight (Higashi, Medic, Littlewood, Diez, Granström & De Hert, 
2013; Perestelo-perez & Serrano-aguilar, 2013).   
Findings from a Spanish psychiatric outpatient setting noted that illness related factors such 
as the type of mood disorder patients were diagnosed with or illness severity were 
insignificantly correlated with medication adherence (Tamburrino, Nagel, Chahal & Lynch, 
2009). However, they used the Medication Adherence Scale (MAS) and the Medical 
Outcomes Study (MOS) – different from the current study - in measuring adherence. 
Regardless, De Las Cuevas, Panate and Sans (2014) did use the same instrument as this 
current study (MMAQ-8), and also noted similar insignificant correlations between 
medication adherence and diagnosis and illness severity. Contrastingly, earlier onset of 
diagnosis was significantly associated with non-continuous antidepressant use within 6 
months of initiating their treatment (p = .034) in a sample of n=189 patients newly dispensed 
with an antidepressant in a psychiatric outpatient clinic during 2006 and 2007 in Hong Kong 
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(Yau, Chan, Wing, Lam, Lin, Lam & Lee, 2014). Al-Jumah, Ahmad Hassali, El Tahir , and Al 
Qhatani (2014), measured antidepressant medication adherence using the MMAQ-8 among 
n=403 psychiatric outpatients in Saudi Arabia. They noted that a shorter duration of illness in 
and less depression severity was associated with higher adherence levels.  
In the current study, the following five illness-related variables were identified: 
 Main diagnosis: This is defined as the primary DSM-IV-TR Axis I and II diagnoses 
reported, and excludes general medical related conditions. 
 Comorbid conditions: This was defined as the type and number of DSM-IV-TR 
diagnoses reported by patients. 
 Age of onset of main diagnosis: This is defined as the age at which patients received 
their primary DSM-IV-TR diagnosis 
 Duration of illness: This is defined as the number of months since patients have 
received their primary diagnosis until December, 2014, upon conclusion of the study, 
as extracted from the database. 
 Severity of illness: Patients’ perceived severity of their condition was defined by the 
participants’ response to the question “Do you think or feel your condition makes it 
difficult for you to do your daily activities?” 
 
2.7.3.    Treatment factors 
Treatment related factors such as length of treatment (Moosa, 2007), complex treatment 
regimens (Blackwell, 1996; Razali & Yahya, 1995) and side-effects (Bostwick, 2010; Taj, 
Tanwir, Aly, Khowajah, Tariq, Syed, Shahzada et al., 2008; Yau et al., 2014) can all have a 
detrimental effect on treatment adherence.  A meta-analysis found that Escitalopram and 
sertraline were superior to other antidepressants when considering both effectiveness and 
safety (Gartlehner, Thieda, Hansen, Gaynes, Deveaugh-Geiss, Krebs & Lohr, 2008). It is 
worth noting that this meta-analysis had several limitations such as different measuring 
instruments used, it included studies with low methodological quality, in different settings 
(inpatient and outpatient) and clinical profiles (single disorder and comorbid diagnoses). 
However, other analyses (Thaler, Morgan, Van Noord, Gaynes, Hansen, Lux, Gartlehner et 
al., 2012; Agency for Healthcare Research and Quality, 2014), have found that no SSRI is 
more superior to the other. Although Zeber and his colleagues (2013) observed that some 
studies did not report a significant correlation with medication-related factors and lower 
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adherence levels (Yood, Mazor, Andrade, Emani, Chan & Kahler, 2008; van Geffen, 
Gardarsdottir, Hulten, Dijk, Egberts & Heerdink, 2009; Wamala, Merlo, Bostrom, Hogstedt & 
Agren, 2007; Wroth & Patman, 2006), the majority of studies included in their systematic 
review did observe significant correlations between poor adherence and various 
antidepressant treatment characteristics such as the use of tricyclic antidepressants 
(Akincigil, Bowblis, Levin, Walkup, Jan & Crystal, 2007; Cooper, Brown, Vu, Palenchar, 
Gonzales, Ford & Powe, 2007; Keller, Hirschfeld, Demyttenaere & Baldwin, 2002), complex 
treatment regimen (Bucci, Possidente &Talbot , 2003), and the presence of unpleasant 
adverse reactions (Shigemura, Ogawa, Yoshino, Sato, & Nomura, 2010).  
In the current study, the following five treatment-related variables were identified: 
 Type of antidepressant: The following categories were identified as classified by the 
MIMS (September, 2014); tricyclic antidepressants, monoamine oxidise inhibitors 
(MAOI), selective serotonin reuptake inhibitors (SSRIs), serotonin and 
norepinephrine selective reuptake inhibitors (SNSRIs), norepinephrine and dopamine 
reuptake inhibitors (NDRIs), melatonergic agents, lithium and, others. 
 Duration of treatment: This is defined as the number of months patients have been 
taking their current antidepressant medication until December, 2014, upon 
conclusion of the study, extracted from the database. 
 Dosage: This is defined as once a day, twice a day, three times daily, or more than 
four times a day. 
 Polypharmacy: This is defined as the number of medications (including all central 
nervous system medications), patients are currently prescribed. 
 Adverse reactions: Patients’ experiences with adverse reactions were defined 
through participants’ response to the question, “Are you currently experiencing any 
adverse reactions from your antidepressant medication?”  
 Knowledge of how to cope with adverse reactions: Patients’ knowledge of how to 
cope with any potential medication-related adverse reactions were defined through 
participants’ response to the question, “Do you know how to handle or cope with any 
potential side-effects from your antidepressant medication?”  
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2.7.4.    Health system factors 
Moosa (2007) provided the following health-care related factors that influence non-
adherence in psychiatry: poor patient-health care provider relationships may cause poor 
adherence; failure of psychiatrists to establish good rapport with patients may govern much 
of the efficacy of care (Pereira & Pinto, 1997). Therefore, a good therapeutic agreement with 
a doctor who is positive about the treatment outcome may lead to better adherence.  Other 
factors that may have a negative impact on adherence include poor services and medication 
distribution systems, lack of staff training, overworked health care providers, insufficient 
ability to provide education and continuity of care to patients, and inability to establish 
community support systems or groups (Carpenter, Morrow, Del Gaudio & Ritzler, 1981; 
Craig, Huffine & Brooks, 1974). Furthermore, Price and Kovar (2013) identified barriers to 
high-quality care, limited support and lacking health insurance as risk factors for non-
adherence to antidepressant medications in their literature review.  
Lack of social support has also been reported to be a predictor of non-adherence to 
antidepressant medication (Voils, Steffens, Flint, & Bosworth, 2005). However, this particular 
international study only included a small sample (n=85) from both in- and outpatients aged 
59 years or older. An international systematic review of systematic reviews found that health 
care system factors such as medication costs and co-payments were found to influence 
adherence rates negatively in chronic illnesses such as arthritis and cancer (Mathes, 
Jaschinski, & Pieper, 2014). Additionally, Banerjee and Varma (2013) assessed factors that 
influenced adherence to depression treatment in an outpatient setting in India observed that 
the majority of patients were non-adherent due to health facility-related factors (long distance 
from health care facilities, long waiting hours and unavailability of medication). Although they 
also measured adherence using the MMAQ-8 (Bengali language), this sample only included 
patients with unipolar depression, as defined by the ICD-10 (World Health Organization, 
1992), and not the DSM-IV-TR classification system used in the current investigation 
(American Psychiatric Association, 2000), as well as excluding patients with other comorbid 
conditions. 
The current study did not investigate other health system-related issues such as staff 
training, the frequency of patient-provider communication, distance from health care 
facilities, waiting hours or medication availability, and this may warrant further study and 
exploration.  
In the current study, the following five health systems-related variables were identified: 
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 Health care system: The types of health care service patients made use of was 
categorised as private or public. Furthermore, the distinction was made between 
patients’ prescribing practitioners, i.e., from a psychiatrist or general practitioner 
 Health insurance: This was defined as patients’ medical aid or social grant status. 
Patients were asked to indicate if they received any financial aid for their treatment in 
the form of medical aid or a social grant by responding “yes” or “no” to the 
corresponding questions.    
 Lack of support: Patients’ perceived need for support with adhering to their 
medication was defined by the participants’ response to the question “Do you feel 
you need more support to help you stick to your antidepressant medication?” 
 
2.7.5.    Moderating factors 
These factors were identified as additional barriers that may restrict or hinder patients from 
taking their prescribed medication optimally, and include poor socio-economic conditions, 
lower level of education and literacy, unstable or poor living arrangements, lack of access to 
clinics (long distance to travel, cost of transport), insufficient  support systems, and stigmas 
and attitudes associated mental disorders (Jin, Sklar, Min Sen Oh, & Chuen Li, 2008; Price 
& Kovar, 2013; Mathes, Jaschinski, & Pieper, 2014).  The availability of support in the form 
of family, friends, or caregivers to assist or supervise medication is associated with 
increased outpatient adherence to treatment (Moosa, 2007, as cited in Fenton, McGlashan, 
Victor & Blyler, 1997). However, these factors are continuously interacting and influencing 
each other, that ultimately results in non-adherent behaviour. For example, patients report 
that treatment effectiveness and barriers to access are among the most critical aspects of 
depression care (Cooper et al., 2000).  
Early literature summarised (Pampallona et al., 2002) and concluded that, although patient 
education was commonly assessed for its impact on treatment adherence, studies did not 
show consistent findings. Although lower levels are generally associated with poorer 
treatment adherence, findings have been mixed and suggested that education level and its 
impact on adherence are still not clearly understood. Additionally, marital status and living 
arrangements (i.e., alone versus with another person) were not significant predictors of 
adherence to treatment in a sample of n=134 patients with Major Depressive Disorder 
(MDD), (Sirey, Bruce, Alexopoulos, Perlick, Raue, Friedman & Meyers, 2001). Similarly, a 
study investigating reasons for premature discontinuation of treatment with SSRIs in n=406 
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patients with MDD, and reported that treatment non-adherence was not significantly 
associated with marital status or education (Goethe, Woolley, Cardoni, Woznicki & Pie, 
2007). More recently, an analysis of n=228 hypertensive patients with depression found that 
education level was not significantly correlated with adherence levels, (Bogner & de Vries, 
2008).   
In the current study, the following five moderating variables were identified: 
 Relationship status: The following relationship categories were identified; married, 
single, widowed, divorced, relationship and, engaged. 
 Education level: The following categories were established to determine the level of 
education; did not attend school, Primary school - Grade 7 completed, some High 
(Secondary) school completed - Grade 9, High (Secondary) school completed – 
Grade 12, Diploma or Degree obtained and, Postgraduate Degree obtained. 
 Living conditions: The following categories were identified to describe participants’ 
living arrangements; live on their own, live with a partner, live with family, live with 
friends or; other. 
 Employment status: The following categories were identified to best describe the 
participants’ current employment status; employed working full­time, employed, 
working part-time, not employed - looking for work, not employed - not looking for 
work, student,  retired and; disabled or not able to work. 
 Stigma: Participants’ experience with stigma was defined by responding Yes or No to 
the question “Are you afraid of what some people may think about you taking 
antidepressant medication?”  
 
Figure 1 illustrates the conceptual framework utilised by the current study. This framework 
was informed by the cited literature, the information that was collected in the study as well as 
consideration for the local context of the setting. Figure 1 represents the various patient-, 
illness-, treatment-, health system- and, moderating variables identified in the current study, 
and illustrates how it is possible that each of the individual variables in the five main groups 
may significantly correlate with variables from any other main variable group or, even with 
individual variables in the same group (between- and within-groups approach). Ultimately, 
these variables may (directly or indirectly) have an influence on adherence rates.  
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Figure 1: Conceptual framework 
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2.8. Consequences of non-adherence 
Although antidepressant medication has been found to reduce depressive symptoms 
(Regier, Hirschfeld, Goodwin, Burke, Lazar & Judd, 1988; Maixner & Greden, 1998, cited in 
Aikens et al., 2005), clinical efficacy of the treatment is compromised when patients do not 
adhere to the prescribed regimen.  Adherence is a primary determining factor of 
pharmacological treatment efficacy in psychiatry, and poor adherence diminishes the clinical 
and therapeutic benefit of these therapies (World Health Organization, 2003). Non-
adherence to medication is associated with a worse prognosis, greater probability of relapse, 
rehospitalisation and increased resource consumption (Melfi, et al., 1998; Erwin & Peters, 
1999; Higashi et al., 2013).  
Firstly, it is associated with a decreased reduction in symptoms, as well as increased risk of 
relapse and hospitalisation and suicide attempts. In addition, financial costs incurred by non-
adherent patients are significantly higher due to increased treatment costs (World Health 
Organization, 2003). According to Thompson, Peveler, Stephenson and McKendrick (2000), 
levels of adherence have been positively associated with treatment outcomes in depression, 
independent of the kind of antidepressant medications used. In addition to the clinical impact 
on the health of patients, higher rates of medication adherence also transforms into financial 
or economic advantages. This comes in the shape of direct savings through the decreased 
use of costly health services caused by worsening symptoms, relapses or rehospitalisation 
of patients. Indirect savings can also be benefited from through the attribution of patients’ 
improved productivity, quality of life, social and work roles (World Health Organization, 
2003).  
 
2.9. Psychological theories of adherence 
Research that investigated the psychological theories explaining adherence over the past 
ten years has been limited, but considerable progress has been made since then (World 
Health Organization, 2003). Although not totally comprehensive and complete, we now have 
information on the extent of the problem of non-adherence to medication in psychiatry, and 
there is an increasing awareness of the positive clinical and public impact it can have. Like 
most health improving behaviours, having to take medication regularly for a long time 
involves a conscious commitment to a new healthy behaviour and requires a change in daily 
habits (World Health Organization, 2003). A brief overview of the main theoretical 
perspectives that describe adherence behaviours is provided in the following section, 
followed by a detailed discussion of the theoretical approach that guided the current study.  
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The following psychological approaches outlined by Leventhal & Cameron (1987), provides 
a helpful overview of the five dominant theoretical perspectives on treatment adherence: 
Biomedical perspective; Behavioural perspective; Communication perspective; Cognitive 
perspective; and Self-regulatory perspective. These suggested theories, models and 
methods provide a conceptual framework to address the challenge of non-adherence. 
Despite all these efforts after decades of research on adherence to develop a conceptual 
understanding of this phenomenon, (DiMatteo & DiNicola, 1982; Sherbourne, Hays, Ordway, 
DiMatteo & Kravitz, 1992; DiMatteo, Giordani, Lepper & Croghan, 2002; DiMatteo, Reiter & 
Gambone, 2009; Zolnierek & Dimatteo, 2009), adherence rates have not improved much. 
This can become challenging in the case of chronic illnesses such as psychiatric diagnoses. 
Although these theories and models offer a conceptual framework for organising the models 
about adherence, each has its own advantages and disadvantages.  No single approach 
provides a comprehensive understanding of adherence, and more recent approaches that 
focus on more specific non-adherent behaviours may provide additional information that can 
inform these existing frameworks (World Health Organization, 2003). Given that the barriers 
to medication adherence are complex and heterogeneous, psychological theories that aim to 
understand these health behaviours must be multifaceted and provide the possibility to be 
modifiable across different settings, illnesses and treatments. Such specialised and 
comprehensive theories can contribute to a greater understanding of the mechanisms of 
health behaviours, and lead to successful treatment interventions and adherence-enhancing 
strategies.  
 
2.9.1. Biomedical perspective 
According to Midence and Meyers (1998), the biomedical approach to adherence assumes a 
paternalistic view, and that patients are passive followers of their doctor’s orders regarding 
their prescribed treatment or therapy. This remains the authoritative perspective in many 
health care settings. Non-adherence is assumed to be the result of patient characteristics 
such as demographics.  Aspects such as gender and age have been found to be predictors 
of medication adherence, especially in the case of antiretroviral medications (Langebeek, 
Gisolf, Reiss, Vervoort, Hafsteinsdóttir, Richter & Nieuwkerk, 2014; De Fatima Bonolo, 
Ceccato, Rocha, de Assis Acúrcio, Campos & Guimarães, 2013; Blackwell, 1992), and these 
factors are viewed as the targets that specialised interventions aims to take into 
consideration. This has helped to clarify the relationships between illness and treatment 
characteristics on one side, and non-adherence on the other. Keeping in line with this 
systematic view, solutions and innovations to promote adherence, such as medication 
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monitoring systems, assessing levels of adherence using biochemical measures, and 
developing new devices to administer medications, are often grounded in this approach 
(World Health Organization, 2003).  
However, according to Munro, Lewin, Swart & Volmink (2007), a major shortcoming of this 
approach is that it ignores factors other than patient characteristics that can impact on 
adherence.  Patients' perspectives of their own illness, psycho-social influences and socio-
economic environment also play a significant role in medication adherence (World Health 
Organization, 2003; Blackwell, 1992). The assumption that patients are merely passive 
compliers makes it unlikely that this theory can contribute significantly to medication 
adherence (Munro et al., 2007). Instead, patients are active decision makers and more 
involved in their own treatment, and do not merely receive and follow instructions. They 
(Munro et al., 2007) suggest that a shift from a paternalistic biomedical model to a model of 
shared decision-making is necessary. 
 
2.9.2. Behavioural perspective 
The Behavioural perspective includes Behavioural Learning Theory (BLT), which concerns 
itself with the environmental context of patients and the training of skills to manage 
medication adherence (World Health Organization, 2003). This approach is primarily 
characterised by the antecedents and consequences of adherence, and their influence on 
behaviour (Munro et al., 2007). Antecedents are either the internal thoughts of a patient or 
the external, environmental cues that contributes to non-adherence. Consequences refer to 
the potential risks or rewards for that particular behaviour. The likelihood of a patient 
following a specific behaviour will depend on their internal thoughts or the external, 
environmental setting and what happens before and after the behaviour occurs (World 
Health Organization, 2003). This perspective emphasises the significance of reinforcement 
(positive and negative), as a method for influencing adherence behaviour. They (Munro et 
al., 2007) note that it would be possible to control the adherence behaviour of patients if one 
could control the events before and after a specific behaviour or act. Practically, these 
principles can be used to develop interventions that can influence behaviour at each level of 
influence (i.e., patient, provider and system) to address adherence problems.  
Adherence promoting strategies incorporating elements of BLT (Haynes, McDonald, Garg & 
Montague, 2002), such as using patient reminders (Dunbar, Marshall & Hovell, 1979; Burke, 
Dunbar-Jacob & Hill, 1997; Atreja, Bellam & Levy, (2005), have been found to improve 
adherence to chronic medications. However, analysis examining interventions derived from 
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BLT to improve adherence to ARV therapy concluded that these interventions were as 
efficacious as those without (Simoni, Pearson, Pantalone, Marks & Crepaz, 2006), or has a 
negative effect when using electronic reminder systems (Mannheimer, Morse, Matts, 
Andrews, Child, Schmetter & Friedland, 2006).  Therefore, further evidence of the utility of 
this approach may be needed. BLT has also been critiqued by Blackwell (1992) for lacking 
an individualised or person-centered approach, and for not considering influences that are 
not related to risks or rewards. These influences include past behaviour, habits, or lack of 
acceptance of a diagnosis (Munro et al., 2007). They (Munro et al., 2007) also report that 
this approach is limited by placing an over-emphasis on external influences on behaviour 
and, should also consider individuals' perceptions of appropriate risks and rewards.  
 
2.9.3. Communication perspective 
According to Ross and Deverell (2004, p. 56), communication is "the cornerstone of every 
patient-practitioner relationship". The Communication approach places an emphasis on the 
encouragement from health care providers to try to improve their own skills in 
communicating with patients (Atreja, Bellam, & Levy, 2005). Prior to this, Leventhal, & 
Cameron (1987) already proposed that improved communication will enhance adherence, 
and that it can be achieved through good health care provider communication skills and 
patient psycho-education. This has led to interventions that aim to develop rapport and, 
educating patients using good communication skills and stressing the benefit of a more 
equal relationship in the treatment journey (World Health Organization, 2003).  
Although adopting a warm and kind interaction style with a patient is a key aspect of this 
approach, it may be insufficient in itself to change the adherence behaviours of patients. 
Blackwell (1992) criticises this perspective by arguing that it disregards attitudinal, 
motivational and interpersonal factors that may interfere with the reception of information 
and the translation of knowledge into applied knowledge or behaviour change. It is also 
cautioned (Munro et al., 2007) that communication interventions in isolation may be unlikely 
to be effective in improving adherence to chronic medications because it ignores the 
influence of external factors, such as the costs and social barriers related to accessing 
health care for treatment. Interventions informed by this approach are also restricted to 
patient-practitioner engagement, and additional social support from family members, friends 
and support groups may be required to influence the patient’s adherence behaviour. 
According to Atreja, Bellam, and Levy (2005), the family's role becomes important if a patient 
is suffering from a chronic or disabling condition that requires continuous care and aid. 
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2.9.4. Cognitive perspective 
Various models have been proposed that emphasise cognitive aspects and processes 
relating to adherence behaviour. Examples of these include the Health Belief Model (HBM), 
(Becker, Maiman, Kirscht, Haefner, Drachman & Taylor, 1979), Social–Cognitive Theory 
(SCT), (Bandura & Simon, 1977), the Theory of Planned Behaviour (TPB), (Ajzen & 
Fishbein, 1980), and the Protection–Motivation Theory (PMT), (Gochman, 1997). These 
theories share the assumption that attitudes, beliefs and expectations of future outcomes are 
major determinants of health related behaviour, and propose that patients will follow 
behaviour that are most likely to lead to positive health outcomes (Munro et al., 2007). 
Although these perspectives have focussed their attention on the ways in which patients 
think about health threats and factors that may hinder or improve positive health outcomes, 
they have been criticised for not always addressing behavioural coping skills well (World 
Health Organization, 2003).  
It is argued that these Cognitive approaches do not recognise that non-voluntary factors 
such as power relationships, devoting time and social structures can affect adherence 
behaviour (Ingham, Woodcock & Stenner, 1991; Gebhardt & Maes, 2001). According to 
Weinstein, (1988), this perspective also gives little attention to the origin of beliefs and how 
they can influence other behaviours. This approach only focuses on a single threat to 
adherence behaviour, and does not consider other potentially competing threats to the 
patient’s mental or physical health (Munro et al., 2007). In addition, two main criticisms of the 
HMB, for example, where stated. Firstly, the relationships between the relevant variables 
have not been explicitly formulated (Stroebe, & de Wit, 1996), and no definitions have been 
constructed for the individual components (Armitage & Conner, 2000). It relies on the 
underlying assumption that these variables are not moderated by each other and has 
additive effect affect health behaviour, and that these variables influence adherence directly 
and remain unmoderated by behavioural intentions (Stroebe, 2000). Secondly, other 
important aspects of health behaviour, such as the positive effects of negative behaviours 
and social influence, are not considered (Stroebe, & de Wit, 1996; Stroebe, 2000]. 
Furthermore, an important limitation of the PMT, for example, is that not all environmental 
and cognitive variables that could influence health behaviour change, such as social 
pressures and stigma, are not taken into consideration (Rogers, 2010). In addition, it sub-
divides perceived efficacy into categories of response and self-efficacy may be inappropriate 
– patients may generally not consider themselves capable of performing adherent 
behaviours without the means to do so (Bandura, 1997). 
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2.9.5. Self-regulatory perspective 
The Self-regulation approach attempts to join environmental aspects and the cognitive 
responses to health threats (Leventhal, Leventhal & Contrada, 2007). The core of this theory 
relates to the importance of the patient’s own cognitive conceptualisation of their illness and 
treatment, and emphasises the necessity to examine individuals' subjective experience of 
health threats to understand the way in which they respond to these threats (Munro et al., 
2007). The theory is based on the assumption that people are active, self-regulating problem 
solvers motivated to avoid and treat health threats (Leventhal, Meyer & Nerenz, 1980; Hale, 
Treharne & Kitas, 2007). The perceptions and beliefs that patients have about their condition 
or therapy and their self-efficacy are seen as mediators between the illness and the 
behavioural response to their health risk (World Health Organization, 2003). Leventhal, 
Leventhal and Schaefer (1992) explain that patients create personal representations of their 
illness and its associated treatment, and it is these representations that guide their decision-
making and adherence behaviour. Adherence, according to this perspective, requires the 
belief that patients have the specific coping skills to manage in their own personal, social 
and cultural environment, the belief that the illness needs to be paid attention to and the 
adaption of their behaviour to improve their health (Edgar & Skinner, 2003; Benyamini, 
Gozlan & Kokia, 2004). However, the self-regulation theory offers little guidance related to 
the development and design of interventions that aim to curb non-adherence in the treatment 
of chronic conditions of promote positive health behaviours (Munro et al., (2007). While this 
approach seems innately suitable, there is a lack of specific suggestions as to how these 
processes would improve adherence (Reynolds, 2003; De Bruin, Sheeran, Kok, Hiemstra, 
Prins, Hospers & van Breukelen, 2012).  Baumeister and Heatherton (1996), also warn 
against under-regulation, where the patient doesn’t exert or manage self-control, as well as 
misregulation, where self-control is misguided or counterproductive, and therefore fails to 
lead to improved health outcomes.   
These models provide a useful conceptual framework for organising ideas about adherence 
(World Health Organization, 2003).  Each has its advantages and disadvantages, and no 
single perspective can universally describe and explain adherence behaviours. Regardless, 
these perspectives have the potential to both improve our understanding of adherence 
behaviours and inform the design of effective interventions to promote adherence to 
antidepressant treatment. Despite this, little empirical evidence was located on the 
effectiveness of these theories in promoting adherence to treatment in chronic conditions 
(Munro et al., 2007). More recent approaches that are simple, yet transferable and adaptable 
across heterogeneous chronic conditions and treatments, and consider the demands of 
following recommended health practices may provide more additional insight.  
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2.9.6.  Information Motivation Behavioural Skills Framework 
A more recently developed approach, the information–motivation–behavioural skills model 
(IMB model), borrowed ideas from previous works to develop a conceptually based, 
generalisable, and simple model to guide complex adherence behaviours (Fisher & Fisher, 
1992), and has been specifically tailored to designing interventions to promote adherence to 
ART (Fisher et al., 1996).  This theory has its roots in the Cognitive perspective, and focuses 
on three components that result in behaviour change: information, motivation and behaviour 
skills (World Health Organization, 2003; Munro et al., 2007): a) information, which is the 
basic knowledge about an illness, and may include how the disease progresses, its 
expected course and effective treatment options available; b) motivation, which 
encompasses the personal attitudes towards, perceived social support for, and the patients’ 
subjective perception of how others with the illness may behave and; c) behavioural skills 
(ability), which includes the specific tools or strategies necessary to perform the adherence 
behaviour such as social support and other self-regulation strategies. The components also 
need to be directly relevant to the desired behaviour to be effective (World Health 
Organization, 2003). Additionally, Fisher, Fisher, Amico & Harman (2006) identified a 
number of moderating factors such as psychological health (fear of stigma or discrimination), 
living situations, access to medical care and services, and substance use, which may affect 
adherence, and were subsequently included in this model.  
According to this theory, patients will adhere to their treatment if they are able to (possess 
the capability to follow instructions), has the information (the knowledge and understanding 
of their condition and treatment) and motivation (the attitude and beliefs about the condition 
and treatment), to engage in adherent behaviours (Fisher et al., 1996).  The IMB model 
demonstrates that information is a prerequisite for changing behaviour, but in itself is 
insufficient to achieve this change (Prochaska, DiClemente & Norcross, 1992). This is 
because this information is influenced by other treatment, illness or social factors that may 
affect adherence, and this needs to be taken into consideration. Motivation and behavioural 
skills are also key determinants and are independent of behaviour change and can also be 
moderated by a range of contextual factors such as living conditions and access to health 
services (Fisher & Fisher, 1992; Fisher, et al., 1996). Information and motivation work mainly 
through behavioural skills which in turn reduce the risk of non-adherent behaviours and, 
when the behavioural skills are uncomplicated or mastered, information and motivation can 
have direct effects on behaviour (Munro et al., 2007). The advantage of IMB lies in its 
simplicity as well as its recent moderately effective application and predictive value in ART 
adherence, which suggests that it may be a promising model for promoting adherence to 
other chronic medication therapies as well (World Health Organization, 2003; Amico, Toro-
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Alfonso & Fishe, 2005; Amico, Barta, Konkle-Parker, Fisher, Cornman, Shuper, Fisher et al., 
2009).  
Considering the advantages of the IMB model (simplicity, generalisability, inclusion of 
moderating factors), this approach was chosen to conceptualise and formulate health 
behaviours related to antidepressant medication adherence in the current study. The 
limitations from the Cognitive perspective were also taken into consideration. The current 
study included non-voluntary factors such as social structures that can affect adherence 
behaviour, as well as focusing on multiple competing threats to adherence behaviour. 
Furthermore, the relationships between the identified variables have been explicitly framed 
and definitions for the individual variables have been clearly formulated. The current study 
also does not rely on the assumption that these variables are not moderated by each other 
and are not simply additive in nature, but is cognisant that these variables influences, and 
are influenced by, several factors that are indirectly related to adherence. In addition, the 
current study also took into consideration environmental and cognitive variables that could 
influence health behaviour change, such as social pressures and stigma. However, other 
limitations of this approach such as patients’ origin of beliefs and positive effects of negative 
behaviours could not be addressed in the current study, and may warrant the need for 
additional investigation in this sample.  
Figure 2 illustrates the conceptualisation of the IMB model (adapted from Fisher et al., 2006) 
as it applies to antidepressant adherence within the scope of the current study.  
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Figure 2: IMB model (adapted from Fisher et al., 2006) 
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2.10. Chapter summary 
The term, adherence was defined in the current study by the application of the MMAQ-8, 
(Morisky, et al., 1986). This was followed by a background discussion of adherence in 
psychiatry. Evidence suggests that non-adherence to treatment is a tremendous barrier in 
health care and is estimated that between 25%-50% of all patients, irrespective of disease, 
prognosis or setting, are non-adherent to their treatment (Morris & Schulz, 1992; Sacket & 
Snow, 1979; Donovan, 1995; Vermeire et al., 2001; Vergouwen et al., 2003; Bambauer et 
al., 2006; Olfson et al., 2006). Some local evidence of non-adherence in psychiatry was also 
provided, however, this was limited. To date, there have been no large-scale studies that 
aim to objectively determine the rate of adherence to antidepressant medications in 
Gauteng, suggesting a shortage of local evidence measuring and describing non-adherent 
behaviours of psychiatric outpatients in this area.  A list of the pharmacological treatments 
identified in the current study was also provided in this chapter. A subsequent discussion on 
various common methods of adherence measuring instruments was provided (Moosa, 
2007). Empirical, descriptive, research that identified various correlates and predictors of 
adherence and non-adherence were also discussed in this chapter (Blackwell, 1996; Nichol 
et al., 1999; Vermeire et al., 2001; Cramer, 2004; Bulloch & Patten, 2010; Chong et al.,  
2011; Kardas et al., 2013), as well as providing an overview of the potential consequences 
of non-adherence in psychiatry. In the final section, the researcher discussed the 
behavioural theories that aim to describe, explain and predict non-adherence (World Health 
Organization, 2003; Munro et al., 2007), and provided the conceptual framework and 
definitions utilised by the current study.  
A tremendous research agenda still remains to understand non-adherent behaviours and to 
design effective interventions that are generalisable across settings and to address non-
adherence to antidepressant medications in psychiatric patients. More accurate, local 
estimations of the prevalence of non-adherence are also needed to address the different 
forms that this behaviour can take on. An improved understanding of adherence behaviour 
could lead to more comprehensive theoretical frameworks and models, and to more effective 
intervention methods of improving medication adherence in psychiatry. However, it was not 
within the scope of this study to recommend potential intervention methods to address non-
adherence in the current study sample, but to determine the rates and describe factors that 
contribute to non-adherence in a specific sample and provincial region of South Africa in 
sufficient detail.  
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CHAPTER 3 
RESEARCH METHODOLOGY 
3.1.  Introduction 
In this chapter, the researcher provides information on the research design and methods of 
this study. The survey research method has been chosen to determine the rate of non-
adherence to antidepressant medication, as well as the factors influencing non-adherence 
amongst psychiatric outpatients in Gauteng, South Africa. The area of study, population, 
sample of the population and sampling technique are described. Subsequently, the research 
instrument used in the study will be elaborated on, which includes a validated, self-reported 
measure of medication-taking behaviour. This is supplemented with additional items 
addressing the circumstances surrounding adherence behaviour. Data collection and data 
analysis procedures are also discussed in this chapter. Lastly, the limitations of the study are 
described.  
 
3.2.  Research questions 
The following research questions have been identified based on the aim of the study. In this 
study, we seek to determine the rates of medication non-adherence, with a specific focus on 
antidepressant medication, and to identify the variables that significantly influence non-
adherence rates in psychiatric outpatients in Johannesburg, Gauteng. With this in mind, two 
main research questions have been identified in the current study, and the second main 
research question has been divided into five more specific sub-questions. The current 
research questions are as follows:  
(1) What are the rates of non-adherence to antidepressant medication in a sample of 
psychiatric outpatients living in Johannesburg, Gauteng?  
2a) Which patient-related variables significantly correlate with antidepressant treatment 
adherence rates in this sample?  
2b) Which illness-related variables significantly correlate with antidepressant treatment 
adherence rates in this sample of psychiatric outpatients?  
2c) Which medication-related variables significantly correlate with antidepressant treatment 
adherence rates in this sample of psychiatric outpatients?  
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2d) Which health system-related variables significantly correlate with antidepressant 
treatment adherence rates in this sample of psychiatric outpatients?  
2e) Which moderating factor-related variables significantly correlate with antidepressant 
treatment adherence rates in this sample of psychiatric outpatients? 
 
3.3.  Study hypotheses 
Studies measuring non-adherence rates and identifying factors that contribute to non-
adherence varies widely in study design, assessment instruments, populations, psychiatric 
conditions, sampling selection methods, treatment settings and treatment regiments 
themselves (Pampallona et al., 2002; World Health Organization, 2003; Kane et al., 2013; 
Hung, 2014; Leo et al., 2005; Procyshyn, et al., 2010; Kardas et al., 2013; Perestelo-perez & 
Serrano-aguilar, 2013; Brown & Bussell, 2011). It is also apparent there is a great deal of 
variability across these studies as to which of these factors are statistically significantly 
correlated with treatment adherence rates. For example, literature previously cited 
suggested that non-adherence to treatment can be expected in approximately 30% – 50% of 
all patients, irrespective of disease, prognosis or setting (Morris & Schulz, 1992; Sacket & 
Snow, 1979; Donovan, 1995). Buckley, Foster and Patel (2009) noted that these rates 
increase further when specific psychiatric conditions such as depression (51 % - 69%), 
Schizophrenia  (30-60%), Bipolar Mood Disorder (21-50%) or other anxiety disorders (57%) 
are considered. In antidepressant medication specifically, Bulloch and Patten (2010) 
reported non-adherence rates of 45.9%. Additionally, of the twenty-four articles (published 
between 1966 and 2011) included in a systematic literature review of psychosocial and 
behavioural factors associated with medication adherence (Zeber et al.,  2013), only five 
indicated that gender was significantly associated with initial medication non-adherence, four 
of which in favour of males, and one indicating that females were more adherent than males. 
A South African study (Mahaye et al., 2012) measured antipsychotic medication adherence 
in a psychiatric outpatient setting in KwaZulu-Natal Province using the MMAQ-8, and also 
observed an insignificant association between gender and adherence. A review (Zeber et al., 
2013) noted that age, gender and race were only significantly associated with initial 
medication non-adherence in a very small number of the twenty-four studies included in their 
review (12, 5 and 3 respectively).  
When illness factors are considered, it was found that an earlier onset of diagnosis was 
significantly associated with antidepressant non-adherence within 6 months of initiating their 
treatment (p = .034), (Yau et al., 2014). Their (Yau et al., 2014) sample included n=189 
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patients newly dispensed with an antidepressant in a psychiatric outpatient clinic during 
2006 and 2007 in Hong Kong. To support their findings, Al-Jumah, Ahmad Hassali, El Tahir , 
and Al Qhatani  (2014), measured antidepressant medication adherence using the MMAQ-8  
among n=403 psychiatric outpatients in Saudi Arabia in a similar observational study design. 
He noted that a shorter duration of illness in and less depression severity (as measured by 
Montgomery–Åsberg Depression Scale), was associated with higher adherence levels. 
However, several authors report finding insignificant correlations between these illness 
factors, as well as other treatment-, health system- and moderating factors and treatment 
adherence (Pampallona et al., 2002; World Health Organization, 2003; Kane et al., 2013; 
Hung, 2014; Leo et al., 2005; Procyshyn, et al., 2010; Kardas et al., 2013; Perestelo-perez & 
Serrano-aguilar, 2013; Buckley et al., 2009; Zeber et al., 2013; Bauer et al., 2014; Zeber, 
Copeland, Good, Fine, Bauer & Kilbourne, 2008). In an attempt to answer the research 
questions stated above, research hypotheses need to be generated. The formulation of the 
current study hypotheses were informed by the literature cited in this study, and is briefly 
discussed in the following section. 
 
3.3.1. Formulation of study hypotheses 
These conflicting findings reported across the studies cited here presented challenges to the 
formulation of the study hypothesis or predicting the direction of significant correlations that 
may arise. For this reason, the researcher opted to identify the common factors informed by 
the literature and formulated individual study hypotheses for each variable related to these 
factors. However, Rice (1989) cautioned that tests for the statistical significance of individual 
components such as in the current study are often biased because it increases the 
probability of finding significant results (i.e., the null hypothesis is rejected when it is actually 
true, or a Type I error). This provided the motivation for the application of the Bonferroni-
Holm correction for multiple comparisons calculator (Holm, 1979). This sequentially rejective 
correction approach has a large probability of rejecting false hypotheses and strongly 
controls the family-wise error rate at level alpha (Holm, 1979). A significance value of p ≤ 
.002 was therefore used to specify the conditions under which the current study hypotheses 
would be rejected. The current study therefore called for a total of 25 hypotheses as five 
overall categories were identified (discussed in chapter 2), and each of these categories 
included five individual variables. Refer to Table 3 for an overview of the variables and an 
outline of the various statistical tests performed to test the different hypotheses of the current 
study. The assumptions of these statistical tests are outlined later in this chapter (see 
section 3.6.6. Data analysis). 
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Table 2: Variables and statistical tests performed to test study hypotheses 
 
 Main categories of variables 
Statistical 
test 
Patient-
related 
variables 
Illness-
related 
variables 
Medication -
related 
variables 
Health 
system-
related 
variables 
Moderating 
variables 
 
 
 
 
 
 
 
Individual 
variables 
a. Age b. Age of 
onset of 
diagnosis 
c. Illness 
duration 
c. Duration of 
current 
treatment 
  Pearson’s 
correlation 
coefficient 
b. Gender 
e. Treatment 
beliefs 
d. Prior 
hospitalisation   
(6 months) 
e. Perceived 
difficulty of 
condition 
d. Current 
experience of 
adverse 
reactions 
e. Knowledge to 
cope with 
adverse 
reactions 
a. Medical aid 
b. Social grant 
c. Prescribing 
practitioner 
d. Health care 
service type 
e. Require 
additional 
support 
e. Perceived 
stigma 
Independent 
sample t-test 
c. Race 
d. Home 
Language 
a. Main DSM-
IV-TR 
diagnosis 
a. Class of 
antidepressant 
b. Daily dosage 
 a. Employment 
status 
b. Education 
level 
c. Relationship 
status 
d. Living 
arrangements 
Analysis of 
variance 
(ANOVA) 
 
 
The null hypotheses for the five main variable categories are the following: 
A. Patient-related variables 
H1: Age is not significantly correlated with antidepressant adherence rates this sample of 
psychiatric outpatients in Gauteng Province of South Africa. 
H2: Gender is not significantly correlated with antidepressant adherence rates this sample of 
psychiatric outpatients in Gauteng Province of South Africa. 
H3: Race is not significantly correlated with antidepressant adherence rates this sample of 
psychiatric outpatients in Gauteng Province of South Africa. 
H4: Home language is not significantly correlated with antidepressant adherence rates this 
sample of psychiatric outpatients in Gauteng Province of South Africa. 
H5: Treatment beliefs is not significantly correlated with antidepressant adherence rates this 
sample of psychiatric outpatients in Gauteng Province of South Africa. 
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B. Illness-related variables. 
H6: Main DSM-IV-TR diagnosis is not significantly correlated with antidepressant adherence 
rates in this sample of psychiatric outpatients in Gauteng Province of South Africa. 
H7: Age of onset of diagnosis is not significantly correlated with antidepressant adherence 
rates in this sample of psychiatric outpatients in Gauteng Province of South Africa. 
H8: Illness duration is not significantly correlated with antidepressant adherence rates in this 
sample of psychiatric outpatients in Gauteng Province of South Africa. 
H9: Prior hospitalisation (6 months) is not significantly correlated with antidepressant 
adherence rates in this sample of psychiatric outpatients in Gauteng Province of South 
Africa. 
H10: Perceived difficulty psychiatric condition is not significantly correlated with 
antidepressant adherence rates in this sample of psychiatric outpatients in Gauteng 
Province of South Africa.  
 
 C. Treatment-related variables  
H11: Class of antidepressant is not significantly correlated with antidepressant adherence 
rates in this sample of psychiatric outpatients in Gauteng Province of South Africa. 
H12: Daily dosage is not significantly correlated with antidepressant adherence rates in this 
sample of psychiatric outpatients in Gauteng Province of South Africa. 
H13: Duration of current treatment is not significantly correlated with antidepressant 
adherence rates in this sample of psychiatric outpatients in Gauteng Province of South 
Africa. 
H14: Current experience of adverse reactions is not significantly correlated with 
antidepressant adherence rates in this sample of psychiatric outpatients in Gauteng 
Province of South Africa. 
H15: Knowledge to cope with adverse reactions is not significantly correlated with 
antidepressant adherence rates in this sample of psychiatric outpatients in Gauteng 
Province of South Africa. 
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 D. Health system-related variables  
H16: Medical aid is not significantly correlated with antidepressant adherence rates in this 
sample of psychiatric outpatients in Gauteng Province of South Africa. 
H17: Social grant is not significantly correlated with antidepressant adherence rates in this 
sample of psychiatric outpatients in Gauteng Province of South Africa in this sample of 
psychiatric outpatients in Gauteng Province of South Africa. 
H18: Prescribing practitioner is not significantly correlated with antidepressant adherence in 
this sample of psychiatric outpatients in Gauteng Province of South Africa. 
H19: Health care service type is not significantly correlated with antidepressant adherence 
rates in this sample of psychiatric outpatients in Gauteng Province of South Africa. 
H20: Requiring additional support is not significantly correlated with antidepressant 
adherence rates in this sample of psychiatric outpatients in Gauteng Province of South 
Africa. 
 
E. Moderating variables. 
H21: Employment status is not significantly correlated with antidepressant adherence rates in 
this sample of psychiatric outpatients in Gauteng Province of South Africa. 
H22: Education level is not significantly correlated with antidepressant adherence rates in this 
sample of psychiatric outpatients in Gauteng Province of South Africa. 
H23: Relationship status is not significantly correlated with antidepressant adherence rates in 
this sample of psychiatric outpatients in Gauteng Province of South Africa. 
H24: Living arrangements is not significantly correlated with antidepressant adherence rates 
in this sample of psychiatric outpatients in Gauteng Province of South Africa. 
H25: Perceived stigma is not significantly correlated with antidepressant adherence rates in 
this sample of psychiatric outpatients in Gauteng Province of South Africa. 
 
3.4.  Research paradigm 
In order to design a research study, it is important to answer the following questions 
(Cresswell, 1994; Cresswell, 2003; Groves, Fowler, Couper, Lepkowski, Singer & 
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Tourangeau, 2009; Goodwin, 2010; Bhattachejee, 2012): a) what epistemology (theory of 
knowledge embedded in the theoretical perspective) informs the research (e.g., 
objectivism)? b) what theoretical perspective (ontology) lies behind the methodology in 
questions (e.g., positivism)? c) what methodology (strategy or plan of action that links 
methods to outcomes) governs our choice and use of methods (e.g., survey research)? d)  
what methods(techniques and procedures) do we propose to use (e.g., questionnaire)? 
Weaver and Olson (2006, p. 460), define a paradigm as, “patterns of beliefs and practices 
that regulate enquiry within a discipline by providing lenses, frames and processes through 
which an investigation is accomplished”. Philosophically, researchers make claims about 
what is knowledge (ontology), how we know it (epistemology), and the processes for 
studying it (methodology), (Cresswell, 1994; Bhattachejee, 2012). In the positivist tradition 
(ontology), social scientists support the idea that the social sciences should match the 
methodology of the natural sciences. This is based on the analogy that society is not 
dissimilar from the human body, namely to “heal” the diseases of society (Babbie & Mouton, 
2011).  
Neuman (2011) describe positivist researchers as scientists who prefer precise quantitative 
data, often using techniques to collect, analyse and summarise data in numerical value, and 
focuses on measuring the rate and frequency of variables in a detailed and structured 
manner in which results can be organised and presented statistically.  Positivist social 
scientists also use experiments, survey and statistics in their search for rigorous measures 
and testing hypotheses (Neuman, 2011). According to Cresswell (2003), positivism adopts a 
deterministic philosophy where a) the problems studied reflect a need to examine causes 
that influence outcomes, b) it reduces phenomena and ideas into a small, discrete set of 
concepts to test, such as the variables that constitute hypotheses, c)  knowledge developed 
is based on careful observation and measurement of the objective reality that exists "out 
there" in the world, d)  developing numeric measures of observations and studying the 
behaviour of individuals are paramount, e) there are laws or theories that govern the world, 
and these need to be tested or verified. For the current research the researcher is concerned 
with observable and measurable phenomena involving people, events or things, the precise 
measurement and quantification through rigorous and controlled design and, determining the 
strength of the relationship between variables through statistical tests (Polit & Beck, 2010). 
In order to answer the research questions from the current study it is necessary for the 
researcher to gather information from a large number of people, generate quantifiable data 
and perform statistical tests on the variables. This positivist, objective, quantitative approach 
is best suited to answer the research questions of the current study, which is to determine 
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the rate of non-adherence to antidepressant medication and identify variables that influence 
these rates through descriptive and correlational statistical methods.  
 
3.5.  Research methodology 
From this quantitative approach to observing phenomena, descriptive, correlational studies 
are often utilised (Carson, 2005), when the goal is to provide an account of the 
characteristics of individuals, groups or behaviours that may inform more complex study 
designs. The overall aim of descriptive studies is to ‘discover new meaning, describe what 
exists, determine the frequency with which something occurs and categorize information’ 
(Burns and Grove, 1999: p. 24). According to Carson (2005), this kind of study uses 
descriptive statistics and reported on the frequency and percentage of various 
characteristics (i.e., medication-taking behaviour). In correlational research, the researcher 
purposefully sets out to examine relationships between variables and assesses the statistical 
relationship (i.e., the correlation) between them with little or no effort to control extraneous 
variables (Stangor, 2010). There are essentially two reasons why researchers are interested 
in statistical relationships between variables (Stangor, 2010): 1) they do not believe that the 
statistical relationship is a causal one (i.e., for example the statistical correlation between low 
adherence rates and prescribing practitioner does not necessarily prove prescribing 
practitioners cause low adherence rates), and 2) the statistical relationship of interest is 
thought to be causal, but the researcher cannot manipulate the independent variable 
because it is either impossible or impractical (i.e., it is likely there are variables that may 
influence adherence rates beyond  the scope of the current study).  Additionally, this method 
is used when researchers set out to generate hypotheses that can be tested in experimental 
research (Parahoo, 1997; Burns and Grove, 1999). One of the implications arising from 
correlational research is that it is able to inform the application of experimental study designs 
that typically set out to test interventions (i.e., to increase treatment adherence), (Carson, 
2005). 
A descriptive, correlational approach was used to gather information about adherence 
behaviour of groups of people in the current study, since we are concerned with defining and 
counting the frequency of variables such as responses among participants, and determine 
relationships between variables (Shields & Rangarajan, 2013). This approach fits within the 
aims of the study, which is to determine and describe the rate of non-adherence to 
antidepressant medication, and to identify variables that may have a significant correlation 
with non-adherence rates in this sample of psychiatric outpatients.   
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3.6. Research design 
According to Goodwin (2010), cross-sectional study designs take a between-subjects 
approach, comparing, for example the adherence rates of various groups of people who take 
a particular treatment. Cross-sectional studies measure variables at one point in time or 
across groups of individuals, usually of different ages (Howitt & Cramer, 2011). The scope of 
the current study is to determine the rate of non-adherence to antidepressant medication in 
psychiatric outpatients in a specific area, and to identify variables that may correlate with 
non-adherence rates. In the current study this research design has the advantage of 
enabling the researcher to measure a number of different variables at the same time.  Howitt 
and Cramer (2011) explain that in these study designs any of these variables might explain 
why something occurs, and it is likely that anything that we are interested in explaining will 
have a number of different causes rather than a single cause. Therefore, by measuring a 
number of different variables at the same point in time, it becomes possible to see which of 
the variables are most strongly related to what it is we are seeking to explain (Howitt & 
Cramer, 2011).  
 
3.7. Research method 
Bhattachejee (2012, p. 73) defines survey research as a “research method involving the use 
of standardized questionnaires or interviews to collect data about people and their 
preferences, thoughts, and behaviours in a systematic manner.” Social scientists often use 
survey research to analyse and evaluate behaviour consisting of predetermined questions 
that are given to a sample of a population (Shaughnessy, Zechmeister & Jeanne, 2011). The 
questions given to the sample group normally use a written questionnaire as the instrument 
or tool to collect the data (Bhattachejee, 2012). However, there are a variety of ways to 
obtain information through surveys. These include telephone surveys, interviews and 
electronic surveys such as email or internet-based (Goodwin, 2010).   Cozby and Bates 
(2012, p. 73), describes surveys as a way that researchers can obtain a snapshot of how 
people behave at a given point in time, relying on self-reported information.  Bhattachejee 
(2012), also states that survey designs can be descriptive, exploratory, or explanatory in 
nature. 
The current study had a specific focus on the antidepressant medication adherence 
behaviours of psychiatric outpatients. It is the purpose of this investigation to describe the 
rate of non-adherent behaviours to antidepressant medication, as well as determining the 
factors that influence non-adherence amongst psychiatric out-patients, particularly in the 
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Gauteng Province of South Africa. Using a survey research design allows the researcher to 
investigate the medication adherence behaviours of this specific group of people by 
collecting and analysing the data gathered from only a few people, the research sample, that 
is thought to be representative of the whole population. The findings of the research survey 
involving a statistically representative sample can then be considered to be generalisable to 
the whole population represented by the sample that was investigated. It is for this reason 
that this design was selected to guide the study rationale. A mixed-mode survey, i.e., 
collecting data from different forms of media, such as written questionnaires, telephone 
interviews and internet survey, was employed by the current study. Mixed-mode surveys 
allow the benefit increasing response rate from respondents, as well as limiting the exclusion 
of potential participants (Tobin et al., 2012). 
An invitation letter was sent via email to all patients on the SADAG registry at the time of the 
study. The letter provided a brief introduction of the study, explaining the nature, objectives, 
and the inclusion and exclusion criteria for taking part as well as the rights of participants. 
The invitation letter also provided patients with options to complete the survey questionnaire. 
This included an electronic link to the online survey questionnaire which patients could 
select, a toll-free telephone number and SMS number which patients could contact during 
office hours and, a fax number was also provided for additional contact methods. Potential 
participants could then choose which method suited them best. 
Bhattachejee (2012) mentions a number of strengths associated with survey research 
designs. Besides being useful for obtaining a variety of unobservable information, such as 
individuals’ attitudes, perceptions or behaviour, it is also ideally suited when collecting data 
about a large group. Furthermore, some respondents may prefer the unobtrusive and 
convenient nature of some of these more remote approaches of data collection.  They can 
respond to the survey questions typically at a time that is suitable for them or in a private 
setting. Finally, survey research is economical in terms of researchers’ time, effort and cost 
than most other methods. It is for this reason that a questionnaire was selected as the 
research tool for this study as it: requires less time and is easier to administer compared to 
many other study designs, and consequently less expensive; can be administered to a large 
group of people in a short period and, their confidentiality can be emphasised.  However, 
each study method has its own strengths and limitations, and survey research is not 
excluded from this. Numerous biases such as, sampling bias, social desirability, and recall 
bias also exist (Bhattachejee, 2012). These will be discussed in more detail, under Section 
3.6: Limitations, together with a discussion on how the researcher attempted to minimise the 
effects of these biases. 
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3.7.1. Population 
Coolican (2009:34) offers a broad definition of a population as “all the existing members of 
that group”.  Pavlichev (2004) defined the target population for a survey as the entire set of 
units for which the survey data are to be used and which the findings are meant to 
generalise. For this particular study the target population is defined as all individuals of 18 
years and older who were at the time of the study, prescribed at least one antidepressant 
medication and who resided in Gauteng Province in South Africa. The geographic 
boundaries of the target population include five (5) districts municipalities, and include the 
City of Johannesburg, City of Tshwane, Ekurhuleni Metropol, West Rand District and, 
Sedibeng District Municipalities (Statistics South Africa, 2011), as illustrated in Figure 3. 
Figure 3: District Municipalities of Gauteng Province, South Africa. 
*Image obtained from: http://www.localgovernment.co.za/provinces/view/3/gauteng 
The total size of the population for Gauteng Province was 12, 272, 263 (City of 
Johannesburg: 4, 434, 827; City of Tshwane: 2, 921, 488; Ekurhuleni Metropol: 3, 178, 470; 
West Rand District: 820, 995; Sedibeng District: 916, 484), (Statistics South Africa, 2011). 
The total size of the target population was determined based on the utilisation or prescription 
patterns of antidepressant medication in this specific region of the country.  The most recent, 
relevant literature available to the researcher at the time of the study was a drug utilisation 
review of antidepressant medication by Laher (2013). The review was conducted using 
information obtained from what was described as, “two (2) datasets from medical 
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warehousing companies” (Laher, 2013, p. ii). These datasets comprised of 1 year’s medical 
records from health care practitioners on prescriptions and patient information. Dataset A 
was collected in 2009, and dataset B in 2011. Although from different socio-economic areas 
(and time), both dataset sources originate from the Johannesburg Metropolitan District 
(Laher, 2013). Data from this review was collected from a total of 7394 patients who were 
prescribed antidepressants (Dataset A n=6 555 + Dataset B n=839), which comprises 
approximately 0.17% of the entire population of the Johannesburg area at that time 
(Statistics South Africa, 2011). 
Le Roux (2014) also described “off-label” prescription patterns of antidepressants among 
adults in South Africa. Although this study had a much larger sample (consisting of over 1, 
220, 289 patients), no provincial demarcation or description could be observed.  Burger, Van 
der Westhuizen, Lubbe, and Serfontein (2009) also conducted an analysis of prescribing 
patterns of antidepressants in South Africa, but focused on children and adolescents only, 
which is not within the scope of the study.  It is to the best of the researcher's knowledge that 
the investigation by Laher (2013) provided the most relevant and applicable information to 
provide a scope of the prescription patterns of antidepressants that is of interest to the 
current study. 
 
3.7.2. Sample and sampling procedure 
With a population size estimated to be n=7394, confidence level specified at 95% and 
confidence interval (margin of error) of 5%, the sample size was calculated to be 366. This 
calculation was done using four popular, free on-line sample-size calculators 
(SurveyMonkey, 2015; Creative Research Systems, 2015; aosoft, 2015; (Maple Tech, 2015). 
A consensus of 366 was found between three of the four calculators used, which motivated 
the researcher’s decision to estimate the size of the population. The excluded sample size 
calculator estimated a sample size of 367, and this difference is likely attributable to slight 
formulation or calculation differences.  
A non-probability, purposive sampling method was utilised in this particular investigation 
based on the time, financial and other resource limitations experienced by a researcher at 
this level. It allowed the investigator to collect a large amount of information in a relatively 
short time at a lower cost.  Random sampling of population is not possible due to the fact 
that participants have to self-identify and report taking antidepressant medication. Unlike 
other types of research in which random samples can be drawn (i.e., from a documented 
sampling frame), there is no ‘master list’ of individuals who are prescribed antidepressant 
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medication for Gauteng Province. Accordingly, the non-random sample in this study may not 
relate to the experiences of all the individuals who are receiving this particular 
pharmacological treatment. However, findings can be generalised to psychiatric outpatients 
who were living in Gauteng Province during this time.  
 
3.7.2.1. Nonprobability sampling technique  
Distinctive of non-probability sampling methods is that samples are chosen based on the 
investigator’s judgement, rather than random (Hughes, 2006). Some researchers view non-
probability sampling procedures as less “superior” when compared to probability sampling 
procedures, because they are not “truly” representative. This is because this sampling 
method does not give all individuals in the population an equal chance to be in the sample 
(Daniels, 2012). Despite this, there are still strong theoretical and practical reasons that 
motivate for their use. This sampling method is often used because the procedures used to 
select data from a sample are easier, quicker and cheaper when compared with probability 
sampling techniques (Howitt & Cramer, 2011). Researchers following a quantitative research 
design may feel that they are compelled to use non-probability sampling techniques due to 
some inability to use probability sampling (e.g., lack of access to a list of the population). 
However, in instances where it is not possible to use probability sampling techniques, non-
probability sampling provides, at least, a feasible alternative.  It ensures that the quantitative 
study design is not simply abandoned because meeting such criteria is time consuming and 
costly to the researcher. This has the potential to reduce the potential for researchers to 
study certain types of population, such as those that are vulnerable or difficult to reach (e.g., 
psychiatric patients), or in cases where a list of the entire population simply does not exist 
(Goodwin, 2010). 
Additionally, a researcher is not always practically able to gain a true random sample, and 
this technique can also be expensive. It is not within the scope or aim of this study to 
generalise the findings to the population as a whole. Information obtained from this non-
probabilistic study may still be valuable as it can contribute to the body of knowledge on this 
health issue. The credibility of findings can be improved by approximating random selection 
methods during sampling procedures, removing as many sources of bias as possible and 
comparing findings with investigations similar in design, nature and instruments. The 
researcher attempted to seek, identify and access the target group, inviting all (within the 
scope of the study) who the researcher had access to, and who were available and willing to 
participate. More information on how these techniques were employed by the current study 
can be found under the Limitations section of this chapter (3.6.5. Sampling method). Often, 
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given the objectives of a study, the nature of the research project, availability of time and 
financial resources, the population and sample size and characteristics, a non-probability 
sample design, for example, purposive sampling can be a favourable choice (Daniels, 2012). 
 
3.7.2.2. Purposive sampling 
Howitt and Cramer (2011, p. 432) describes purposive sampling as sampling “with a 
particular purpose in mind, such as when a particular sort of respondent is sought” rather 
than a representative sample. It is a type of haphazard sample obtained from predetermined 
types of individuals (Cozby & Bates, 2012). A purposive sample is a non-representative set 
of a larger population, and is fashioned to serve a very specific theoretical or practical need 
for a research study. For the current research project the researcher had a specific group in 
mind, (i.e., psychiatric outpatients currently prescribed at least one antidepressant 
medication). It was not possible to identify and target this entire study population due to a 
lack of information. This meant that the study  population are not all known and gaining 
access to patients were therefore difficult as it presented challenges in identifying potential 
participants. Daniels (2012) described circumstances in which non-probability sampling 
would be more favourable than probability sampling techniques. Non-probability sampling 
techniques such as purposive sampling used in this particular study may be more 
appropriate when the a) objectives of the study are explanatory or descriptive in nature, b) 
time is a valuable resource, c) there is a need to target specific groups in the population, d) 
there is no need to make inferences from the sample, e) the purpose of the study is to 
provide an illustrative example, f) a homogenous population that is difficult to access and, g) 
an accurate sampling frame is not available. 
The current study meets the above criteria as it provided an illustrative example that is 
descriptive in nature, the target population under investigation is difficult to access, an 
accurate sampling frame does not exist and, it is not within the scope of the study to 
generalise its findings to the broader population. These reasons motivated the researcher’s 
choice of sampling method.  
 
3.7.2.3. Inclusion and Exclusion Criteria 
The sampling frame included participants who were, at the time of the study:  
 living in Gauteng Province,  
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 18 years and older,  
 diagnosed with a psychiatric condition and,  
 prescribed at least one antidepressant medication.   
In terms of the Mental Health Care Act (MHCA) (South African Government, 2004), all  
psychiatric outpatients were considered voluntary health care service users, and therefore 
considered to have the capacity to make an informed decision about their own mental health 
care and also to give informed consent to participate in this investigation. However, patients 
who were admitted to hospital for their psychiatric condition and were being treated on an 
inpatient basis were not considered voluntary users and/or able to make informed decisions 
about their health. For this reason, patients who were treated as inpatients were excluded 
from the current study.       
 
3.7.3. Research Instrument 
3.7.3.1 Structured, non-clinical component 
A structured non-clinical (i.e. non clinician administered) questionnaire was developed that 
comprised of four sections to elicit specific information; 1) socio-demographic information, 2) 
information about diagnosis, and 3) medication. This was supplemented with a scientifically  
validated self-report 4) medication adherence scale (Morisky, Green, & Levine, 1986).  
The development of the questionnaire was informed by the conceptualisation framework of 
the study, and pilot tested locally at a psychiatric outpatient clinic at a public regional referral 
hospital in Johannesburg, Gauteng (Janse van Rensburg et al., 2014). Socio-demographical 
information included the following items: gender, age, race, marital status, living 
arrangements, employment status, educational level, main language, disability grant status 
and medical aid status.  
The clinical profile included items on type and duration of psychiatric diagnosis (according to 
DSM-IV-TR Axis I, II & III criteria), recent hospitalisation, prescribing practitioner, and 
perceived difficulty of their psychiatric condition. Information regarding medication included 
type, frequency of intake, duration and number of antidepressant medication they are 
currently taking, perceived adverse reactions, perceptions and beliefs about treatment and 
stigma associated with antidepressant medication.  
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3.7.3.2. Adherence rating scale component 
Adherence was measured using the eight-item Morisky Medication Adherence 
Questionnaire (MMAQ-8) in English which is an updated version of the original published 
version MMAQ-8 (Morisky et al., 1986), and one of the most commonly used self-report 
adherence scales (Lavsa, Holzworth & Ansani, 2011). Although the validity and reliability of 
the original scale were established in patients with hypertension, it has since also been 
validated in patients on tricyclic antidepressants (George, Peveler, Heilinger & Thompson 
(2000). Similar to the current study, Mahaye and colleagues (2012), investigated adherence 
to antipsychotic medication at an outpatient setting in KwaZulu-Natal Province, and also 
used the MMAQ-8. The need for contextual consensus also motivated the choice to use the 
MMAQ-8 in this particular investigation. The MMAQ-8 is a structured self-report measure of 
medication-taking behaviour that has been used widely in various countries, such as 
Germany, Brazil, Ethiopia, Nigeria, Malaysia and Iran,  and medical and psychiatric illnesses 
such as hypertension, diabetes, tuberculosis and mood disorders, in both inpatient and 
outpatient settings (De La Cuevas & Penate, 2015; Al-Qazaz, Hassali, Shafie, Sulaiman, 
Sundram & Morisly, 2010; Korb-Savoldelli, Gillaizeau, Pouchot, Lenain, Postel-Vinay, Plouin, 
Sabatier et al., 2012; Lee et al.,, 2013; Fadare, 2014;  Tesfay, Girma, Negash, Tesfaye, & 
Dehning, 2013; Jamous, 2014; Aikens et al., 2005; Lupattelli, Spigset, Björnsdóttir, Hämeen-
Anttila, Mårdby, Panchaud & Nordeng, 2015). 
According to Tan, Patel and Chang (2014, p. 1), the Morisky scale has advantages over 
other patient self-report adherence instruments due to its “widespread use in different 
diseases, populations and countries, high degree of concordance with pharmacy fill data or 
electronic monitoring devices, and does not contain many items, resulting in less response 
burden.” Additionally, the simplicity of questions and ease of scoring of instrument holds 
additional benefit, as it does not require a skilled professional to administer (Lavsa et al., 
2011). Each item on the MMAS measures a specific medication-taking behaviour (Morisky et 
al., 2008). Each of the first seven (7) items is presented in a dichotomous (“yes or no”) 
format, and the eighth (8th) question is answered on a five-point Likert-rating scale: 
(“never/rarely”, “once in a while”, “sometimes”, “usually”, and “all the time”).  According to 
Lavsa, et al,. (2011, p. 4), “patients generally want to answer yes when asked questions,  
and the questions in this scale are worded in such a way that answering yes identifies non-
adherent behaviours”. By “reversing the wording of the questions about the way patients 
might experience failure in following their medication regimen, since there is a tendency for 
patients to give their physicians or other health care providers positive answers.” (Morisky et 
al., 2008, p. 2).  
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To reduce response bias, the questions on the MMAQ-8 are phrased in such a way to 
reduce social desirability bias, where six (6) of the first seven (7) questions that must be 
answered negatively by responding “no”, and item five (5) answered positively by responding 
“yes”. Each ‘‘no’’ response in the scale for items 1 through 7 is scored as 1, and each ‘‘yes’’ 
response is scored as 0 (except for item 5 where each ‘‘yes’’ response is scored as 1 and 
each ‘‘no’’ response is scored as 0). For Item 8 on the five-point Likert-rating, the scores 0 to 
4 was standardised by dividing the result by 4 to calculate a summated score with a 
maximum of 8 (Morisky et al., 2008).  
It is worth noting that some consensus and discrepancies exist with regards to the 
categorisation or coding of the total scores or into different levels of adherence (i.e., high, 
medium/moderate and, low). Fadare's (2014) investigation in a Nigerian out-patient setting 
used the following codes/ categories to classify adherence levels; High: (0), Medium: (1-2), 
and Low (0>2). In the South African context, (Mahaye et al., 2012), trichotomised categories 
into: High (8), Moderate (5>7) and Low (0>4) in a psychiatric out-patient setting. However, in 
a validation study of a French version of the MMAQ-8 in hypertensive adults (Korb-Savoldelli 
et al., 2012), scores were categorised as Low (0 <6), Moderate/ Medium (6 to <8), and High 
(8). This categorisation was similar in an investigation by in patients with type-2 diabetes in 
Korea (Lee et al., 2013), a study in a Palestinian military setting (Jamous, 2014), a 
multinational, web-based study across 18 countries in Western, Northern, and Eastern 
Europe; North America; and Australia (Lupattelli et al., 2015), and, in a translation of the 
Malaysian version of the MMAQ-8 both used the same classification (Al-Qazaz et al., 2010). 
To support this, a recent validation study of the MMAQ-8 (Morisky et al., 2008) also 
categorised highly adherent patients with a total score of 8 on the scale, medium adherers 
had a score of 6 to <8, and low adherers a score of 0 <6. It is in support of the evidence 
above that the researcher was motivated to categorise adherence levels of the total MMAQ-
8 scores  of the current study into the following groups - Low (0 <6), Medium (6 to <8), and 
High (8) - as it is the most commonly utilised, implemented and scientifically supplemented 
categorisation. 
 
3.7.3.2.1. Validity and reliability of the medication adherence scale 
As previously mentioned, the scale was originally developed as a four-item self-report 
measure of adherence in patients with hypertension, and has been supplemented with 
additional items addressing the circumstances surrounding adherence behaviour (Morisky et 
al., 1986). More recently, (Morisky et al., 2008) the 8-item scale was found to be significantly 
correlated with the previously validated 4-item scale and had improved psychometric 
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properties, namely a Pearson correlation of 0.64; p <.05 and, Cronbach’s alpha value of 
0.83, (being above the acceptance threshold).  The MMAQ-8 was found to have a moderate 
level of reliability and high levels of concurrent and predictive validity, particularly in low-
income, minority patients, which was validated with a chemical marker for actual medication-
taking behaviour (Morisky et al., 1990).  
 
3.7.4. Data collection 
A database containing information on psychiatric out-patients from the South African 
Depression & Anxiety Group (SADAG) was accessed to invite potential participants to the 
study. The South African Depression and Anxiety Group (SADAG) is a non-profit, Section 21 
company established 20 years ago to provide mental health care advocacy to users across 
South Africa. SADAG is currently South Africa’s largest and most recognised advocacy 
initiative and support network for individuals and families affected by mental illness (See 
Appendix VI for Certificate of Registration). SADAG, routinely provides its members with, for 
example, different free telephonic counselling initiatives, such as the: Suicide Crisis Line; 
Trauma Line; Bipolar Helpline; Sleeping Disorder Helpline; Substance Abuse Helpline; 
Mental Health Helpline; and the Support Group Helpline. It also boasts with a national 
mental health referral service, and provides free mental health information. SADAG’s work is 
guided by a Scientific and Advisory Board of registered mental health professionals, 
including psychiatrists and psychologists, and functions closely with patients and other 
health care providers on an ongoing basis. Patients are often referred to SADAG after their 
discharge from hospital for additional information, telephone counselling and other support 
services such as support groups. These include patients diagnosed with various psychiatric 
conditions, and come from varying socio-economic backgrounds. Basic information is 
collected from patients when they contact SADAG for information or support (SADAG, 
2014).  
This information relates to patients; contact information, basic socio-demographical 
information such as gender, age, main language and Province of residence. It also includes 
some clinical information such as their primary DSM-IV-TR diagnosis, and the types of 
psychotropic medication they are prescribed. Although the DSM-5 (American Psychiatric 
Association, 2013) was already available a year prior to the current study, these revised 
diagnostic criteria was not yet widely used in South Africa, and the diagnoses recorded in 
this sample group was mostly done prior to the publishing of the DSM-5, and still relied upon 
the DSM-IV-TR (American Psychiatric Association, 2000) criteria. This provided the 
researcher enough justification to keep the research aligned to the DSM-IV-TR criteria.  
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The founder/director of SADAG granted approval for access to the database (Appendix V). 
After ethical clearance to conduct the study was obtained from the Ethics Committee of the 
Department of Psychology at UNISA (Appendix IV), potential participants were invited to 
participate.  
It is important that this information is routinely updated, and this occurs on an annual basis. 
In line with this organisational procedure, patients were contacted, introduced to the study 
and invited to participate. Signed informed consent was obtained from respondents via fax or 
email before data collection commenced. Once informed consent had been received 
(Appendix I), participants were assigned a coded participant number and were requested to 
complete the structured, non-clinical questionnaire (Appendix II). The survey was completed 
in one of three formats or modes that were deemed most convenient for the participant, 
(telephone interview, and self-completed paper-and-pen based or online / web-based).  
Participants’ responses were captured and coded according to the structured datasheet 
(Appendix III) in a designated database using the Statistical Package for the Social Sciences 
(SPSS) ® computer software version 22. Data collection commenced in October, 2014, after 
ethical approval was obtained, and invitations to participate in the survey were sent to a total 
of n=635 patients. Reminders were sent during the second, fourth and seventh weeks of 
data collection, and data collection stopped in December 2014.  
During this process, follow-up telephone calls were made to respondents who had 
incomplete information or missing items, in an attempt to minimise the impact of incomplete 
survey data as much as possible. Despite the investigators’ utmost efforts, not all missing 
information could be obtained, and such cases were therefore excluded from the analysis. 
Respondents who did not meet the inclusion criteria were then extracted from the database. 
The total number of patients that were included in the final analysis of the study was n=377. 
Figure 4 outlines the framework used to extract the relevant data from the completed 
database.    
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Figure 4: Data extraction framework 
 
3.7.5. Data analysis 
The data analysis assessed the mode in which participants completed the survey (manually, 
telephone or on-line), as well as demographic information such as age and age group, sex, 
main language spoken at home, relationship status, race, living arrangements, medical aid 
and social grant status, educational level. Clinical information included type of DSM-IV-TR 
Axis I, II and II diagnosis (grouped into mood-, anxiety-, substance use or abuse-, psychotic-, 
personality disorders, general medical conditions and conditions normally diagnosed during 
childhood and adolescence), duration lived with diagnoses (in months), hospitalisation within 
the six months prior to the data collection and perceived difficulty of their psychiatric 
condition. According to the literature cited in Chapter 2, the above mentioned variables may 
contribute to non-adherence to treatment in psychiatric conditions. The aim of the analysis 
was to determine if these variables were not only significantly correlated with adherence to 
antidepressant medications in this study sample, but also to determine if significant 
correlations existed between these variables. 
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Medication information assessed included the type of psychotropic medication currently 
taken. For analysis purposes, medications were divided into the common groups of 
psychotropic drugs, according to the Monthly Index of Medicine Specialities (MIMS), 
September 2014: antidepressants (tricyclic antidepressants, monoamine oxidise inhibitors 
(MAOI), selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine 
selective reuptake inhibitors (SNSRIs), norepinephrine and dopamine reuptake inhibitors 
(NDRIs), melatonergic agents and, lithium. The duration of current pharmacological 
treatment medication use (in months), was recorded, the prescribing practitioner and 
whether the patient was receiving private or public health care treatment, and the frequency 
of medication intake. Whether patients perceived any adverse reaction from their 
antidepressant treatment was also assessed, along with knowledge of how to cope with any 
potential adverse reactions. Beliefs about their medication and perceived stigma were also 
assessed. 
The information obtained through the research instrument was collected, coded and stored 
on the Statistical Package for Social Sciences (SPSS) V20.0 software (IBM® SPSS® 
Statistics), for analysis. All categorical and numerical variables were analysed and described 
using standard descriptive and correlational methods. Descriptive results were expressed as 
frequencies (n=), and percentages (%) of the sample. Between-group tests were conducted 
using the Chi-square χ2 test to assess the relationships between categorical variables. 
Fisher’s exact test was used for 2 x 2 tables or where the requirements for the χ2 test could 
not be met. The relationship between continuous and categorical variables was assessed by 
the t-test or ANOVA for more than two categories. The relationship between two continuous 
variables was assessed by Pearson’s correlation coefficient. The accepted level of 
significance (alpha level and p-value) was < .05 for the appropriate statistical tests, and 2-
tailed level of significance was reported on. 
Normality was assessed to determine sample skewness and kurtosis and testing 
significance using the Shapiro-Wilk test (Bland, 2000). The total score on the MMAQ-8 scale 
was treated as the dependant variable across three independent variables (gender, age 
category and language). For gender (male and female), the results showed a statistically 
insignificant deviation from the normal distribution (p = .26). Similarly, statistical insignificant 
deviations across the five different age categories (18 – 29 years; 30 – 39 years; 40 – 49 
years; 50 – 59 years; 60 years and older), as well as the three main race groups (Black; 
White and other South Africans) were also found (p  = .48 and p = .511 respectively). 
Therefore, parametric correlational statistical tests were used where appropriate.  To 
minimise the impact of outlying variables on the study results, those who indicated the spoke 
languages other than Afrikaans or English comprised only a small percentage of the study 
 72 
 
sample (11.4%), and were grouped into the “other official SA languages” category (i.e., 
Northern Sotho: n=6; Sotho: n=10; Swazi: n=3; Tswana: n=8; Venda: n=1; Xhosa: n5; and 
Zulu: n=10). Similarly, patients who indicated they were Coloured (n=23), Indian (n=7) or 
Mixed race (n=2) were also grouped into the “other SA populations”. Data from a total of 
n=377 participants were included for the final analysis of the data.  
 
3.8. Limitations of the study 
Controversy still remains regarding the measurement of adherence in patients, as there is 
currently no “gold standard” to assess these rates (Vitolins, Rand, Rapp, Ribisl, & Sevick, 
2000; Dolder, Lacro, Dunn, & Jeste, 2002; Culig & Leppée, 2014). Therefore, each 
adherence measurement approach has its own strengths and weaknesses, and each rests 
on the judgement of the investigator and the nature of the study. Although self-report 
measures are easy-to-use, inexpensive, useful and convenient tools for measuring 
adherence, especially in certain study designs such as the current observational study, they 
are also subject to measurement bias such as social desirability, recall bias and response 
bias (Shi et al., 2010), which are discussed below. 
 
3.8.1. Self-reporting of adherence  
There have been mixed findings about the accuracy of self-reported or subjective 
measurement of adherence to medication. There is also strong evidence to support its 
validity (McDonald, Garg & Haynes, 2002; Farmer, 1999). Recent investigations have found 
that self-reporting questionnaires actually show a moderate-to-high concordance when 
compared with electronic-based monitoring systems  (Garber, Nau, Erickson, Aikens, & 
Lawrence, 2004; Shi et al., 2010). Self-reporting on medication was also reported to be an 
acceptably valid measure of adherence in psychiatric patients when compared to their 
objective measurement (blood serum levels) (Jónsdóttir, Opjordsmoen, Birkenaes, Engh, 
Ringen, Vaskinn, Andreassen, 2010). Although these particular studies did not look at the 
MMAQ-8 specifically as self-report instrument, and it is true that the type of self-report used 
may matter when comparing with non-self-reporting measures (Garber et al., 2004), Krousel-
Wood, Islam, Webber, Re, Morisky and Muntner (2009) did find a statistically significant 
correlation (r = 0.46; p < .001) between the MMAQ-8 scale and pharmacy script rates. 
Additionally, Osterberg & Blaschke (2005) concluded that self-reports can easily and 
effectively measure adherence. Furthermore, it has been reported that self-reporting on 
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medication is a reasonably valid measure of adherence in psychiatric outpatients when 
compared with an objective measurement of blood serum levels (Garber et al., 2004; 
Jónsdóttir et al., 2010), as well as with other objective measures of adherence in several 
different illness populations (Krousel-Wood et al., 2009; Nguyen, La Caze, & Cottrell, 2014).  
 
3.8.2. Social desirability 
Crutzen and Göritz (2010) described social desirability as intentional deception by 
individuals when there is some perceived negative consequence of admitting to non-
adherence. Patients may provide inaccurate or biased (typically in a positive way or 
upwardly) information regarding their medication-taking behaviour (Morisky & Dimatteo, 
2011). Patients may therefore have the tendency to distort their responses according to the 
perceived expectations of health care providers (Furr, 2010).  
If a patient says that he or she is not taking their medication, it would, almost certainly, be 
safe to believe them.  However, patients who claim to be adherent to their treatment may be 
underreporting their non-adherent behaviours to avoid any potentially negative associations 
such as health care provider disapproval. However, it was clearly and explicitly stated 
(during the informed consent procedure, beginning of the survey questionnaire as well as 
prior to completing the adherence scale component) that patients need not fear any negative 
outcomes or repercussions based on the information the information they provide. This 
method was employed in an attempt to reduce the bias of social desirability in the current 
study. 
This tendency of individuals to distort responses (typically in a positive way or upwardly 
biased) that are, according to them, consistent with what is expected of them is what 
Crutzen and Göritz (2010) described as social desirability. To minimise the potential impact 
of potential social desirability bias in the current study, a brief message was presented to 
patients before completing the adherence scale component of the research instrument. 
Assurance was provided that their responses would not count against them in any way, that 
no personal information is linked to their responses, which was protected by assigning a 
unique identifier to all participants, and that they would continue to receive their treatment 
regardless of their responses on the survey questionnaire. They were reminded that it was to 
the benefit of the study that they be honest in their responses. It is worth noting that the 
research was not able to infer the levels of social desirability of participants in the study due 
to the largely remote nature of investigation.  
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3.8.3. Recall bias 
Alternatively, patients may also have the tendency to recall/ remember incorrectly when or 
whether they took their medications (recall bias), therefore making inaccurate attributions 
about the origins of memories, knowledge and their beliefs about their medication-taking 
behaviour (Delgado-Rodríguez & Llorca, 2004). Individuals may find it even more difficult to 
remember or accurately retrieve events that happened in the past if a long period has 
passed between the time of the event and the time of recall (Lupattelli et al., 2015). 
Research investigations of past events may therefore be susceptible to the restrictions of a 
patient’s memory, as well as the potential influence of their illness (or treatment) on his or 
her memory (Hassan, 2005). . This means that the data being collected can be flawed, and 
thereby unreliable (Hasssan, 2005; Pannucci & Wilkins, 2010). To minimise the potential 
impact recall bias may have on data from the current study, some methodological 
approaches were considered such as the use of standardised and pilot-tested 
questionnaires and reduced length of recall period where possible. 
Standardised questionnaires are tested across different setting on different populations, and 
the development of such tests aim specifically to reduce any bias that may influence the 
collection of data. The current study utilised a scientifically validated adherence measuring 
instrument tested across different populations, settings, illnesses and treatments (Toll et al., 
2007; Tan, Patel  & Chang, 2014; Suárez et al., 2011; Mahaye et al., 2012; Lavsa, et al., 
2011). This instrument also does not enquire about very specific information that may have 
occurred a long time ago. In cases where patients were asked to recall a specific event 
(such as when they missed a dose of their prescribed antidepressant), they were not 
expected to recall specific information that occurred more than two weeks prior to the study. 
Additionally, Coughlin (1990) stated that aspects such as interviewing technique and the 
motivation of respondents are methods that play a central role in reducing recall bias. These 
aspects are also under the control of the investigator, and were carefully considered during 
the data collection phase. The current study attempted to address these issues by also 
relying upon and adhering to a semi-structured, non-clinician administered questionnaire that 
was previously pilot-tested in public psychiatric outpatient setting in Johannesburg, Gauteng 
(Janse van rensburg et al., 2014), which should be similar to the current study target 
population. As previously mentioned, assurance was provided to participants that their 
responses would not count against them in any way, that no personal information is linked to 
their responses, and that they would continue to receive their treatment regardless of their 
responses on the survey questionnaire. This served as a motivation for patients to provide 
honest answers as there would be no negative consequences to them.  
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3.8.4. Interviewer bias 
Interviewer bias is described by Privitera (2013), as the tendency for the approach, words, or 
expressions of a researcher to influence the responses of a participant when they are in 
contact. These aspects also highlight the importance of investigator skills and 
characteristics. Recognition and awareness of this bias by the researcher, attention to the 
characteristics of the respondents and, adequate training will maximize the accuracy of the 
survey findings. Researcher selection, training, skills and approach to questioning are 
therefore key determinants of the quality of the data that is being collected and play an 
important role in reducing this potential bias. The researcher undertook training in 
administering this specific questionnaire in similar psychiatric outpatient settings. 
Additionally, the researcher was also involved in the pilot-testing of the questionnaire.  
 
3.8.5. Sampling method 
This relates to information gathered in a process that does not give all the individuals in the 
population equal chances of being selected (non-random sampling method), (Bhattachejee, 
2012). The sampling method in this particular study is not random, and the results may not 
be generalisable to the general public. However, the findings from the current study may be 
generalisable to the specific sub-population of psychiatric outpatients receiving 
antidepressants and, who live in the Gauteng Province of South Africa. Participants were 
selected on the basis of the purposive judgment of the researcher the ability to access a 
large number of potential participants who are difficult to identify or target. However, Daniel 
(2012) stated that in certain investigations, not dissimilar from the current study,  non-
probability sampling may actually be a methodological strength; when the nature of the study 
has a descriptive or exploratory purpose, when time is a limited resource, when a very 
specific target population needs to be reached, when the aim is not to make statistical 
inferences and generalise, when an accurate sampling frame is not available and, when 
ease of procedural and practical implementation is of importance. The reader can refer back 
to section 3.5.2.2. as to how these issues relate to the current investigation.  
 
3.9. Ethical considerations 
The current study was conducted according to the ethical guidelines and principles of the 
international Declaration of Helsinki (World Medical Association, 2013).Participants were 
protected by informing them of the nature and purpose of the research, their rights and that 
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their participation was on a voluntary basis. In the current study, the researcher 
acknowledged the rights of the respondents to choose to participate in the study by 
explaining the purpose and informing them of their rights regarding their participation and 
withdrawal during the process. Potential participants were given the opportunity to decide 
voluntarily whether to take part in the study or not. Other than the possibility that participants 
may potentially feel inconvenienced by the survey, no additional expected risks were 
anticipated with taking part in this research. This possible inconvenience was likely to be 
minimal as the survey was kept brief and took approximately ten to fifteen minutes to 
complete. Furthermore the questionnaire could be completed at any convenient time, place 
and in one of three modes that was convenient to potential respondents. Additionally, 
participants could possibly experience slight psychological discomfort by divulging personal 
information for research purposes. Emphasis was placed on the anonymous and confidential 
nature of the information during the introduction of the study and informed consent form. The 
SADAG 24-hour emergency helpline number was also provided to all participants if they felt 
they needed support. Confidentiality of participant information was maintained by using a 
unique coded identifier for participants during the entire research process. No names were 
linked to the information at any point, and all results were reported anonymously.  
 
3.9.1. Confidentiality 
Confidentiality was maintained by using a unique coded identifier for participants during the 
entire research process. No names were linked to the information at any point, and all 
results were reported anonymously. This confidentiality agreement (Appendix II) was clearly 
stated in the informed consent form provided to the participants. Only the researcher was 
able to identify participants and, all files and data were kept in a password-protected 
computer and locked filing cabinet at SADAG premises to ensure safety of information. 
 
3.9.2. Informed consent 
Respondents should never be deceived or lied to when they participate in a study. Before 
completing the questionnaire, participants were asked to read and sign a patient information 
and informed consent form. This form included clearly articulated information about the aim 
of the study and how the results were to be used, the voluntary nature of participation, 
freedom to withdraw at any time and assurance of confidentiality. It was clearly stated that 
by completing the form, informed consent was being granted by participants to take part in 
 77 
 
the study. The nature and purpose of the study were explained to potential participants in 
their own language and at their level of understanding, and they were given the opportunity 
to have any questions they might have had answered satisfactory. However, the research 
instrument was only made available in the English language. 
 
The following was clearly and explicitly explained verbally so that participants were fully 
aware of the following key aspects relating to this study:     
i. The goal and reason for conducting the research  
ii. How long research may take and what is required from them 
iii. How it was to be done, e.g. questionnaire/interviews 
iv. Any possible risks and/or benefits of taking part 
v. The right to withdraw at any time without any negative repercussions 
vi. Measures taken to ensure personal information is kept safe 
 
3.9.3. Non-maleficence, beneficence and justice 
All participants were treated with respect during the research process. Further consideration 
by the researcher was kept in mind to limit any potential emotional harm to participants. 
Careful attention was paid to the emotional state of participants during any contact sessions. 
If any questions in the interview made participants feel uncomfortable or the topic became 
too sensitive, they were given the choice to stop, withdraw, continue at another time, or 
make use of the counselling or support group services. A SADAG toll-free helpline number 
was also provided in the unlikely event of a participant experiences an emergency situation 
during the completion of the questionnaire and follow-up and referral services were 
facilitated. This supported the patients’ right to access health care if needed and could assist 
patients with emergency referral services to their closest, relevant health care provider.   
 
3.9.4.    Voluntary participation 
The right to self-determination is based on the principle of respect for persons taking part in 
research studies. It means participants had the right to decide themselves whether to 
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participate in any study or not, without being penalised in any way (Brink, 1996). As 
psychiatric outpatients, participants of 18 years and older are (according to the Mental 
Health Care Act (South African Government, 2004)), considered voluntary users of health 
care services. In the initial dialogue between the researcher and the prospective participant, 
the researcher asked the participant if they wanted to take part in the study without forcing or 
coercing them in any way. In essence, the researcher adhered to the principle of voluntary 
participation, which states that patients should participate only by free and informed choice. 
In addition, participants were notified that they were free to leave the study at any time, 
whether or not the questionnaire was completed. 
 
3.9. Chapter summary 
The researcher provided information on the research design and methods of this study. A 
quantitative, descriptive survey research method was chosen to determine the rate of non-
adherence to antidepressant medication, as well as the factors influencing non-adherence 
amongst psychiatric out-patients in Gauteng, South Africa. The area of study, population, 
sample of the population and sampling technique were also described. The current study 
took place in the Gauteng Province of South Africa, and the target population was identified 
as psychiatric outpatients who were, at the time of the study, prescribed (in part) least one 
antidepressant medication. Purposive sampling technique was utilised to identify and reach 
the target sample. Subsequently, the research instrument used in the current study was 
elaborated on (structured, non-clinical questionnaire), which included a validated, self-
reported measure of medication-taking behaviour (MMAQ-8). Data collection and data 
analysis procedures were also discussed, and concluded with the study limitations and 
ethical considerations.   
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CHAPTER 4 
RESULTS 
4.1. Introduction 
This chapter reports and discusses the findings of the investigation phase of this research 
study. The purpose of this study was to determine levels of antidepressant medication 
adherence amongst psychiatric outpatients in Gauteng, and identify possible factors that 
may contribute to this non-adherence. Non-adherence to medication is a significant public 
health concern that prevents patients from realising the full benefits of their treatment, and 
negatively impacts on individuals, their families and the health care system (World Health 
Organization, 2003). The researcher is therefore of the opinion that it is important to 
determine the rates of non-adherence to antidepressants and identify possible factors that 
may contribute to this; as a lack of this information presents a key challenge to quality care 
for patients with psychiatric disorders currently prescribed this medication. In line with the 
objectives of the study discussed in the previous chapter, the following section will report on 
the results of the current study by: a) describing the socio-demographical, clinical profile and 
medication information of psychiatric outpatients who completed the survey; b) reporting on 
the levels of non-adherence to antidepressant medications of this sample of psychiatric 
outpatients; and c) identify variables relating to patient characteristics, psychiatric condition, 
antidepressant treatment, health system and moderating variables that have a significant 
influence antidepressant adherence rates. 
 
4.2. Data analysis 
The data were analysed using the SPSS® version 22. Data was coded from the structured, 
non-clinical questionnaire completed by psychiatric outpatients who were prescribed at least 
one antidepressant medication. Patient demographics, clinical and medication information 
and possible contributors to non-adherence rates of patients for all categorical and numerical 
variables were analysed and described using descriptive and, where indicated, correlational 
statistical methods. Between-group tests were conducted using the Chi-square χ2 test to 
assess the relationships between categorical variables. Fisher’s exact test was used for 2 x 
2 tables or where the requirements for the χ2 test could not be met. The relationship 
between continuous and categorical variables was assessed by the t-test or ANOVA for 
more than two categories. The relationship between two continuous variables was assessed 
by Pearson’s correlation coefficient. Due to the many study hypotheses, the Bonferroni-Holm 
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correction for multiple comparisons calculator was applied, which has a large probability of 
rejecting false hypotheses and strongly controls the family-wise error rate at level alpha 
(Holm, 1979). A significance value of p ≤ .002 was therefore used to specify the conditions 
under which the current study hypotheses would be rejected. 
 
4.3. Results 
 4.3.1. Sample 
The majority of the patients were female (79.58%; n=300), between 18 and 39 years of age 
(57.3%; n=116), English speaking (57.56%; n=217), married (n=143; 37.93%) and living with 
their family (n=165; 43.77%), completed a diploma or degree (40.85%; n=154) and were 
employed full-time (56.5%; n=213), as well as having access to medical aid support 
(67.37%; n=254).  The majority of patients completed the survey questionnaire through the 
online method (81.43%; n= 307). 
Table 3: Summary of socio-demographical information of the total sample of psychiatric outpatients in Gauteng (n=377). 
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4.3.2. Medication adherence questionnaire 
The total scores on the MMAQ-8 ranged between a minimum of 0.25 and 8. The average 
score for the total sample of n=377 psychiatric outpatients in the current study was 5.59 (SD 
=2.08), suggesting low levels of antidepressant adherence rates in general across the entire 
sample. More specifically, nearly half of all patients (n=180; 47.7%) reported with low 
antidepressant medication adherence rates, while a third of psychiatric outpatients reported 
with medium levels of adherence, and only a fifth of all patients reported with high rates of 
antidepressant medication adherence. This is illustrated in Figure 5. 
Figure 5: Distribution of antidepressant adherence rates of the total sample of psychiatric outpatients in 
Gauteng (n=377)
 
 
The literature previously cited suggested that non-adherence to treatment can be expected 
in approximately 30% – 50% of all patients, irrespective of disease, prognosis or setting 
(Morris & Schulz, 1992; Sacket & Snow, 1979; Donovan, 1995; Buckley, Foster and Patel 
(2009) noted that these rates increase further when specific psychiatric conditions such as 
depression (51 % - 69%), Schizophrenia  (30-60%), Bipolar Mood Disorder (21-50%) or 
other anxiety disorders (57%) are considered. In antidepressant medication specifically, 
Bulloch and Patten (2010) reported non-adherence rates of 45.9%.  Locally, Mahaye, et al. 
(2012) reported low adherence in 37% in a sample of psychiatric outpatients in the KwaZulu-
Natal Province using the same adherence measuring instrument as the current study 
(MMAQ-8). However, they (Mahaye et al., 2012) focused on antipsychotic medication in a 
smaller sample (n=92) of schizophrenic patients specifically. Furthermore, Janse van 
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Rensburg (2007) noted that nearly half (47%) of patients admitted to a general public 
hospital in Gauteng for any psychiatric disorder were non-adherent to their respective 
medications at that time (Janse van Rensburg, 2007). The results from the current study 
suggests that non-adherence to antidepressant medication in this sample of psychiatric 
outpatients reflect that of findings reported in both international and local contexts. This 
lends strength to the current study argument that non-adherence to antidepressant 
medication presents a significant concern in local psychiatric outpatient settings.  
In response to Question 8, patients were asked to rate on a five-point Likert scale how often 
they have difficulty remembering to take their antidepressant medication. Although nearly 
half of patients indicated that they never or rarely forget to take their antidepressant 
medication (n=187; 49.6%), the other half of the sample did however report increased 
difficulty in remembering to take their medication at the prescribed treatment regime. This is 
still a significant proportion of patients that could benefit from targeted adherence 
interventions. Question 1 and 8 in this scale support each other in the measurement of 
medication taking behaviour by firstly determining the scope of antidepressant non-
adherence, and secondly determining the degree to which these behaviours occur among 
psychiatric outpatients. In addition, more than one in ten patients reported that they did not 
take their antidepressant medication the day prior to completing the survey questionnaire 
(n=52; 13.8%).  Furthermore, more than a third of psychiatric outpatients (n=140; 37.13%) 
indicated that they missed a daily dose of their medication in the two weeks preceding the 
study.  
The current study did not dichotomously group patients into adherent and non-adherent 
categories, but instead complied with the MMAQ-8 scoring guidelines that grouped patients 
into three adherence categories namely, low-, medium- and high adherence. However, 
responses from specific questions on the MMAQ-8 may be used to categorise patients as 
non-adherent. For example, it may be stated that 13.8% of psychiatric outpatients were non-
adherent to their antidepressant medication the day prior to completing the survey 
questionnaire. Additionally, it can be stated that more than a third of psychiatric outpatients 
(n=140; 37.13%) were non-adherent two weeks preceding the study. Finally, nearly half of 
the patients indicated that they are sometimes non-adherent to their antidepressant 
medication (n=183; 48.54%). Table 4 provides the distribution of the total sample of 
psychiatric outpatients’ responses to the 8-item self-report medication adherence 
questionnaire (MMAQ-8) in frequencies and percentages of the total study sample. During 
data collection, specific reference to antidepressant medication was made.  
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Table 4: Distribution of responses to the MMAQ-8
*
 by psychiatric outpatients in Gauteng (n=377) 
Self-report Medication Adherence 
Questionnaire Questions Response Frequency (n=) Percentage (%) 
1. Do you sometimes forget to take 
your medication? 
Yes 183 48.5 
No 194 51.5 
2. Were there any days during the 
past 2 weeks when you did not take 
your medication? (ed.) 
Yes 140 37.1 
No 237 62.9 
3. Have you ever cut back or stopped 
taking your medication without 
telling your doctor because you felt 
worse when you took it? 
Yes 123 32.6 
No 254 67.4 
4. When you travel or leave home, do 
you sometimes forget to bring 
along your medication 
Yes 87 23.1 
No 290 76.9 
5. Did you take your medication(s) 
yesterday? 
Yes 52 13.8 
No 325 86.2 
6. When you feel like your symptoms 
are under control, do you 
sometimes stop taking your 
medication? 
Yes 114 30.2 
No 263 69.8 
7. Taking medication every day is a 
real inconvenience for some 
people. Do you ever feel hassled 
about sticking to your treatment 
plan? 
Yes 138 36.6 
No 239 63.4 
8. How often do you have difficulty 
remembering to take all your 
medicine? 
Never/ rarely 187 49.6 
Once in a while 112 29.7 
Sometimes 55 14.6 
Usually 21 5.6 
All the time 2 .5 
* Morisky, Green & Levine, 1986.  
 
In response to Question 1 patients were asked if they “sometimes forget to take” their 
antidepressant medication. Nearly half of the patients indicated that they do sometimes 
forget to take their medication (n=183; 48.54%). This is the most frequently reported reason 
for non-adherent behaviour in this particular sample of psychiatric outpatients. Other 
frequently reported reasons  for non-adherence to antidepressant medication as measured 
by the MMAQ-8 includes: “feel(ing) hassled about sticking to their antidepressant treatment 
plan”, (n=138; 36.6%),  “cut(ting) back or stopped taking antidepressant medication without 
telling their doctor because they felt worse when they took it”, (n=123; 32.62%), or 
“stop(ped) taking antidepressant medication when feeling like symptoms were under control” 
(n=114; 30.2%).  
Based on the high rates of poor adherence behaviours observed in the current study, it 
appears that non-adherence to antidepressant medication in psychiatric outpatients 
represents a significant health concern. The following chapter discusses these findings and 
provides recommendations that may be relevant to the target population.  
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The majority of the participants preferred to complete the survey questionnaire on-line 
(81.43%; n= 307), while 13.53% (n=51) completed the questionnaire telephonically, and 
5.04% (n=19) completed it manually (pen-and-paper). The large proportion of on-line 
responses could be attributed to several factors; Firstly, the primary recruitment method was 
through online advertising on a website, which provided an electronic link to the survey 
questionnaire and may have facilitated convenience;  secondly, compared to other modes of 
completion, the online mode provided more anonymity to participants, which may have been 
more suitable to them; thirdly, the majority of the sample (57.3%) were in the younger age 
categories (19 – 39 years), and may feel less intimidated and more accustomed to 
technology; and fourthly, the majority of participants indicated that they are employed and 
working full-time, and therefore may have less time available to use other methods. The 
benefits of using online questionnaires to conduct surveys may have had a strong influence 
on the large proportion of completed responses in the total sample. Results from the one-
way ANOVA indicated mean MMAQ-8 scores of 6.39, 5.42 and 6.3 for manual, online and 
telephone completion groups respectively, and resulted in a statistically significant effect (F 
(2, 374)  = 5.64, p = .004). A Tukey post-hoc test revealed that the mean MMAQ-8 score 
was statistically significantly lower among those who completed the survey on-line compared 
to those who completed the questionnaire telephonically (M = 5.1, SD = 2.1, p = .012). 
However, there were no statistically significant differences between on-line and manual 
groups (p = .11) or between manual and telephone groups (p = .985).  
 
Figure 6: Mean MMAQ-8 scores of sample of psychiatric outpatients in Gauteng by mode of completion (n=377)
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The results shown in Figure 1 above clearly indicate that the on-line method of completing 
the survey had a significant effect on total MMAQ-8 scores, with a much lower mean score 
for this group. This does not necessarily mean that individuals who preferred the online 
mode of administration are less adherent to their antidepressant medication, but the 
assumption can be made that poor or low adherence in this sample is more likely to be 
reported through more indirect methods. Patients may be more likely to report on non-
adherence when they are not directly faced with their health care provider for fear of possible 
repercussions. It is also worth noting that the reason for the insignificant correlation found 
between the differences in mean MMAQ-8 scores of patients who completed the survey 
manually (6.39) and online (5.42), which is greater by 0.6 than the difference in mean 
MMAQ-8 scores of patients who completed the survey telephonically (6.3), may be due to 
the small number of patients who completed the survey telephonically (n=51). These 
findings are discussed in greater detail in the following chapter. 
 
4.3.3. Patient-related variables 
4.3.3.1. Gender 
The gender distribution of participants in this study was 79.58% (n=300) female and 20.42% 
(n=77) male, with a ratio 3.9 females to 1 male. Seedat, Williams, Herman, Moomal, 
Williams and Jackson (2009) investigated the mental health service use by South Africans 
based on the first nationally representative epidemiological survey that assessed the 
prevalence of common mental health disorders in the country (Herman et al., 2009). 
Although the study did not find significant gender differences for accessing mental health 
services in the 12 months preceding the study, women did have higher rates of treatment 
seeking for any psychiatric condition, and especially for mood disorders.  Additionally, 
stratification by gender provided the following predictors of service use (Seedat et al., 2009) 
study: (i) women with any psychiatric condition were more likely to receive any kind of 
treatment compared to men and; (ii) men diagnosed with a mood disorder specifically were 
less likely be receiving treatment. The reasons for these findings could not be inferred from 
the study. Furthermore, a review on antidepressant use in South African by privately insured 
mental health care users (Roux, 2014) found that 14.8% of all patients (n = 1 220 289) and 
9.3% of men compared to 19.4% of women were prescribed at least one antidepressant. 
Findings by Laher (2013) also concluded that females formed the majority of users (66%) of 
antidepressants in a drug utilisation review from the Gauteng Province.  
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These gender differences in mental health service use between men and women may 
influence the skewed representation of women in this current survey. If more females access 
mental health services in South Africa and fewer males receive this specific treatment under 
investigation, then it is unsurprising to see a biased representation of females in the current 
study. 
Results from the Pearson's chi-square test did reveal that the proportion of males (6.5%; 
n=5) in this study diagnosed with Schizophrenia  or any other psychotic disorder was 
statistically significantly more when compared to the proportion of females (1%; n=3) with 
the same diagnosis (χ2 (1) = 8.903, p = .003). Additionally, compared to females (45.1%; 
n=170), males (12.5%; n=47) were significantly less likely to present with only one DSM-IV-
TR diagnosis (χ2 = 11.055, p = .05). Male patients in this study sample (88.3%; n=68) were 
also found to be significantly less likely to indicate that their condition required treatment with 
medication (χ2 = 5.274, p = .022) when compared to females (95.3%; n=286).  With regards 
to the antidepressant medication category specifically, females (8.3%; n=25) were found to 
be significantly more likely to be prescribed a tricyclic type (χ2 = 6.872, p = .009) when 
compared to males (0%; n=0). These results will be discussed in greater detail in the 
following chapter.  
However, results from the Pearson's chi-square test found no significant correlations 
between males and females and any other socio-demographical variables such as age 
group (p = .323), main language spoken (p = .536), relationship status (p = .212), race (p = 
.266), living arrangements (p = .063), employment status (p = .966), level of education (p=  
.621), or if they were the beneficiaries of medical aid or social grant support (p = .433 and p 
= .872, respectively).  Additionally, gender was not correlated with any clinical-related 
variables such as DSM-IV-TR main diagnosis (p = .347), any mood disorder (p = .338), any 
anxiety disorder (p = .487), any substance use or abuse disorder (p = .446), or ADHD (p = 
.344). Additionally, hospitalisation within 6 months prior to this study (p = .268), perceived 
difficulty of condition (p = 0.628), patients’ prescribing practitioner (p = .44), and type of 
health care service (p = 0.138), were also not significantly correlated with gender.  In terms 
of medication-related variables, males and females did not differ significantly by type of 
sedative/hypnotic (p = .331), anxiolytic (p = .891), anti-psychotic medication (p = .308), or 
antidepressant type medication prescribed.   
Additionally, knowledge of how to cope with possible medication-related adverse reactions 
(p = .169), current experience of adverse reactions (p = .321), the need for additional 
adherence support (p = .311), medication perceived as necessary (p = .231), and perceived 
social stigma, did not reveal any significant gender differences. Results from the 
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independent sample t-test also revealed that there was no statistically significant difference 
between the mean MMAQ-8 scores of males (M = 5.34, SD = 2.07) and females (M = 5.64, 
SD = 2.07, t (375), = -1.12, p = .841). 
 
4.3.3.2. Age 
The age of participants ranged from 18 to 77 years, with the mean age 39.07 years, range of 
59, and standard deviation of 12.66. The median age was 37 years, with a mode of 29. The 
confidence level (95%) was 1.28, suggesting a high level of representativeness. Nearly two 
thirds of patients (57.3%; n=216) were younger than 40 years. One in five patients (21.49%; 
n=81) were in the 40-49 age group, and one in five (21.22%; n=80) were fifty years or older. 
Results from the one-way ANOVA revealed a statistically significant difference in the mean 
age of patients who completed the survey through the three different modes (F (2, 374) = 
14.07, p = .001). A Tukey post-hoc test revealed that the mean age was statistically 
significantly lower among those who completed the survey on-line (M = 37.5, SD = 11.59 
years) compared to those who completed the questionnaire telephonically (M = 45.16, SD = 
3.43, p = .001), or manually (M = 48.16, SD = 18.01 years, p = .001).  However, there were 
no statistically significant differences in the mean age of patients who completed the survey 
manually and telephonically (p = .633). Specifically, patients who were between 18 - 39 
years were significantly more likely to complete the survey on-line compared to patients who 
were older than 40 years (p = .05). These results will be discussed in greater detail in the 
following chapter.  
However, in the current study, age was not correlated with any clinical variables such as 
DSM-IV-TR main diagnosis (p = .095), any mood disorder (p = .377), any anxiety disorder (p 
= .275), any substance use or abuse disorder (p = .055), Schizophrenia  or any other 
psychotic disorder (p = .664), ADHD (p = .402), personality disorder (p = .267) or any 
general medical condition (p = .912). Furthermore, hospitalisation within 6 month prior to this 
study (p = .867), perceived difficulty of condition (p = .218), patients’ prescribing practitioner 
(p = .518), and type of health care service (p = .692), were also not significantly correlated 
with age.   
In terms of medication-related variables, age did not correlate significantly between patients 
who were prescribed respiratory stimulants, (p = .596), any sedative/ hypnotic (p = .536), 
any anxiolytic (p = .994), or any anti-psychotic medication (p = .522), and patients who did 
not receive the same medication. With regards to the antidepressant medication category 
specifically, age was found to have an insignificant correlation between patients who were 
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prescribed any tricyclic (p = .853), any MAOI (p = .164), any SSRI (p = .620), any SNRI (p = 
.886), any NDRI (p = .279), any tetracyclic agent (p = .385), any melatonergic agent (p = 
.164), lithium (p = .726), or any other type (p = .618), and patients who were not prescribed 
the same medication. Finally, the Pearson’s product moment correlation found a statistically 
insignificant correlation between age and total MMAQ-8 score at 2-tailed analysis (r (377) = 
1, p = .224). 
 
4.3.3.3. Population 
Nearly four out of every five patients (79.58%; n=300) indicated their race as being White. 
Slightly more than one in ten patients (11.94%; n=45) were Black. A study that investigated 
the mental health service use of South Africans with mood, anxiety and substance abuse 
disorders (Seedat et al., 2009) found a significant difference between racial groups with 
respect to the type of services accessed. They (Seedat et al., 2009) classified service 
providers as general medical providers (medical doctor, nurses or other health professionals 
not in a mental health setting), mental health specialists (psychiatrist, psychologist, other 
mental health professionals), human services (religious or spiritual advisor, social worker), 
and complementary and alternative medicine (CAM) (traditional healer, chiropractor or other 
healer not in a health setting). The mental health and general medical sectors together were 
also defined as `any health care’. Their study found that Black South Africans were most 
likely to have accessed the CAM sector, while White South Africans were more likely than 
Black South Africans to have seen a psychiatrist, as well as having used other mental health 
services. They (Seedat et al., 2009) further considered the effect of race in patients with a 
12-month disorder and stratified by gender. It was also reported that White females and 
males and Coloured females had the highest odds of seeking mental health services, which 
could explain the large variation between race categories, particularly between White and 
Black South Africans.  
In South Africa, in order to receive a diagnosis of a mental health condition, one has to be 
evaluated by a psychiatrist or psychologist, and can only be prescribed an antidepressant 
medication by a psychiatrist or medical doctor. The low rates of Black South Africans that 
access these services, and higher access rates by Whites South Africans, may explain the 
large discrepancy between these two groups in the current study sample. The current survey 
questionnaire specifically enquired who participants’ prescribing practitioners are, with 
medical doctor or psychiatrist as the only choices provided. Therefore, data on alternative 
referring/ prescribing practitioners where not collected in the current study. 
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Results from the one-way ANOVA revealed a statistically significant differences in the mean 
age of patients and population (race) (F (2, 374) = 21.84, p = .001). A Tukey post-hoc test 
revealed that the mean age was statistically significantly lower among Black South Africans 
(M = 30.71, SD = 9.79 years, p = .028), when compared to White South Africans (M = 40.77, 
SD = 12.49 years) or South Africans from any other population (Indian, Coloured and Mixed 
race) (M = 34.94, SD = 12.43 years). There were no statistically significant differences in the 
mean age of White South Africans or South Africans from any other population (p =.293). 
Additionally, there was no significant difference between population and total MMAQ-8 
scores (p = .5). 
 
4.4.3.4. Home language 
More than half of patients in this study (57.56; n=217) reported English as their home 
language. One in three (31.03%; n=117) patients were Afrikaans speaking. One in ten 
patients (11.41%; n=43) indicated that their home language was one of the remaining 9 
official South African languages (i.e., Northern Sotho, Sotho, Swazi, Tswana, Venda, Xhosa 
and Zulu). The survey questionnaire was distributed in English language only. This is likely 
the cause for the large number of patients who indicated that this is the main language 
spoken by them. It is also the second most spoken language in Gauteng Province (13.3%), 
where the survey was conducted (Statistics South Africa, 2011). Results from the one-way 
ANOVA also revealed a statistically significant differences in the mean age of patients and 
main language spoken (F (2, 374) = 9.16, p = .001). A Tukey post-hoc test revealed that the 
mean age was statistically significantly lower among those who spoke any South African 
language (M = 31.49, SD = 10.51 years) other than English (M = 40.24, SD = 13.29 years, p 
= .001) or Afrikaans (M = 39.71, SD = 11.21 years, p = .001). However, there were no 
statistically significant differences in the mean age of patients who spoke English and 
Afrikaans as a main language (p = .927). Additionally, there was no significant difference 
between main language and total MMAQ-8 scores (p = .672).  
This suggests that the main language spoken by patients did not have a significant influence 
on the reported levels of adherence on the MMAQ-8. Due to the limited time and financial 
resources available, the researcher chose to make the survey available in English only, and 
not to translate the survey questionnaire into other languages. This is a possible avenue for 
further investigation.  
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4.3.3.5. Perceived need for pharmacological treatment of condition 
Nearly all patients (88.3%; n=333) indicated that they felt their psychiatric condition required 
the treatment of antidepressant medication. Results from the Pearson's chi-square test 
found no significant correlations between patients who indicated the need for 
pharmacological treatment of their condition and those patients who did not (6.1%; n=23), 
and any socio-demographical variables such as mode of completion (p = .377), age group (p 
= .994), main language spoken (p = .59), relationship status (p = .753), racial group (p = 
.266), living arrangements (p = .167), employment status (p = .723), level of education (p =  
.137), or if they were the beneficiaries of medical aid or social grant support (p = .574 and p 
= .259, respectively). However, gender was found to be significantly correlated with this 
variable. Results from the Chi-square test revealed that males were significantly more likely 
to indicate that their condition does not require pharmacological treatment (χ2 (1) = 5.27, p = 
.022).  
Furthermore, no clinical information such as diagnostic-related variables was significantly 
correlated with patients’ perceived need for antidepressant treatment of their psychiatric 
condition. This included the type and number of DSM-IV-TR diagnoses patients had 
received (p = .706), prior hospitalisation within six months preceding the study (p = .091), 
condition perceived as difficult or interfering with daily routines (p = .797), their prescribing 
practitioner (p = .522), or type of health care service provider (p = .403) were also not 
significantly correlated with patients’ perceived need for pharmacological treatment of their 
condition. In addition, medication related information such as type of treatment prescribed, 
did not have a significant correlation with patients’ perceived need for pharmacological 
treatment of their psychiatric condition. The number of antidepressants patients were taking 
(p = .229), their daily dosage (p = .514), current experience of medication-related adverse 
reactions (p = .827), knowledge of how to cope with these possible adverse reactions (p = 
.614), or perceived social stigma (p = .438), were also not significantly correlated with 
patients’ perceived need for pharmacological treatment of their condition.  
Finally results from the independent t-test indicated that there was no significant correlation 
between patients who believe their psychiatric condition requires the treatment of 
antidepressants (M = 5.71, SD = 2) compared to those who did not feel their condition 
required antidepressant medication, and their total MMAQ-8 scores (M = 4.6, SD = 2.42, 
t(375), = 3.364, p < .006). 
In summary, although the majority of patient-related variables such has age (p = .224), 
gender (p = .841), race (p = .5) or home language (p = .672) did not significantly correlate 
with low adherence rates in psychiatric outpatients in the current study sample, patients’ 
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beliefs about their treatment did have a significant correlation with low adherence rates (p < 
.006). Specifically, psychiatric patients who indicated they did not believe that their 
psychiatric condition requires the treatment of antidepressant medication (M = 4.6, SD = 
2.42), reported with lower adherence rates when compared to patients who indicated they 
believe that their psychiatric condition requires the treatment of antidepressant medication 
(M = 5.71, SD = 2). However, when the Bonferroni-Holm correction for multiple comparisons 
(Holm, 1979) calculation was considered, this resulted in a statistically insignificant 
correlation, as it is greater that p = .002. Therefore, under the Bonferroni-Holm correction 
conditions the results indicate that we fail to reject the following study null hypotheses 
concerning patient-related variables: 
H1: Age is not significantly correlated with antidepressant adherence rates this sample of 
psychiatric outpatients in Gauteng Province of South Africa.  
H2: Gender is not significantly correlated with antidepressant adherence rates this sample of 
psychiatric outpatients in Gauteng Province of South Africa. 
H3: Race is not significantly correlated with antidepressant adherence rates this sample of 
psychiatric outpatients in Gauteng Province of South Africa. 
H4: Home language is not significantly correlated with antidepressant adherence rates this 
sample of psychiatric outpatients in Gauteng Province of South Africa. 
H5 Treatment beliefs is not significantly correlated with antidepressant adherence rates this 
sample of psychiatric outpatients in Gauteng Province of South Africa 
This means that in the current study sample none of the patient-related variables correlate 
significantly with antidepressant adherence rates.  
 
4.3.4. Illness-related variables 
  4.3.4.1 Diagnostic profile 
A description of the clinical profile of the 377 participants, including Axis I DSM-IV-TR 
diagnoses, Personality Disorders (Axis II), and Mental Disorders Due to a General Medical 
Condition (Axis III), is provided. Participants could select more than one diagnosis if it was 
applicable. Five broad categories for Axis I were considered when participants’ diagnoses 
were reviewed. These were: Mood Disorders (n=317; 84.1%); Anxiety Disorders (n=165; 
43.8%); Schizophrenia and Other Psychotic Disorders (n=8; 2.1%); Substance-Related 
 92 
 
Disorders, (n=10; 2.7%); and Disorders Usually First Diagnosed in Infancy, Childhood, or 
Ado lescence (n=11; 2.9%). In the current study, this refers specifically to Attention-
Deficit/Hyperactivity Disorder (ADHD). Additionally n=23 (6.1%) of patients were diagnosed 
with an Axis II Personality Disorder and 5.3% (n=20) had other general medical conditions 
(Axis III) that may relevant to their psychiatric diagnosis.   
DSM-IV-TR Axis II diagnoses that were documented for participants included: Borderline 
Personality dDsorder (BPD), (5.04%; n=4 males and n=15 females); Anti-social Personality 
Disorder, (ASPS), (n=4 females; 1.06%); and Schizoid Personality Disorder (ScPD), (n=3 
females; 0.8%). Only two (n=2) patients were diagnosed with only an Axis II condition, 
without any Axis I comorbid diagnosis. General medical diagnoses were documented for 
(n=23) participants and included: epilepsy (n=7); diabetes (n=4), metabolic syndrome (n=2); 
and other conditions (n=9), (i.e., breast cancer (n=1), Parkinson’s disease (n=1), Prader Willi 
Syndrome (n=1), traumatic head injury (n=1), and stroke (n=1).  
Of the total sample, only n=18 (1.8%) had any type of Mood Disorder identified in the study 
and a comorbid DSM-IV-TR Axis III diagnosis (general medical condition). In terms of main 
Axis I and II DSM-IV-TR diagnoses, Figure 8 below shows that Major Depressive Disorder 
was the most common diagnosis (59.7%; n=39 males and n=187 females) indicated by 
participants, followed by Bipolar Mood Disorder (n=82; 21.8%; n=12 males and n=70 
females), and Generalised Anxiety Disorder s (23.1%; n=18 males and n=69 females). N=9 
(2.4%) patients indicated a main diagnosis of Panic Disorder With or Without Agoraphobia. 
Although Social Anxiety dDsorder was reported in nearly one in ten patients (10.13%; n=38), 
data revealed that this diagnosis did not present in patients in isolation from other mood or 
anxiety disorders.  
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Figure 7: Distribution of individual Axis I & II DSM-IV-TR diagnoses of sample of psychiatric outpatients in Gauteng 
(n=377)
 
Key: Major Depressive Disorder (MDD); Bipolar Mood Disorder (BMD); Dysthymic Disorder (DysD); Major 
Depressive Episode-Postpartum Onset (MDE_Postpartum); Generalised Anxiety Disorder (GAD); Obsessive-
Compulsive Disorder (OCD); Panic Disorder With or Without Agoraphobia (PDwA); Posttraumatic Stress 
Disorder (PTSD); Social Phobia (SoP); Specific Phobia (SpP); Substance Abuse or Dependence - Alcohol 
(SU_ALC); Substance Abuse or Dependence - Cannabis (SU_CAN); Substance Abuse or Dependence - 
Cocaine (SU_COC); Brief Psychotic Disorder (BrPD); Schizophrenia (SCH); Schizoid Personality Disorder 
(ScPD); Antisocial Personality Disorder 
 
The mean number of disorders for each patient was 1.67, with the median and mode 
observed as 1, and standard deviation was found to be 0.960.  More than half (n=217; 
57.6%) of patients had a single diagnosis, while one in four (n=98; 26%) had received two 
diagnoses. One in ten patients (n=39; 10.34%) indicated they were diagnosed with three 
comorbid disorders. The minimum diagnosis per patient is one, and the maximum is seven, 
with a sum of 630 DSM-IV-TR diagnoses recorded across n=377 patients. This is illustrated 
in Table 4 below. Finally, the number of diagnoses did not have a significant correlation with 
patients’ total MMAQ-8 scores (p = .84). In the current study, n=226 patients reported with a 
diagnosis of MDD, and a significant portion of these (n=19 males and n=58 females) 
reported with a comorbid Anxiety Disorder of any type (34.1%).  
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Table 5: Distribution of number of DSM-IV-TR diagnoses of sample of psychiatric outpatients in Gauteng (n=377) 
Number of DSM-IV-
TR diagnoses 
Frequency 
(n=) 
Percentage 
(%) 
Cumulative 
Percentage 
(%) 
1 217 57.6 57.6 
2 98 26.0 83.6 
3 39 10.3 93.9 
4 17 4.5 98.4 
5 5 1.3 99.7 
7 1 .3 100.0 
 
Patients’ main diagnosis did not correlate significantly with any demographic variables such 
as age groups (p = .334), relationship status (p = .775), employment status (p = .815), living 
arrangements (p = .224), education level (p = .367), race (p = .747), or medical aid or social 
grant support (p = .957 and p = .309 respectively). Furthermore, patients’ total MMAQ-8 
scores was not significantly correlated with any specific DSM-IV-TR main diagnosis (p = 
.095), any Mood Disorder (p = .962), any Anxiety Disorder (p = .67), any Substance-Related 
Disorder (p = .993), Schizophrenia and Other Psychotic Disorders (p = .782), ADHD (p = 
.576), any personality disorder (p = .914) or any general medical condition (p = .947).  
Additionally, the presence of any comorbid anxiety disorder (p = .663), comorbid substance 
use or abuse disorder (p = .623), comorbid Schizophrenia  or Other Psychotic Disorder (p = 
.719) or comorbid Axis II Personality Disorder (p = .791), showed no significant correlation 
with MMAQ-8 scores between patients who reported with these diagnoses and that did not 
.Hospitalisation within 6 months prior to this study (p = .867), perceived difficulty of condition 
(p = .218), patients’ prescribing practitioner (p = .518), and type of health care service (p = 
.692) were also not significantly correlated with patients’ total MMAQ-8 scores.   
 
4.3.4.2. Age at which initial diagnosis was received 
The mean age at which patients received their initial diagnosis is 30.97 years old (std. 
deviation 12.85), and ranges between 9 to 70 years old. The median and mode was 30 
years and 25 years respectively. The number of months patients have lived with their 
diagnoses ranges from 1 to 491 (years?), with a mean of 94.62 (7.88 years). The median 
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number of months is 59, and the mode is 11 months. The standard deviation is 98.66. The 
confidence level (95%) was found to be 9.99. One in ten patients received their first 
psychiatric diagnosis between the ages of nine and fifteen years (10.34%), while nearly a 
quarter of the study sample received their initial diagnosis before the age of twenty 
(24.93%). More than half of patients in the current study were diagnosed between 20 and 40 
years of age (n=201; 53.32%).  
A Tukey post-hoc test revealed that the mean average age at which patients received their 
main diagnosis was statistically significantly lower (therefore at a younger age) among those 
who spoke other official South African languages (M = 25.74, DS = 10.23 years) when 
compared to patients who spoke English (M = 31.03, SD = 13.43 years, p = .035) or 
Afrikaans (M = 32.77, SD = 12.2 years, p = .006). There were no statistically significant 
differences between the English and Afrikaans language groups (p = .458).  
 
Table 6: Frequency distribution of age at which the sample of psychiatric outpatients received their initial diagnosis 
(n=377). 
Age (years) at 
which main 
diagnosis was 
received 
Frequency  
(n) 
Percentage 
(%) 
Cumulative Percentage 
9 - 15 39 10.34 10.34 
16 - 20 55 14.59 24.93 
21 - 25 50 13.26 38.20 
26 - 30 47 12.47 50.66 
30 - 35 63 16.71 67.37 
36 - 40 41 10.88 78.25 
41 - 45 24 6.37 84.62 
46 - 50 26 6.90 91.51 
51 - 55 15 3.98 95.49 
56 - 60 10 2.65 98.14 
60 + 7 1.86 100.00 
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It is worth noting that the average age of patients and the average age at which patients 
received their diagnosis follow similar trends across the study sample. This may reflect the 
similar findings observed under heading 4.4.3.4. Home language’, namely that the mean age 
was statistically significantly lower among those who spoke other South African languages 
(M = 31.49, SD = 10.51 years) when compared to English (M = 40.24, SD = 13.29 years, p = 
.001) or Afrikaans (M = 39.71, SD = 11.21 years, p = .001). Figure 8 provides an illustration 
of the similarity in trends between the mean age of the study sample at time of data 
collection and mean age at receiving initial psychiatric diagnosis across the different 
language groups. These findings will be discussed in greater detail in the following chapter.   
Figure 8 on the following two pages clearly illustrate the similar trends between the mean 
age of patients at time of data collection and the mean age at which they received their initial 
psychiatric diagnosis across the various socio-demographical variables identified in the 
current study. These trends may indicate that socio-demographical factors do not have a 
significant influence on the age at which patients receive their initial diagnosis. This may 
suggest that patients in the current study sample access mental health care service similarly 
across age. Alternatively, it seems that patients’ socio-demographical profile does not have 
an influence on the age at which they receive their first psychiatric diagnosis. These findings 
may be useful for those who wish to target age-specific interventions aimed at improving 
adherence rates in this sample.  
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Figure 8: Mean age of sample at time of data collection compared to mean age at receiving initial diagnosis of sample of 
psychiatric outpatients in Gauteng across socio-demographical variables (n=377) 
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4. 3.4.3. Previous hospitalisation 
Participants were asked if they had been hospitalised for their psychiatric condition in the six 
months prior to the study. The majority of patients (82.76%; n=312) responded that they had 
not been hospitalised, while one in six patients (17.24%; n=65) indicated that they had been 
hospitalised in the past six months (n=10 males; n=55 females). As noted previously, gender 
(p = .268) and age (p = .867) were not significantly correlated with hospitalisation 6 months 
prior to the study. Other socio-demographical variables such as mode of questionnaire 
completion (p = .753), main language (p = .726), population grouping (p = .856), relationship 
status (p = .296), living arrangements (p = .75), employment status (p = .305), and education 
level (p = .654) were not significantly correlated with hospitalisation 6-months prior to 
participation in this study. More specifically, main DSM-IV-TR diagnosis (p = .616), any 
Mood Disorder (p = .213), Substance-Related Disorders (p = .815), Schizophrenia or Other 
Psychotic Disorders (p = .192), any Personality Disorder (p=0.556) or general medical 
condition (p = .136) were also not significantly correlated with hospitalisation 6-months prior 
to participation in this study  
Additionally, the presence of a comorbid Anxiety Disorder (p = .124), comorbid Substance-
Related Disorder (p = .622), comorbid Schizophrenia and Other Psychotic Disorders (p = 
.427), or comorbid Personality Disorder (p = .566) was also not significant correlated with 
hospitalisation 6 months prior to the study. However, when compared to patients who did not 
have the same comorbid DSM-IV-TR diagnoses, patients diagnosed with Generalised 
Anxiety Disorder (χ2 = 6.702, p = .01), any Specific Phobia (χ2 = .494, p = .023) or Bipolar 
Mood Disorder (χ2 = 3.926, p = .048), were significantly more likely to have been 
hospitalised for their psychiatric condition in the 6 months preceding the study. Patients who 
indicated that they were hospitalised for their psychiatric condition 6 months prior to the 
study were significantly less likely to have received their prescriptions from a general 
practitioner (χ2 = 14.803, p = .04). These findings will be discussed in greater detail in the 
following chapter.  
Patients who reported hospitalisation 6 months prior to the study was not significantly 
correlated with perceived difficulty of their psychiatric condition (p = .421), perceived the 
need for pharmacological treatment (p = .091), type of health care system accessed (p = 
.337), current experience of medication-related adverse reactions (p = .317) or perceived 
social stigma (p = .221), Finally, patients’ MMAQ-8 scores were also not significantly 
correlated with hospitalisation in the six months prior to the study (p = .867). These findings 
may indicate that recent hospitalisation (6 months prior to study) by patients in the current 
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study sample is not significantly influenced by their demographical or treatment profile, but 
instead by their clinical profile.   
4.3.4.4. Perceived difficulty of condition 
Participants were asked if their psychiatric condition makes it difficult for them to take care of 
their daily tasks by responding “Yes” or “No”. Three quarters of patients (76.13%; n=287) 
indicated that their condition make it difficult for them to perform their daily activities, 
whereas nearly a quarter of (23.87%; n=90) patients did not experience the same challenges 
to performing daily activities as a result of their psychiatric condition. The perceived difficulty 
of patients’ psychiatric condition was also not significantly correlated with demographical 
variables such as age group (p = .532), main language (p = .561), population (p = .23), 
relationship status (p = .873), living arrangements (p = .487), employment status (p = .791), 
or education level (p = .255).   
However, a significant correlation was shown between the participants’ perceived difficulty of 
(psychiatric) condition and clinical-related variables, namely main diagnosis (p = .001). 
Specifically, patients who had been diagnosed with any DSM-IV-TR Mood Disorder (p = 
.004) were significantly more likely to indicate that their condition makes it difficult for them to 
perform their daily activities. However, when analysed individually, none of the specific mood 
disorders identified in this study (Major Depressive Disorder, Bipolar Mood Disorder, 
Dysthymic Disorder and Major Depressive Episode – Postpartum Onset) was significantly 
correlated with perceived difficulty of condition.  
Additionally, the presence of any DSM-IV-TR Axis II or III disorder was also not significantly 
correlated with perceived difficulty of condition. Furthermore, the presence of any DSM-IV-
TR Anxiety Disorder or any Substance-Related Disorder was also not significantly correlated 
with perceived difficulty of condition. Patients in the current study who were diagnosed with a 
Mood Disorder and any comorbid Anxiety Disorder (χ2 = 5.075, p = .024), or comorbid 
Schizophrenia  (χ2 = 16.159, p = .01) were significantly more likely to indicate that their 
condition makes it difficult for them to perform their daily activities.   These results will be 
discussed in greater detail in the following chapter.  
In summary, none of the illness-related variables such has main DSM-IV-TR diagnosis (p = 
.095), age of onset of psychiatric illness (p = .52), illness duration (p = . 548), perceived 
difficulty of psychiatric condition (p = . 218) or recent (6 months prior to the study) 
hospitalisation (p = . 274) were significantly correlated with  antidepressant adherence rates 
in this study sample. Therefore, the results indicate we fail to reject following study 
hypotheses concerning illness-related variables: 
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H6: Main DSM-IV-TR diagnosis is not significantly correlated with antidepressant adherence 
rates in this sample of psychiatric outpatients in Gauteng Province of South Africa. 
H7: Age of onset of diagnosis is not significantly correlated with antidepressant adherence 
rates in this sample of psychiatric outpatients in Gauteng Province of South Africa. 
H8: Illness duration is not significantly correlated with antidepressant adherence rates in this 
sample of psychiatric outpatients in Gauteng Province of South Africa. 
H9: Prior hospitalisation (6 months) is not significantly correlated with antidepressant 
adherence rates in this sample of psychiatric outpatients in Gauteng Province of South 
Africa. 
H10: Perceived difficulty psychiatric condition is not significantly correlated with 
antidepressant adherence rates in this sample of psychiatric outpatients in Gauteng 
Province of South Africa. 
This means that in the current study sample, none of the illness-related variables correlate 
significantly with antidepressant adherence rates.  
 
4.3.5. Medication-related variables 
4.3.5.1. Number of medications 
A total of 762 central nervous system (CNS) medications were recorded across the entire 
study sample of 377 patients. The total number of psychotropic medications for patients 
ranged between one and seven, (M = 2.1, SD = 1.22). Half of all patients (50.13%; n=189) 
were prescribed between one and three medications. The number of antidepressants 
patients were prescribed did not have a significant correlation with any socio-demographical 
variables such as age group (p = .935), gender (p = .173), main language spoken (p = .238), 
relationship status (p = .886), population (p = .525), living arrangements (p = .312), 
employment status (p = .853), level of education (p =  .497), or if they were the beneficiaries 
of medical aid or social grant support (p = .054 and p = .39, respectively).  
However, patients in this sample who were prescribed a total of three antidepressants 
(n=18; 4.8%) were significantly more likely to have received a diagnosis of a comorbid 
Substance-Related Disorders (χ2 (2) = 6.489, p = .039), and specifically Cocaine Abuse or 
Dependence (χ2 (2) = 10.696, p = .005). No other significant correlations were observed 
when any other DSM-IV-TR diagnoses were considered in the analysis. Additionally, the 
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number of antidepressants prescribed did not have any significant correlations with other 
clinical-related variables such as the type (p = .077) or number (p = .708) of DSM-IV-TR 
diagnoses, hospitalisation within six months prior to the study (p = .075), perceived difficulty 
of psychiatric condition (p = .163), duration of treatment (p = .94), prescribing practitioner (p 
= .372) or type of health care system (p = .523).  No significant correlations were observed 
between the number of psychotropic medications (p = .52) or number of antidepressants (p 
= .81) patients were prescribed and their total MMAQ-8 scores. The findings reported in this 
paragraph will be elaborated on in the following chapter.  
 
4.3.5.2. Medication category 
Table 7 illustrates the distribution (in frequencies and percentages) of all 762 psychotropic 
medications recorded for the entire study sample of 377 psychiatric outpatients as classified 
according to the Monthly Index of Medical Specialities (MIMS) September, 2014. The most 
frequent medication category prescribed to patients were antidepressants, comprising of 
nearly two thirds (64.44%; n=491) of all the CNS medications recorded in this study. The 
most common class of all antidepressants prescribed (n=491) was selective serotonin re-
uptake inhibitors, which comprised of nearly half (n=236; 48.07%) of all the antidepressants 
prescribed. The most commonly prescribed SSRI was Escitalopram, comprising of a third 
(n=74; 31.36%) of all SSRI’s prescribed. The number of antidepressant medications that 
participants reported being prescribed ranged between one (1) and three (3) antidepressants 
prescribed to each patient (M = 1.32).   
As seen in table 5, of all antidepressants from any category, Escitalopram was also the most 
commonly prescribed antidepressant of all comprising of (n=74; 15.07%) all antidepressants 
prescribed to participants in this sample. This was followed by venlafaxine, which was the 
most commonly prescribed SNRI (n=57; 67.86%), and then Fluoxetine (n=60; 25.42%), also 
an SSRI. The fourth most commonly prescribed CNS medication was quetiapine, an anti-
psychotic of the atypical class (n=55), and it was also the most common atypical anti-
psychotic prescribed (63.22%). The second most common atypical anti-psychotic prescribed 
was risperidone (n=12; 13.79%). Other common CNS medications include citalopram 
(n=64), comprising of 19.49% of all SSRI prescribed to patients in this study; bupropion, 
(n=45), the most commonly prescribed NDRI (95.74%), and sertraline (n=45), comprising of 
18.64% of all SSRI’s prescribed. Table 7 presents the distribution of all the psychotropic 
medications that the sample of psychiatric outpatients in Gauteng (n=377) were prescribed 
at the time of the current study.  
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Table 7: Distribution of psychotropic medications of psychiatric outpatients in Gauteng (n=377)   
 
Medication Category 
Frequency in total 
prescriptions (n)
Percentage of total 
prescriptions (%)
Medication 
classification
Frequency in drug 
category (n)
Percentage in drug 
category (%)
Active ingredient
Frequency in drug 
classification (n)
Percentage in drug 
classification (%)
Central Nervous System 
Stimulants
11 1.44
Respiratory 
Stimulants
11 100.00 Methylphenidate 11 100.00
Loprazolam 3 42.86
Temazepam 2 28.57
Epilizine 1 14.29
Flurazepam 1 14.29
Zolpidem 21 84.00
Zopiclone 4 16.00
Alprazolam 23 26.74
Clobazam 20 23.26
Lorazepam 16 18.60
Diazepam 5 5.81
Oxazepam 3 3.49
Etifoxine 1 1.16
Others 4 5.56 Buspirone 4 100.00
Amitriptyline 22 88.00
Imipramine 2 8.00
Mianserin 1 4.00
Tranylcypromine 1 50.00
Moclobemide 1 50.00
Escitalopram 74 31.36
Fluoxetine 60 25.42
Citalopram 46 19.49
Sertraline 44 18.64
Paroxetine 12 5.08
Venlafaxine 57 67.86
Duloxetine 26 30.95
Vortioxetine 1 1.19
Bupropion 45 95.74
Reboxetine 2 4.26
Lamotrigine 45 77.59
Mirtazapine 13 22.41
Melatonergic Specific 2 0.41 Agomelatine 2 100.00
Lithium 15 3.05 Lithium Carbonate 15 100.00
Others 22 4.48 Trazodone 22 100.00
Butyrophenones 3 3.09 Haloperidol 3 100.00
Quetiapine 55 63.22
Risperidone 12 13.79
Olanzapine 8 9.20
Aripiprazole 5 5.75
Clonazepam 4 4.60
Ziprasidone 2 2.30
Flupenthixol 1 1.15
Others 7 7.22 Sulpiride 7 100.00
Anticholinergics 2 0.26 Anticholinergics 2 100.00 Orphenadrine 2 100.00
Lamotrigine 19 33.33
Sodium Valproate 15 26.32
Clonazepam 12 21.05
Carbamazepine 5 8.77
Pregabalin 3 5.26
Topiramate 3 5.26
89.69
57 100.00
84
47
58
48.07
17.11
9.57
11.81
Noradrenaline & 
dopamine re-uptake 
Tetracyclic 
Atypical anti-
psychotpics
Anti-epileptics 
7
25
21.88
78.13
68
25
94.44
5.09
2 0.41
236
Benzodiazepines
Tricyclic
Mono-Amine Oxidase 
inhibitors 
Selective serotonin re-
uptake inhibitors
Serotonin & 
noradrenaline re-
uptake inhibitors
Benzodiazepines
Others
87
9.45
64.44
12.73
7.48
Anxiolytics
Antidepressants
Anti-psychotics
Anti-epileptics
32
72
491
97
57
Sedative Hypnotics 4.20
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Patients who were prescribed a tricyclic antidepressant (such as amitriptyline, comprising of 
88% of all tricyclics prescribed), were significantly more likely to have a diagnosis of Bipolar 
Mood Disorder (BMD) (χ2 (1) = 7.348, p = .007), or Borderline Personality Disorder (BPD), 
(χ2 (1) = 9.106, p = .003). 16% of patients on tricyclic antidepressants also had a diagnosis 
of BPD, compared to only 3.41% of patients with the same diagnosis who were not 
prescribed this type of antidepressant. Furthermore, patients with a diagnosis of BMD were 
also significantly more likely to receive a prescription for lithium (χ2 (1) = 7.638, p = .006). In 
addition to BMD, lithium was also significantly correlated with the diagnosis of brief psychotic 
disorder (χ2 (1) = 6.821, p = .001) as well as cocaine use or abuse disorder (χ2 (1) = 11.147, 
p = .001). Although the local SASOP treatment guidelines does not make reference to 
amitriptyline in the treatment if BMD, particular reference is made to lithium as an effective 
treatment in the acute manic and depressive phase of this condition (Emsley et al., 2013). 
This may be due to the mood-stabilising effect this treatment has earned its reputation for. 
Selective serotonin re-uptake inhibitors (SSRI’s) were not significantly correlated with any 
DSM-IV-TR Axis I or II diagnosis in this study sample. Antidepressants in the “Other” class 
(in this study only trazodone was recorded) was found to be significantly correlated with the 
diagnosis of Alcohol Abuse or Dependence (χ2 (1) = 6.71, p = .01) and Cocaine Abuse or 
Dependence (χ2 (1) = 7.137, p = .008). Trazodone was also found to be significantly 
correlated with a diagnosis of Schizoid Personality Disorder, (χ2 (1) = 4.161, p = .041). 
Reference to Trazodone is made (Emsley et al., 2013) for the treatment of dementia, 
particularly Substance-Induced Dementia, which supports the significant correlations 
observed between this medication and Substance-related Disorders observed in the current 
study sample. These significant correlations will be discussed in greater detail within the 
context of the study in the following chapter.  
The prescription of any noradrenaline and dopamine re-uptake inhibitor (NDRI) was not 
significantly correlated with any DSM-IV-TR Axis I or II diagnosis. Although MDD was 
significantly correlated with the prescription of an NDRI medication in the current study 
sample (χ2 (1) = 4.563, p = .033), closer inspection into the specific NDRI’s identified in the 
study (Buproprion and Reboxetine), no statistically significant correlations were observed 
between these two medications (p =.057 and p =.221 respectively). These results will be 
elaborated on in the following chapter.  
Table 8 summarises the correlations between DSM-IV-TR Axis I and II diagnoses identified 
in the current study sample and the class of antidepressants psychiatric outpatients were 
prescribed. Pearson Chi-Square, Fishers Exact test and p -values are presented. Significant 
correlations in the table are highlighted in bold and grey-scale shaded background. 
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Table 8:  Correlations between DSM-IV-TR Axis I & II diagnosis and prescribed antidepressant medication classes for psychiatric outpatients in Gauteng (n=377) 
Pearson 
Chi-
Square 
value
p value
Fishers 
Exact 
test 
value
Pearson 
Chi-Square 
value
p 
value
Fishers 
Exact 
test 
value
Pearson 
Chi-Square 
value
p 
value
Fishers 
Exact test 
value
Pearson 
Chi-Square 
value
p 
value
Fishers 
Exact 
test 
value
Pearson 
Chi-
Square 
value
p 
value
Fishers 
Exact test 
value
Pearson 
Chi-Square 
value
p 
value
Fishers 
Exact test 
value
Pearson Chi-
Square value
p 
value
Fishers 
Exact test 
value
Pearson Chi-
Square value
p 
value
Fishers 
Exact test 
value
Pearson Chi-
Square value
p 
value
Fishers 
Exact test 
value
Major Depressive Disorder .174 (a) .677 .414 1.343 (b) .246 .519 .139 (a) .709 .746 .008 (a) .928 1 4.563 (a) .033 .04 .05 (a) .823 .884 .083 (b) .773 1 2.589 (a) .108 .116 .132 (a) .716 .824
Bipolar Mood Disorder 7.348 (a) .007 .011 .797 (a) .372 1 1.625 (a) .202 .239 .608 (a) .435 .494 .017 (a) .897 .866 1.255 (a) .263 .271 .797 (b) .372 1 7.683 (c) .006 .015 1.804 (a) .179 .222
Dysthymic Disorder .287 (b) .592 1 .022 (d) .883 1 .287 (b) .592 1 1.159 (b) .282 .597 .59 (b) .442 1 .287 (b) .592 .489 .022 (d) .883 1 .168 (b) .682 1 .251 (b) .617 1
Major Depressive Disorder - 
Post-partum Onset .581 (c) .446 1 .044 (b) .835 1 2.096 (b) .148 .162 3.627 (c) .057 .077 .000 (c) .984 1 1.486 (c) .223 .615 .044 (b) .835 1 .339 (c) .561 1 .507 (c) .477 1
Generalised Anxiety Disorder .755 (a) .385 .47 .821 (b) .365 .409 1.587 (a) .208 .257 .013 (a) .91 1 1.149 (a) .284 .277 .017 (a) .896 1 .603 (b) .437 1 .083 (c) .773 1 .002 (a) .968 1
Obsessive-compulsive Disorder .206 (c) .65 1 .131 (b) .718 1 .32 (a) .572 .659 2.211 (a) .137 .192 1.55 (c) .213 .335 .842 (c) .359 .552 .131 (b) .718 1 .009 (c) .926 1 1.518 (c) .218 .383
Panic Disorder w. & w/o 
Agoraphobia 1.837 (c) .175 .227 2.513 (b) .113 .239 .004 (a) .947 1 .732 (a) .392 .457 .003 (a) .959 1 2.397 (a) .122 .134 .293 (b) .588 1 .743 (c) .389 .42 .017 (c) .896 .751
Post-traumatic Stress Disorder .597 (c) .44 .436 .174 (b) .667 1 .293 (a) .589 .696 .098 (a) .754 1 1.079 (c) .299 .401 1.903 (c) .168 .287 .174 (b) .677 1 .036 (c) .85 1 .041 (c) .84 .691
Social Phobia 1.092 (c) .296 .493 .225 (b) .635 1 .248 (a) .618 .725 3.473 (a) .062 .067 .185 (c) .667 .802 .161 (a) .688 .816 3.535 (b) .06 .192 1.751 (c) .186 .381 1.692 (c) .193 .26
Specific Phobia (any) .215 (b) .643 1 .016 (d) .899 1 1.061 (b) .303 .56 3.44 (b) .064 .126 1.155 (b) .282 .336 .55 (b) .458 1 .016 (d) .899 1 .125 (b) .723 1 .187 (b) .655 1
Alcohol Use or Abuse Disorder .507 (c) .447 1 .038 (b) .845 1 1.118 (b) .29 .434 9.949 (c) .002 .007 1.041 (c) .308 .602 1.297 (c) .255 .601 .038 (b) .845 1 .296 (c) .587 1 6.71 (c) .01 .057
Cannabis Use or Abuse Disorder .36 (b) .549 1 .027 (d) .869 1 3.809 (b) .051 .071 4.163 (b) .041 .076 .241 (b) .642 .496 .921 (b) .337 1 .027 (d) .869 1 .21 (b) .647 1 1.85 (b) .174 .261
Cocaine Use or Abuse Disorder .143 (b) .706 1 .011 (d) .918 1 3.29 (b) .07 .143 7.013 (b) .008 .049 .293 (b) .588 1 1.851 (a) .174 .284 .011 (d) .918 1 11.147 (b) .001 .078 7.137 (b) .008 .113
Brief Psychotic Disorder 3.482 (b) .062 .187 .016 (d) .899 1 1.061 (b) .303 .56 .867 (b) .352 1 .441 (b) .507 1 .748 (b) .387 .395 .016 (d) 0899 1 6.821 (b) .009 .115 .187 (b) .665 1
Schizophrenia .36 (b) .549 1 .027 (d) .869 1 .009 (b) .924 1 .015 (b) .902 1 .739 (b) .39 1 .083 (b) .773 .568 .027 (d) .869 1 .21 (b) .647 1 .314 (b) .575 1
Attention Deficit/ Hyperactivity 
Disorder .111 (c) .739 .535 .06 (b) .806 1 .012 (c) .913 1 .11 (c) .740 1 .303 (c) .582 .638 1.23 (c) .267 .386 .06 (b) .806 1 .775 (c) .379 .346 .702 (c) .402 1
Schizoid Personality Disorder .215 (b) .643 1 .016 (d) .899 1 .027 (b) 0869 1 .213 (b) .644 .532 .441 (b) .507 1 .748 (b) .387 .395 .016 (d) .899 1 .125 (b) .723 1 4.161 (b) .041 .165
Anti-social Personality Disorder .287 (b) .592 1 .022 (d) .883 1 .287 (b) .592 1 .017 (b) .895 1 .548 (b) .459 .421 .287 (b) .592 .489 .022 (d) .833 1 .168 (b) .682 1 .251 (b) .617 1
Borderline Personality Disorder 9.106 (c) .003 .016 .089 (b) .765 1 .001 (a) .971 1 .12 (c) .729 1 2.263 (c) .132 .133 .107 (c) .744 1 .089 (b) .765 1 .226 (c) .635 .485 .005 (c) .942 1
a) 0 cells (0%)  have an expected count of less than 5
b) 2 cells (50%) have an expected count of less than 5
c) 1 cells (25%) have an expected count of less than 5
d) 3 cells (75%) have an expected count of less than 5
Main DSM IV-TR diagnosis
Tricyclic MOAI SSRI SNRI Tetracyclic Melatonergic Lithium OtherNDRI
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There were no significant correlations observed between specific antidepressant medication 
such as tricyclics (p = .672), MOAI’s (p = .331), SSRI’s (p = .735), SNRI’s (p = .666), NDRI’s 
(p =.694), tetracyclic antidepressants (p =.948), melatonergic agents (p =.569), lithium (p = 
.361) or antidepressants in the “Other” category (p = .742) and patients’ total MMQ-8 scores.  
 
4.3.5.3. Duration on current antidepressant medication 
The number of months patients have been taking their current antidepressant medication 
ranged from 1 to 447 (37.25 years) (M = 58.77 months/ 4.9 years; SD = 81.21 months/ 6.7 
years). The median number of months was 25, and the mode was 4 months.  
Many of these patients may have volunteered to participate in the study soon after having 
received a psychiatric diagnosis or having been discharged from hospital. These patients 
may have contacted or have been referred to SADAG for additional outpatient support 
services by their respective health care providers. The standard treatment phase for 
antidepressants (The South African National Department of Health, 2012; Emsley et al., 
2013) namely acute, continuation, and maintenance, ranges between 1 and 12 months. 
However, only a third of patients (33.2%; n=125) in this study were on their current 
antidepressant(s) for twelve months or less, suggesting the majority of patients required 
chronic pharmacological treatment for their conditions.  
 
Figure 9: Distribution of the number of months psychiatric outpatients have been on their current 
antidepressant(s)
 
 107 
 
Half of all patients (n=191; 50.7%) were on their current antidepressant(s) for up to two 
years (24 months), while 5% of patients (n=19) have been on their current antidepressant for 
more than two decades (240 months). The disproportionate distribution of the number of 
months patients have been on their current antidepressant(s) may be a reflection of the 
chronic nature of psychiatric conditions discussed in Chapter 2. It is also worth noting that 
these findings only relate to patients’ current antidepressant prescription, and no information 
of previous pharmacological treatments was recorded. Therefore, patients may have been 
treated with antidepressants for a longer duration than what has been identified in this 
current study. Finally, the number of months patients have been on their current 
antidepressant treatment was not significantly correlated with any socio-demographical 
variables, clinical variables or medication-related variables. Similarly, insignificant 
correlations were observed when patients’ total MMAQ-8 scores were considered for 
analysis.  
 
4.3.5.4. Daily dosage 
The majority of participants (65.25%; n=246) only needed to take a single dose of 
antidepressant medication per day. A third (30.5%; n=115) needed to take their dose twice 
daily. No significant correlations were observed between any socio-demographic variables 
and the number of times patients had to take their medication. When clinical variables were 
considered for analysis, patients diagnosed with MDD (n=226) were significantly more likely 
to be required to take their medication four times daily χ2 (3) = 9.303, p = .026 when 
compared to patients without this diagnosis. However, only two (n=2; 0.53%) of the study 
sample reported a daily antidepressant dosage of four times daily. The significant correlation 
reported here may be as a result of the low number of patients in the current study sample 
who needed to take their antidepressant medication four or more times a day. A significant 
correlation was also found for patients who had been diagnosed with ADHD χ2 (3) = 18.813, 
p < .001, and the number of daily medication dosages. Patients who had received a 
diagnosis of ADHD were more likely to report a daily antidepressant dosage of four times or 
more. No significant correlations were observed when other clinical-related variables were 
considered for analysis. Patients’ daily dosage also did not show a significant correlation 
with patients’ total MMAQ-8 scores (p = .406).  
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4.3.5.5. Current experience of adverse reactions 
Participants were asked if they were currently experiencing any adverse reactions from their 
antidepressant medication. A slight majority of patients in the study (54.38%; n=205) 
reported no adverse reactions to the antidepressant medications, whereas n=172 patients 
(45.62%) indicated that they were experiencing adverse reactions to the antidepressant 
medications). The current study did not include descriptions of the type of adverse reactions 
to antidepressant medication that were experienced. Therefore due to this particular 
limitation in this study the results are only indicative of whether a patient is attributing the 
presence of any adverse reaction to their antidepressant medication. It is suggested that this 
area should be explored further in subsequent studies. These findings can only comment on 
patients’ subjectively perceived medication-related adverse reactions, and is not able to 
distinguish this from any other symptoms that may be related to the patient’s condition. This 
limitation should be taken into account when results are interpreted.  
The reported presence of medication-related adverse reactions did not have a significant 
correlation with any socio-demographic or clinical-related variables identified in the study. 
However, when specific medication categories were considered in the analysis, patients who 
were prescribed sedative-hypnotics from the “Other” class (Zolpidem and Zopiclone was 
identified in this study) were significantly more likely to report that they perceived medication-
related adverse reactions (χ2 (1) = 5.404, p = .02) when compare to patients who were not 
prescribed these medications. Furthermore, patients who reported that they perceived 
medication-related adverse reactions showed some degree of correlation with medication 
adherence rates. Specifically, psychiatric outpatients from the current study who indicated 
they perceived antidepressant-related adverse reactions scored lower on the MMAQ-8 (M = 
5.35, SD = 2.16) when compared to patients who did not report perceived antidepressant -
related adverse reactions (M = 5.78, SD = 2), but only approached statistical significance 
(t(375) = 2.536, p = 0.51). 
 
4.3.5.6. Knowledge to cope with adverse reactions 
Participants were asked if they were able to cope with the adverse reactions from the 
medication. Of all the patients (n=377), less than half (48.5%; n=183) indicated that they 
know how to deal with possible adverse reactions from their antidepressant medication, 
while the majority (51.5%; n=194), did not.  Of the 172 patients that indicated they were 
experiencing adverse reactions, only 70 (40.7%) stated that they knew how to deal with 
possible antidepressant medication-related adverse reactions. The majority of patients 
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(n=102; 59.3%) stated that they do not know how to cope with the potential adverse 
reactions of their antidepressant medication.  
Patients’ knowledge of how to cope with possible adverse reactions from medications did not 
have any significant correlation with any socio-demographical variables. No significant 
correlations were observed for clinical-related variables either. However, knowledge of how 
to cope with possible adverse reactions had a significant negative correlation with the 
number of months patients have lived with their main diagnosis, and number of months 
patients have been on their current antidepressants. The smaller the number of months 
since receiving their diagnosis, the more likely the patients were to indicate that they did not 
know how to deal with possible medication-related adverse reactions (r = -.225, p < .001). 
Similarly, as the number of months the patients have been taking their current 
antidepressant decreased (r = -.133, p < .001) the more likely patients were to indicate that 
they do not know how to deal with possible medication-related adverse reactions. Therefore, 
psychiatric outpatients in the current study who received their initial diagnosis more recently 
and consequently have been prescribed their current antidepressant medication more 
recently. These individuals were more likely to indicate that they did not know how to deal 
with possible antidepressant medication-related adverse reactions. These trends may reflect 
that time is sometimes needed for the patients to adjust to taking antidepressant medication 
or to learn coping strategies to manage the potential medication-related adverse reactions. 
Alternatively, patients who have received their initial diagnosis a longer time ago and have 
been taking their current antidepressant treatment for a longer duration may have gained 
knowledge and experience in in how to cope with the related adverse reactions.  
Finally, patients’ knowledge of how to cope with possible adverse reactions from 
medications had a significant correlation to their total MMAQ-8 scores (t(375) = 20.135, p < 
0.001). Psychiatric outpatients who reported that they did not know how to cope with the 
possible antidepressant medication-related adverse reactions had a significantly lower mean 
score on the MMAQ-8 (M = 5.14, SD = 2.25) compared to patients who reported that they 
knew how to deal with potential antidepressant medication-related adverse reactions (M = 
6.05, SD = 1.76). This may be an area of opportunity for adherence interventions to target, 
and medication-related psycho-education and support may prove beneficial in increasing 
adherence in this population.  
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Figure 10: Knowledge to cope with adverse reactions and adherence levels of psychiatric outpatients in Gauteng (n=377) 
 
 
In summary, although the majority of medication-related variables such as class of 
antidepressant (p = .289), daily dosage (p = .406), duration of current antidepressant 
treatment (p = .052) or the experience of medication-related adverse reactions (p = .51) 
were not significantly correlated with low adherence in the current study, a statistically 
significant correlation was observed in patients who reported that they do not know how to 
deal with potential antidepressant medication-related adverse reactions (p < 0.001). 
Specifically, psychiatric patients who indicated they did not know how to cope with the 
possible antidepressant medication-related adverse reactions had a significantly lower mean 
score on the MMAQ-8 (M = 5.14, SD = 2.25), compared to patients who reported they know 
how to cope with the possible antidepressant medication-related adverse reactions (M = 
6.05, SD = 1.76). Additionally, when the Bonferroni-Holm correction for multiple comparisons 
(Holm, 1979) calculation was considered, this still resulted in a statistically significant 
correlation, as it is smaller than p = .002.  
The results therefore indicate that we fail to reject the following study null hypotheses 
concerning medication-related variables: 
H11: Class of antidepressant is not significantly correlated with antidepressant adherence 
rates in this sample of psychiatric outpatients in Gauteng Province of South Africa. 
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H12: Daily dosage is not significantly correlated with antidepressant adherence rates in this 
sample of psychiatric outpatients in Gauteng Province of South Africa. 
H13: Duration of current treatment is not significantly correlated with antidepressant 
adherence rates in this sample of psychiatric outpatients in Gauteng Province of South 
Africa. 
H14: Current experience of adverse reactions is not significantly correlated with 
antidepressant adherence rates in this sample of psychiatric outpatients in Gauteng 
Province of South Africa. 
Alternatively, the researcher rejects the study null hypothesis namely, H15  that states 
knowledge to cope with adverse reactions is not significantly correlated with antidepressant 
adherence rates in this sample of psychiatric outpatients in Gauteng Province of South 
Africa.  
This means that we can accept that class of antidepressant, daily dosage, duration of 
current treatment and current experience of adverse reactions is not significantly correlated 
with antidepressant adherence rates in the current study sample. However those who 
reported they do not know how to cope with potential antidepressant medication adverse 
reactions, scored significantly lower on the MMAQ-8 compared to patients who reported they 
know how to cope with potential antidepressant medication adverse reactions and therefore 
knowledge to cope with adverse reactions significantly correlates with antidepressant 
adherence rates. 
 
4.3.6. Health system-related variables 
  4.3.6.1. Medical aid and social grant status 
The majority of patients indicated that they did have medical aid (67.37%; n=254), and a 
third of patients do not have medical aid (32.63%; n=123). Additionally, the majority of 
patients indicated that they do not receive any form of a social grant (93.9%; n=354). Only a 
very small number of patients (n=23; 6.1%) were recipients of some form of social grant. 
From the total sample, (n=100; 26.53%), one in four patients indicated that they do not have 
access to either form of financial support (medical aid or social grant) for mental health care 
treatment.  
Results from the independent sample t-test also revealed that patients who had medical aid 
support were significantly younger (M = 37.83, SD = 11.96 years), when compared to those 
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who did not (M = 41.65, SD = 13.66 years), t(375) = -2.77, p = .009. Additionally, those who 
had social grant support were significantly older (M = 47.22, SD = 16.62 years) when 
compared to those who did not (M = 38.55, SD = 12.19 years), t(375) = 3.22, p = .001. 
Finally, there was no statistically significant correlation between patients who had medical 
aid (p = .648), or social grant support (p = .782) and total MMAQ-8 scores when compared 
to patients who did not receive the same kind of financial benefits. 
 
4.3.6.2. Prescribing practitioner 
The majority of patients received their prescription for their medication from a psychiatrist 
(males = 67.53%, n=52; females = 72%, n=216; total = 71.09%; n=268), while nearly a third 
(28.91%; n=109) indicated that they receive their prescription from a general practitioner. No 
socio-demographical variables such as mode of completion (p = .22), gender (p = .44). age 
group (p = .705), main language spoken (p = .577), relationship status (p = .536), population 
(p = .767), living arrangements (p = .562), employment status (p = .482), level of education 
(p =  .825), or if they were the beneficiaries of medical aid or social grant support (p = .916 
and p = .208, respectively) were significantly correlated with patients’ prescribing 
practitioners.  
Patients’ prescribing practitioner did not have a significant correlation with the majority of 
DSM-IV-TR Axis I and II diagnoses, except for Bipolar Mood Disorder (BMD), and Borderline 
Personality Disorder (BPD). Patients diagnosed with BMD were significantly more likely to 
receive their prescribed treatment from a psychiatrist (24.4%) than form a general 
practitioner (3.96%), χ2 (1) = 16.125, p < .001. Similarly, patients who were diagnosed with 
BPD were also significantly more likely to receive their prescribed treatment from a 
psychiatrist (4.24%) than form a general practitioner (0%), χ2 (1) = 16.125, p < .001). In 
addition, patients who reported that they were hospitalised for their psychiatric condition 
within six months prior to the study were significantly more likely to receive their medication 
from a psychiatrist χ2 (1) = 14.803, p < .001, as well as patients who made use of private 
health care services χ2 (1) = 6.719, p = .009.  
In addition, there were no significant correlations observed between patients’ prescribing 
practitioners and any drug category, specific pharmacologic treatment class or other 
medication-related information such as number of medications prescribed or current 
experience of adverse reactions. Finally results from the independent t-test indicated that 
there was no significant correlation between patients who receive their prescribed 
medication from a psychiatrist (M = 5.6, SD = 2.09) compared to those who receive their 
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treatment from a general practitioner, and their total MMAQ-8 scores (M = 5.4, SD = 2.05, 
t(375), = 1.221, p = .502). These findings will also be discussed in greater detail in the 
following chapter. 
 
4.3.6.3. Health care system type 
Participants were asked if they make use of a public or a private funded health care service. 
Three quarters of patients indicated that they receive their prescription of antidepressant 
medication from a private health care provider (75.33%; n=284), while one in four (24.67%; 
n=93) indicated they receive their antidepressant medication from a public/ government 
health care provider. No socio-demographical variables such as mode of completion (p = 
.332), gender (p = .138), main language spoken (p = .072), relationship status (p = .079), 
race grouping (p = .09), or living arrangements (p = .341), were significantly correlated with 
health care system type used by patients. However, patients older than 60 years of age were 
significantly more likely to make use of public health care services (16.1%) compared to 
private health care users (3.9%) of the same age (χ2 (4) = 19.555, p = .022. Additionally, 
patients who were unable to work were significantly more likely to make use of public health 
care services compared to patients who were employed (χ2 (5) = 16.164, p = .006. Patients 
who indicated that they did not have medical aid support were significantly more likely to 
make use of public health care services (49.5%) compared to patients who reported that 
they made use of private health care services  (χ2 (1) = 15.92, p = .001. Finally, patients who 
indicated that they received social grant support were also significantly more likely to make 
use of public health care services (19.4%) compared to patients who reported that that they 
made use of private health care services  s (χ2 (1) = 37.858, p = .001. These results will be 
discussed in greater detail in the following chapter. 
The type of health care service patients made use of (private or public), did not have any 
significant correlations with any diagnostic information or clinical-related variables such as 
type and number of DSM-IV-TR diagnoses, hospitalisation within six months prior to the 
study, or perceived difficulty of condition. In addition, there were no significant correlations 
observed between the two types of health care systems and the majority of drug categories 
or specific medication classes.  
However, the prescription of specific sedative hypnotic-, anxiolytic-, antidepressant-, and 
anti-epileptic medications did show significant correlations with the type of health care 
services patients reported making use of. More specifically, patients who made use of 
private health care services (7%) were significantly more likely to receive a prescription for 
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Zolpidem (a sedative hypnotic) when compared to public health care users (1.1%), (χ2 (3) = 
10.348, p = .016). Additionally, although the proportion of patients who received a 
prescription for Sertraline, an SSRI type antidepressant, who made use of private health 
care services (13.7%) was much larger than public health care users receiving the same 
treatment (5.4%), this difference only approached statistical significance (χ2 (6) = 10.702, p 
= .052). In addition, public health care patients were significantly more likely to receive a 
prescription for Buspirone (3.2%), an anxiolytic medication, (χ2 (1) = 5.511, p = .019, 
Amytripteline (11.8%), a tricyclic antidepressant medication, (χ2 (3) = 11.826, p = .008, 
Lithium (9.7%), an antidepressant, (χ2 (1) = 10.494, p = .003. and Clonazepam (8.6%), an 
anti-epileptic medication, (χ2 (7) = 19.665, p = .006, when compared to private health care 
users receiving the same treatment (0.4%, 3.9%, 2.1% and 2.1% respectively). These 
findings may be the result of the difference in access and availability of specific psychotropic 
medications found across the public and private health care settings. Typically, the options 
to prescribe a greater variety of psychotropic medication are limited in the local public 
setting. No other medication related variables significantly correlated with patients’ type of 
health care system. Finally results from the independent t-test indicated that there was no 
significant correlation between private (M = 5.68, SD = 2.05) compared to public health care 
system users, and their total MMAQ-8 scores (M = 5.3, SD = 2.1, t(375), = .1.95, p = .163). 
 
4.3.6.4. Perceived need for support 
Participants were asked if they needed additional support to help them stay adherent to their 
medication regime. More than one in four patients (27.85%; n=105) indicated that they felt 
they did need additional support.  There were no significant correlations observed between 
patients who indicated that they required additional support to adhere to their medication 
regime and any of the socio-demographical variables such as age, gender, race or home 
language. There were also no significant correlations observed between patients who 
indicated that they required additional support to adhere to their medication regime and any 
individual DSM-IV-TR diagnosis or the majority of other clinical variables.  
However, the number of months since patients have received their main diagnosis (t(375) = 
6.606, p = .011), as well as the number of months they have been on their current 
antidepressant medication (t375) = 4.345, p = .038), were significantly correlated with 
patients’ reported need for additional adherence support. Specifically, patients who reported 
that they need additional support to help them stay adherent to their antidepressant 
medication had received their diagnosis significantly more recently (M = 70.91, SD = 87.95 
months) compared to patients who reported that they did not need additional support to help 
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them stay adherent to their treatment regimen (M = 103.78, SD = 101.17). Furthermore, 
patients who reported that they need additional support to help them stay adherent to their 
medication had been on their current antidepressant medication for a significantly shorter 
time period (M = 45.75, SD = 71.41 months) compared to patients who reported that they did 
not need additional support to help them stay adherent to their antidepressant treatment (M 
= 63.41, SD = 84.35).  
Finally, patients who reported that they need additional support to help them stay adherent 
to their medication (M = 4.24, SD = 2.21) had a significantly lower MMAQ-8 score t(375) = 
13.001, p < 0.001) compared to patients who reported that they do not need additional 
support (M = 6.1, SD = 1.78) to help them stay adherent to their medication had been on 
their current antidepressant medication (M = 6.1, SD = 1.78). This may be an area of 
opportunity for adherence interventions to target, and psycho-social support may prove 
beneficial in increasing adherence in this population, and is discussed in the following 
chapter. 
In summary, although the majority of health system-related variables such as medical aid 
benefit (p = .648) or social grant status (p = .782), prescribing practitioner (p = .502), or type 
of health care service use (p = .163) were not significantly correlated with low adherence in 
the current study, a statistically significant correlation was observed in patients who reported 
that they need additional support to stay adherent to their antidepressant medication regime 
(p < 0.001). Specifically, psychiatric patients who reported they did need additional support 
to help them stay adherent to their medication had a significantly lower MMAQ-8 score (M = 
4.24, SD = 2.21) compared to patients who reported that they did not need additional 
support to help them stay adherent to their medication (M = 6.1, SD = 1.78).  
Additionally, when the Bonferroni-Holm correction for multiple comparisons (Holm, 1979) 
calculation was considered, this still resulted in a statistically significant correlation, as it is 
smaller than p = .002. Therefore, the results indicate we fail to reject the following study null 
hypotheses concerning health system-related variables: 
H16: Medical aid is not significantly correlated with antidepressant adherence rates in this 
sample of psychiatric outpatients in Gauteng Province of South Africa 
H17: Social grant is not significantly correlated with antidepressant adherence rates in this 
sample of psychiatric outpatients in Gauteng Province of South Africa in this sample of 
psychiatric outpatients in Gauteng Province of South Africa 
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H18: Prescribing practitioner is not significantly correlated with antidepressant adherence in 
this sample of psychiatric outpatients in Gauteng Province of South Africa 
H19: Health care service type is not significantly correlated with antidepressant adherence 
rates in this sample of psychiatric outpatients in Gauteng Province of South Africa 
However, the researcher rejects the study null hypothesis H20 that states requiring additional 
support is not significantly correlated with antidepressant adherence rates in this sample of 
psychiatric outpatients in Gauteng Province of South Africa.  
This means that medical aid, social grant, prescribing practitioner and health care service 
type, do not correlate significantly with adherence rates to antidepressant medication in the 
current study sample. However, those who reported they required additional support  to help 
them stay adherence to their antidepressant medication scored significantly lower on the 
MMAQ-8 compared to patients who reported they do not need additional support  to help 
them stay adherence to their antidepressant medication. Therefore the need for additional 
support correlates significantly with low antidepressant adherence rates in the current study 
sample.  
 
4.3.7. Moderating variables 
4.3.7.1. Relationship Status 
Figure 11 illustrates the number of patients in different relationship statuses by age groups. 
Figure 11: Distribution of sample of psychiatric outpatients in Gauteng by relationship status and age group (n=377) 
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The majority of patients (37.93%; n=143) were married. Nearly a third of patients (29.44%; 
n=111) were single. Results from the one-way ANOVA revealed a statistically significant 
differences in the mean age of patients and relationship status (F (5, 371) = 21.84, p = 
0.001). A Tukey post-hoc test revealed that the mean age was statistically significantly lower 
among those who were married (M = 42.15, SD = 10.77 years, p = .007), single (M = 33.47, 
SD = 11.57 years, p = .003), in a relationship (M = 32.89, SD = 11.28 years, p = .001), or 
engaged (M = 32.92, SD = 9.37 years, p = .001), when compared to widowed (M = 54.38, 
SD = 10.09 years) or divorced (M = 48.61, SD = 11.96 years). There were no statistically 
significant differences in the mean age of divorced or widowed patients (p = .757). 
Additionally, there was no significant difference between relationship status and total MMAQ-
8 scores (p = .278).  
 
4.3.7.2. Living arrangements 
The majority of patients indicated they live with a family member (43.77%; n=165). Nearly a 
third of patients (29.71%; n=112) live with a partner, and one in five patients indicated that 
they live on their own (21.49%; n=81). Results from the one-way ANOVA revealed a 
statistically significant difference in the mean age of patients and living arrangements (F (3, 
373) = 9.44, p = .001). A Tukey post-hoc test revealed that the mean age was statistically 
significantly lower among patients who were living with family (M = 35.64, SD =11.8 years, p 
= .001), when compared to patients who were on their own (M = 43.47, SD = 13.84 years), 
or had other living arrangements (M = 34.94, SD = 12.43 years). Additionally, there was no 
significant difference between the different living arrangement categories and total MMAQ-8 
scores (p = .482). 
 
4.3.7.3. Employment status 
More than half of patients (56.5%; n=213) were working full-time, and more than one in ten 
patients were unemployed and looking for work (12.47%; n=47). Results from the one-way 
ANOVA revealed a statistically significant difference in the mean age of patients and 
employment status (F( 5, 371) =32.16, p = .001). A Tukey post-hoc test revealed that the 
mean age was statistically significantly lower among students (M = 24.27, SD = 7.42 years, 
p = .001), when compared to all other employment levels. Additionally, patients who were 
disabled or unable to work were significantly older (M = 58.7, SD = 11.37 years, p = .001) 
when compared to all other employment levels. However, there were no statistically 
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significant differences in the mean age of patients who were employed full-time and half-time 
(p = .1), unemployed and looking for work (p = .153), and those who were unemployed and 
not looking for work (p = .136). Additionally, there was no significant difference between 
employment status and total MMAQ-8 scores (p = .294). 
 
4.3.7.4. Education level 
The majority (40.85%; n=154) of patients had obtained a diploma or degree, while a third of 
patients (34.48%; n=130) completed high school, and one in six patients (17.77%; n=67) 
completed a post-graduate qualification. Results from the one-way ANOVA revealed a 
statistically significant difference in the mean age of patients and level of education (F (3, 
373) = 3.2, p = .023). A Tukey post-hoc test revealed that the mean age was statistically 
significantly higher among those who had not completed high school (M = 45.69, SD = 17.37 
years), when compared to patients who had completed high school (Gr. 12), (M = 37.7, SD = 
12 years, p = .017), who had a diploma or degree (M = 39.61, SD = 11.86, p = .013) or a 
post-graduate degree (M = 37.94, SD = 12.94 years, p = .039). These results will be 
discussed in greater detail in the following chapter. Additionally, there was no significant 
difference between education level and total MMAQ-8 scores (p = .838). Finally, patients 
who completed high school or any higher education level were also significantly less likely to 
be the recipients of social grant support, when compared to patients who completed some 
high school or less (p = .23). 
 
Figure 12: Distribution of sample of psychiatric outpatients in Gauteng by education level and age group (n=377) 
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4.3.7.5. Perceived stigma 
Participants were asked if they were afraid of what some people may think about them 
taking antidepressant medication. More than half of the patients (n=200; 53.05%) indicated 
that they had fears of stigma relating to the pharmacological treatment of their psychiatric 
condition. There were no significant associations observed among patients who reported 
that they had fears of stigma relating to the pharmacological treatment of their psychiatric 
condition and the majority of socio-demographical variables. However, patients who 
indicated that they are recipients of a social grant (9%) were significantly less likely to 
indicate that they were afraid of what some people may think about them taking 
antidepressant medication compared to patients who indicated that they do have a fear of 
what others may think of them taking antidepressant medication for their psychiatric 
condition (χ2 (2) = 5.03, p = .025).  Patients who receive social grant benefits may be more 
exposed to other patients in similar circumstances, compared to other (privately insured) 
patients who may be more isolated during their treatment process. Social grant recipients 
typically congregate to receive their benefits at a particular location on a specific day. This 
opportunity to meet others in similar circumstances may be missed by patients who do not 
receive social grant benefits, and may reflect the findings above. However, further 
investigation is required to determine the causal relationship between these variables.  
Finally, patients who reported that they fear social stigma had a significantly lower MMAQ-8 
score (M = 5.11, SD = 2.21) compared to patients who did not (M = 6.1, SD = 1.78), t(375) = 
14.911, p < 0.001. This may be an area of opportunity for adherence interventions to target, 
and community engagement and advocacy, psycho-social support and education may prove 
beneficial in increasing adherence in this population, and will be discussed in greater detail 
in the following chapter.  
In summary, although the majority of moderating variables such as employment status (p = 
.294), level of education (p = .838), relationship status (p = .278) or living arrangements (p = 
.482) were not significantly correlated with antidepressant adherence rates in the current 
study, a statistically significant correlation was observed in patients who reported that they 
had fears of stigma relating to the pharmacological treatment of their psychiatric condition (p 
< 0.001). Specifically, psychiatric patients who indicated they did have fears of stigma 
relating to the pharmacological treatment of their psychiatric condition had a significantly 
lower MMAQ-8 score (M = 5.11, SD = 2.21) compared to patients who reported that they did 
not have fears of stigma relating to the pharmacological treatment of their psychiatric 
condition (M = 6.1, SD = 1.78). Additionally, when the Bonferroni-Holm correction for multiple 
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comparisons (Holm, 1979) calculation was considered, this still resulted in a statistically 
significant correlation, as it is smaller than p = .002.  
Therefore, the results indicate we fail to reject the following study hypotheses concerning 
moderating variables: 
H21: Employment status is not significantly correlated with antidepressant adherence rates in 
this sample of psychiatric outpatients in Gauteng Province of South Africa 
H22: Education level is not significantly correlated with antidepressant adherence rates in this 
sample of psychiatric outpatients in Gauteng Province of South Africa 
H23: Relationship status is not significantly correlated with antidepressant adherence rates in 
this sample of psychiatric outpatients in Gauteng Province of South Africa 
H24: Living arrangements is not significantly correlated with antidepressant adherence rates 
in this sample of psychiatric outpatients in Gauteng Province of South Africa 
However, the researcher rejects the study null hypothesis H25  that states that perceived 
stigma is not significantly correlated with antidepressant adherence rates in this sample of 
psychiatric outpatients in Gauteng Province of South Africa. Specifically, those who reported 
they fear social stigma scored significantly lower on the MMAQ-8 compared to patients who 
reported they do not fear social stigma related to their antidepressant treatment. This means 
that employment status, education level, relationship status, and living arrangements do not 
significantly correlate with antidepressant adherence levels in the current study sample. 
However, perceived stigma correlated significantly with adherence rates to antidepressant 
medication in the current study sample. 
 
4.4. Chapter summary 
In this chapter the reader was first introduced to the study results with a description of the 
socio-demographic profile of psychiatric outpatients who took part in the current study. The 
majority of patients were White (79.36%), female (79.58%), married (37.93%) and living with 
family (43.77%), were younger than 40 years of age (57.3%), English speaking (57.56%), 
obtained a diploma or degree (40.85%), working full-time (56.5%) and had medical aid 
(67.37%). Slightly less than half of the total sample (47.7%) reported with low antidepressant 
medication adherence rates. The results from the current study suggests that non-
adherence to antidepressant medication in this sample of psychiatric outpatients reflect that 
of findings reported in both international and local contexts. This lends strength to the current 
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study argument that non-adherence to antidepressant medication presents a significant 
concern in the local psychiatric outpatient setting. Table 9 presents the study hypotheses 
could be accepted and rejected based on the analysis of the results. These results are 
discussed in greater detail in the following chapter. 
Table 9: Summary of study hypotheses accepted and rejected 
Variable groups 
 
Individual variables 
Significance 
level 
(p value)  
Patient-related variables 
 
H1: Age .224 
H2: Gender .841 
H3: Race .5 
H4: Home Language .672 
H5: Treatment beliefs .006 
Illness-related variables 
 
H6: Main DSM-IV-TR diagnosis .095 
H7: Age of onset of diagnosis .52 
H8: Illness duration .548 
H9: Prior hospitalisation (6 months) .274 
H10: Perceived difficulty of condition .218 
Treatment-related variables 
 
H11: Class of antidepressant .289 
H12: Daily dosage .406 
H13: Duration of current treatment .052 
H14: Current experience of adverse reactions .51 
H15: Knowledge to cope with adverse reactions .001* 
Health system-related variables 
 
H16: Medical aid .648 
H17: Social grant .782 
H18: Prescribing practitioner .502 
H19: Health care service type .163 
H20: Require additional support .001* 
Moderating variables 
 
H21: Employment status .294 
H22: Education level .838 
H23: Relationship status .278 
H24: Living arrangements .482 
H25: Perceived stigma .001* 
*Significant at Bonferoni-Holm correction 
 
Table 9 reports on the results of the statistical tests used to determine if there were any 
significant correlations between adherence rates and the individual variables used to test the 
study hypotheses. Although treatment beliefs (H5) resulted in a significant correlation (p < 
.006), the Bonferroni-Holm correction for multiple comparisons (Holm, 1979) calculation was 
considered and resulted in a statistically insignificant correlation, as it is greater that p = 
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.002. Therefore, we also fail to reject H5. There was a strong positive correlation between 
adherence rates and duration of current treatment (i.e., younger patients were more likely to 
report with lower levels of adherence), (p = .052), this was statistically insignificant.  
There was a statistically significant correlation between adherence rates and knowledge to 
cope with adverse reactions (H12), (p < 0.001). Specifically, psychiatric patients who 
indicated they did not know how to cope with the possible antidepressant medication-related 
adverse reactions had a significantly lower mean score on the MMAQ-8 (M = 5.14, SD = 
2.25), compared to patients who reported they know how to cope with the possible 
antidepressant medication-related adverse reactions (M = 6.05, SD = 1.76). Additionally, 
when the Bonferroni-Holm correction for multiple comparisons (Holm, 1979) calculation was 
considered, this still resulted in a statistically significant correlation, as it is smaller than p = 
.002. For this reason we reject H12 that states knowledge to cope with adverse reactions is 
not significantly correlated with antidepressant adherence rates in this sample of psychiatric 
outpatients in Gauteng Province of South Africa. There was a statistically significant 
correlation between adherence rates and require additional support (H12 ), (p < 0.001). 
Specifically, psychiatric patients who reported they did need additional support to help them 
stay adherent to their medication had a significantly lower MMAQ-8 score (M = 4.24, SD = 
2.21) compared to patients who reported that they did not need additional support to help 
them stay adherent to their medication (M = 6.1, SD = 1.78). Additionally, when the 
Bonferroni-Holm correction for multiple comparisons (Holm, 1979) calculation was 
considered, this still resulted in a statistically significant correlation, as it is smaller than p = 
.002. For this reason we reject H20 that states requiring additional support is not significantly 
correlated with antidepressant adherence rates in this sample of psychiatric outpatients in 
Gauteng Province of South Africa. There was a statistically significant between adherence 
rates and perceived stigma (H25) ( (p < 0.001). Specifically, psychiatric patients who 
indicated they did have fears of stigma relating to the pharmacological treatment of their 
psychiatric condition had a significantly lower MMAQ-8 score (M = 5.11, SD = 2.21) 
compared to patients who reported that they did not have fears of stigma relating to the 
pharmacological treatment of their psychiatric condition (M = 6.1, SD = 1.78). Additionally, 
when the Bonferroni-Holm correction for multiple comparisons (Holm, 1979) calculation was 
considered, this still resulted in a statistically significant correlation, as it is smaller than p = 
.002. For this reason we reject H25 that states perceived stigma is not significantly correlated 
with antidepressant adherence rates in this sample of psychiatric outpatients in Gauteng 
Province of South Africa. There was no statistical significant correlations observed between 
adherence rates and any other variables identified, and therefore fail to reject the remaining 
study hypotheses. These findings are discussed in the following chapter. 
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CHAPTER 5 
DISCUSSION AND RECOMMENDATIONS 
5.1. Introduction 
In the previous chapter the researcher discussed the results after statistical analysis of the 
data collected from a sample of psychiatric outpatients living in the Gauteng Province of 
South Africa. In this final chapter, the rates of non-adherence to antidepressant medications 
in this sample, as well as the variables that were found to be significantly associated with 
these rates are discussed. This chapter initially provides a brief description of the current 
study sample, following a discussion of the results relating to research findings in the 
literature. Recommendations based on the findings and suggestions regarding possible 
directions for future studies are also provided. An overview of the limitations identified in the 
study is provided and a brief summary concludes the chapter. 
 
5.2. Summary of research design 
An observational, descriptive multi-mode survey research approach was carried out to 
systematically collect data through three methods from a sample of psychiatric outpatients 
using a structured non-clinical questionnaire. Participants were eligible if they were  a) 18 
years or older, b) prescribed at least one antidepressant medication, c)  not currently 
hospitalised i.e. treated as an out-patient, and d) living in Gauteng Province, South Africa at 
the time of the study. The survey questionnaire included socio-demographical information, a 
clinical- and medication profile as well as the 8-item Morisky Medication Adherence 
Questionnaire (Morisky et al., 1986). A convenience sampling method was used to select 
patients through an invitation sent via personal email or telephone call. This sampling 
method was selected as it allowed the researcher to obtain basic data and trends regarding 
non-adherence to antidepressant medication without the complications of using a 
randomised sample, as well as reduce relative costs and time. It also offers a fair degree of 
external validity with regards to the context (local), and time (current), and sample (patients).  
Data collection commenced in October 2014, after ethical approval was obtained from the 
Department of Psychology Ethics Committee of UNISA and the South African Depression 
and Anxiety Group. Data collection was completed in December 2014, and was cleaned and 
coded according to a structured coding sheet (Appendix III).  
 124 
 
Data from a total of n=377 patients were included in the final analysis and was reported on 
anonymously and in a manner that didn’t allow for individual participants to be identified. All 
categorical and numerical variables were analysed and described using standard descriptive 
and correlational methods using SPSS® (22) software.  
 
5.3. Discussion and conclusions 
5.3.1. Discussion of findings  
The majority of the patients were female (79.58%; n=300), between 18 and 39 years of age 
(57.3%; n=116), English speaking (57.56%; n=217), married (n=143; 37.93%) and living with 
their family (n=165; 43.77%), completed a diploma or degree (40.85%; n=154) and were 
employed full-time (56.5%; n=213), as well as having access to medical aid support 
(67.37%; n=254).  The majority of patients completed the survey questionnaire online 
(81.43%; n= 307). The large proportion of online responses in this study could be 
attributable to several factors: firstly, the primary recruitment method was through online 
advertising on the SADAG website and electronic newsletter providing a link to the survey 
questionnaire, and may have facilitated convenience;  secondly, compared to other modes 
of completion, the online provided more anonymity to participants, which may have been 
more preferable to the targeted population; thirdly, the majority of participants indicated that 
they are employed and working full-time and therefore, may have less time available to 
participate in other methods of data collection and; fourthly, the majority of the sample 
(57.3%) were in the younger age categories (19 – 39 years), and may feel less intimidated 
and more accustomed to the use of electronic devices. Results from the current study 
revealed that the mean age was statistically significantly lower among those who completed 
the survey online (M = 37.5, SD = 11.59 years) compared to those who completed the 
questionnaire telephonically (M = 45.16, SD = 3.43, p = .001), or manually (M = 48.16, SD = 
18.01 years, p = .001), supporting the current study findings above.  
Results indicated that those who completed the survey online scored a significantly lower (p 
= .006) score on the MMAQ-8 compared to those who completed it manually or 
telephonically. This does not necessarily indicate that individuals who preferred the online 
mode of administration are less adherent to antidepressant medication when compared to 
other modes of administration, but likely reflect that low adherence in this study is more likely 
to be reported through the online mode of survey administration which may offer patients a 
greater degree of anonymity compared to manual or telephonic modes. However, there was 
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no statistically significant correlation observed between age and antidepressant adherence 
in the current study (p = .224).  
The gender distribution of patients in this study was 79.58% (n=300) female, and 20.42% 
(n=77) male, with a 3.9:1 ratio. In South Africa, women have higher rates of mental health 
treatment seeking overall, and especially for mood disorders (Seedat et al., 2009). 
Furthermore, the prevalence of major depression in South Africa is significantly higher 
among females (95% Confidence Interval (CI)), for both lifetime prevalence (1.75 times more 
likely, (CI) 1.3 – 2.4), and 12-month prevalence (2.17 times more likely, (CI) 1.5 – 3.2) when 
compared to males (Tomlinson et al., 2009). These authors provide evidence that women 
are more likely to be diagnosed with major depression, therefore requiring mental health 
treatment, as well as being more likely to seek out mental health services for this condition to 
receive treatment. Since antidepressants are used as first-line pharmacological treatment in 
conditions such as major depression (The South African National Department of Health, 
2012; Emsley et al., 2013), but also several anxiety disorders (Royal College of 
Psychiatrists, 2012), an indication of the gender-based use of mental health services could 
also be inferred from information on medication prescription data. A drug utilisation review 
that focussed specifically on antidepressant use in South African by privately insured mental 
health care users (Roux, 2014) found that only half of the men in the data set were receiving 
antidepressants when compared to women. Findings by Laher (2013) also concluded that 
females formed the majority of receivers (66%) of antidepressants in a drug utilisation 
review. These gender differences in mental health service use and treatment between men 
and women may influence the skewed representation of women in this current survey. If 
more women than men access mental health services in South Africa, it is not surprising to 
find that more females would represent the large majority in a study investigating the 
adherence rate of antidepressant medications. These findings may account for the 
disproportionately large number of females found in the current study. 
The racial distribution of patients in the current study was also disproportionately in favour of 
White South Africans. Nearly four out of every 5 patients (79.58%; n=300) were White. 
Slightly more than one in ten patients (11.94%; n=45) identified as Black South Africans. A 
study that investigated the mental health service use of South Africans with mood, anxiety 
and substance abuse disorders (Seedat et al., 2009) found a significant difference between 
racial groups with respect to the type of mental health services accessed. The study found 
that Black patients were more likely to have accessed the complementary and alternative 
medicine (CAM) sector, while White patients were more likely than Black patients to have 
seen a psychiatrist or other mental health professionals such as psychologists. In South 
Africa, psychotropic medication such as antidepressants must be prescribed by a 
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psychiatrist or medical doctor. The low rates of Black South Africans that access these 
services, and higher rates of White South Africans that do, may explain the large 
discrepancy between these two groups in the current study sample. This survey 
questionnaire makes specific reference to medical doctors or psychiatrists only when asking 
about their prescribing practitioner, and no alternative options were recorded. Previous 
findings from the local context also observed that White females and males and Coloured 
females had the highest likelihood of seeking mental health services (Seedat et al., 2009), 
which may explain the unrepresentative racial distribution in this study. It is therefore likely 
that younger White females in the current study who are working and have had an influence 
on their access to medical aid study may have been more likely to access professional care. 
Access to these services was observed to decrease with age, and is reflected in 
employment status. 
 
5.3.1.1.  Discussion of medication adherence  
Nearly half of the patients indicated that they do sometimes forget to take their medication 
(n=183; 48.54%). Other common reasons  for non-adherence to antidepressant medication 
measured by the MMAQ-8 includes: “feel(ing) hassled about sticking to their antidepressant 
treatment plan”, (n=138; 36.6%),  “cut(ting) back or stopped taking antidepressant 
medication without telling their doctor because they felt worse when they took it”, (n=123; 
32.62%), or “stop(ped) taking antidepressant medication when feeling like symptoms were 
under control” (n=114; 30.2%). The average score for the total sample of n=377 psychiatric 
outpatients in the current study was 5.59 (SD =2.08), suggesting low levels of 
antidepressant adherence rates in general. More concerningly, when considering the 
distribution of the adherence rates in the sample, nearly half of the total sample (n=180; 
47.7%) reported with low antidepressant medication adherence rates. In addition, more than 
one in ten patients reported non-adherence to their antidepressant medication the day prior 
to completing the survey questionnaire (n=52; 13.8%), while more than a third of psychiatric 
outpatients (n=140; 37.13%) reported non-adherence in the two weeks preceding data 
collection.  
The results from the current study suggests that non-adherence to antidepressant 
medication in this sample of psychiatric outpatients reflect that of findings reported in both 
international and local contexts (Morris & Schulz, 1992; Sacket & Snow, 1979; Donovan, 
1995; Buckley, Janse van Rensburg, 2007; Foster & Patel, 2009; Bulloch & Patten, 2010; 
Mahaye, et al., 2012). This lends strength to the current study argument that non-adherence 
to antidepressant medication presents a significant concern in local psychiatric outpatient 
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settings. Non-adherence to antidepressant medication is an important predictor of relapse 
and recurrence with significant implication for long-term prognosis (Yau et al., 2014), and is 
associated with decreased reduction in symptoms, as well as increased risk of suicide 
(Weiss & Gorman, 2005).  
Adherence is a key determining factor of pharmacological treatment efficacy in psychiatry, 
and poor adherence diminishes the clinical and therapeutic benefit of these therapies (WHO, 
2003). The results found in this sample in Gauteng highlighted the high rates of non-
adherence by determining the scope of the problem, as well as identifying factors that 
influence these rates. Collaboration and supporting patients’ adherence to antidepressant 
medications throughout their treatment process should be a primary focus area for any who 
are concerned with providing care to psychiatric patients. 
 
5.3.1.2.  Discussion of patient-related variables 
Statistical analysis of the data revealed that patients’ age in years (p = .15), gender (p = 
.841), home language (p = .511), and race (p = .5), was not significantly associated with 
adherence levels in this particular study. The results of these analyses indicate that these 
specific patient-related variables as measured in this study did not have a significant 
correlation with antidepressant medication adherence in this sample. A systematic literature 
review by Zeber and colleagues (2013) on the psychosocial and behavioural factors 
associated with initial medication non-adherence in both chronic physical and mental 
disorders observed that gender was not associated with treatment adherence  in a majority 
of the studies. From the twenty-four articles included in the review (published between 1966 
and 2011), only five indicated that gender was significantly associated with initial medication 
non-adherence, four of which in favour of males, and one indicating that females were more 
adherent than males. Similarly, a local study by Mahaye and colleagues (2012) measured 
antipsychotic medication adherence in a psychiatric outpatient setting in KwaZulu-Natal 
Province using the MMAQ-8, and also observed an insignificant association between gender 
and adherence. However, in contrast with the current study, they found that age (p = .045) 
and race (p = .055) were significantly correlated with medication adherence rates. However, 
differences in clinical and treatment characteristics such as diagnosis and prescribed 
medication may not be comparable to the current study sample characteristics (mostly 
young and White and female), which is not demographically heterogeneous enough. This 
may account for the discrepancies between the above observations and findings from the 
current study.  
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A systematic review (Zeber et al., 2013) noted that age, gender and race were only 
significantly associated with initial medication non-adherence in a very small number of the 
twenty-four studies included in their review (12, 5 and 3 respectively). Observations 
regarding patient factors such as age, gender and race from the current study seem to be in 
line with the majority of previous observations made by other investigators (Fischer et al., 
2010; Shrank et al., 2006, 2010; Wroth & Pathman, 2006; Fischer, Stedman & Lii J, et al., 
2010;  Shrank, Hoang, Ettner, et al., 2006; Shrank, Choudhry, Fischer, et al., 2010; Ekedahl 
& Månsson, 2004), suggesting that these factors may not have a significant correlation with 
antidepressant non-adherence in this sample.  This provides support to the findings from the 
current investigation. Although findings between various studies have not been consistent, a 
reasonable explanation for these findings may be that patients included in these studies vary 
widely across settings and illnesses.  
Patients in the current study who indicated they do not believe their psychiatric condition 
requires the treatment of antidepressants (M = 4.6, SD = 2.42) had a statistically significant 
lower score on the MMAQ-8 when compared to patients who indicated they do believe their 
psychiatric condition requires the treatment of antidepressants (M = 5.71, SD = 2), (t(375), = 
3.364, p < .006). A qualitative study by Sharif, et al. (2003) investigating reasons for non-
adherence to treatment in psychiatry in the South African context, reported that patients’ 
beliefs about treatment and its efficacy were commonly given as reasons for non-adherence. 
Furthermore, Janse van Rensburg and colleagues (2014) also reported that one of the 
common reasons psychiatric outpatients from a public, regional referral hospital in Gauteng 
gave for not adhering to their medication regime, was patient beliefs about medication. 
However, they did not report whether it had a significant correlation with medication 
adherence. Males from the current study (88.3%; n=68) were also found to be significantly 
less likely to indicate that their condition requires treatment with medication (χ2 = 5.274, p = 
.022) when compared to females (95.3%; n=286).  
Although the majority of patient-related variables such has age (p = .224), gender (p = .841), 
race (p = .5) or home language (p = .672) were not significantly correlated with adherence 
rates in psychiatric outpatients in the current study sample, patients’ beliefs about their 
treatment did have a significant correlation with low adherence rates (p = .006). Specifically, 
psychiatric patients who indicated they did not believe that their psychiatric condition 
requires the treatment of antidepressant medication (M = 4.6, SD = 2.42), reported with 
lower adherence rates when compared to patients who indicated they believe that their 
psychiatric condition requires the treatment of antidepressant medication (M = 5.71, SD = 2). 
However, when the Bonferroni-Holm correction for multiple comparisons (Holm, 1979) 
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calculation was considered, this resulted in a statistically insignificant correlation, as p = .006 
is greater than p = .002.  
In the current study, none of the patient variables, namely age (p = .224), gender (p = .841), 
race (p = .5), home language (p = .672) or treatment beliefs (p = .006) were statistically 
significantly correlated with adherence rates in the study sample. We can therefore conclude 
that we fail to reject the following study hypotheses: H1, H2, H3, H4, and H5.  
It can be challenging for psychiatric patients who need to navigate the uneven terrain of 
accessing mental health treatment for a condition that has been highly stigmatised (Sirey et 
al., 2001). Interventions targeting false illness and medication beliefs may be effective in 
increasing antidepressant adherence in this sample. Additional focus and study may be 
required to address gender-specific issues regarding treatment beliefs. This may further 
increase antidepressant adherence rates among males specifically.  
 
5.3.1.3.  Discussion of illness-related variables 
Since antidepressants have become the primary treatment modality for depression (Emsley 
et al., 2013), it was not surprising to see that the majority of patients in this study was 
diagnosed with MDD (n=225; 59.7%). The average age at which patients received their 
diagnosis is 30.97 (SD = 12.85 years) and have lived with their diagnosis for an average of 
7.88 years.  
Patients’ adherence levels was not significantly correlated with any illness-related variables 
such as specific DSM-IV-TR main diagnoses (p = .095), any Mood Disorder (p = .962), any 
Anxiety Disorder (p = .67), Substance-Related Disorder (p = .993), Schizophrenia or Other 
Psychotic Disorder (p = .782), ADHD (p = .576) or any Personality Disorder (p = .914). 
Similar insignificant observations regarding other illness-related variables such as the 
number of diagnosed conditions (p = .708), age at which diagnosis was received (p = .52), 
and duration of illness (p =.548) were observed when considered in the analysis of the data. 
Finally, patients’ perceived difficulty of their condition was also not significantly correlated 
with antidepressant adherence (p = .218). Similar findings have been made in a psychiatric 
outpatient setting in the United States and Spain (Tamburrino, Nagel, Chahal, & Lynch, 
2009; De Las Cuevas, Peñate and Sanz (2014), noting insignificant associations between 
the type of mood disorder patients were diagnosed with, or illness severity and medication 
adherence. Although the two studies (Tamburrino et al., 2009; De Las Cuevas et al., 2014) 
used different measurements in measuring adherence rates (Medication Adherence Scale 
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(MAS) and MMAQ-8, respectively). These results suggest that illness-related variables do 
not have a significant correlation with adherence to antidepressant medication in this 
sample.  
In contrast to the current study, Yau and associates (2014) found that an earlier onset of 
diagnosis was significantly associated with non-continuous antidepressant use within 6 
months of initiating their treatment (p = .034). Additionally, antidepressant medication 
adherence using the MMAQ-8  among n=403 psychiatric outpatients in Saudi Arabia noted 
that a shorter duration of illness in and less depression severity was associated with higher 
adherence levels (Al-Jumah et al., 2014).  
The different findings between the studies discussed above and this current investigation 
could be explained by the differences in health care settings across countries or the 
prioritisation, level of training or support relating to psychiatric services in general of 
antidepressant medication adherence. In addition to this, in an outpatient setting, access to 
services or treatment can become a barrier to utilising services, and mental health literacy 
and stigma may play a significant role in the presentation of patients’ clinical features and 
profile. Finally, differences between study outcome measurements (clinical rating and 
adherence scales) and study design, clinical profile and sample sizes may also explain the 
variation between observations made involving illness-related variables and antidepressant 
medication adherence.  
Patients in the current study who were diagnosed with any DSM-IV-TR Mood Disorder (p = 
.004) and Schizophrenia (p = .01), as well as the presence of a comorbid Anxiety Disorder (p 
= .024) were, however, significantly more likely to indicate that their condition makes it 
difficult for them to perform their daily activities. However, these conditions did not have 
significant correlations with adherence rates in patients from the current study. Furthermore, 
the proportion of males in the current study (6.5%; n=5) diagnosed with Schizophrenia or 
Other Psychotic Disorder was statistically significantly more when compared to the 
proportion of females (1%; n=3) with the same diagnosis (χ2 (1) = 8.903, p = .003).  
Overall, none of the illness-related variables such has main DSM-IV-TR diagnosis (p = .095), 
age of onset of psychiatric illness (p = .52), illness duration (p = . 548), perceived difficulty of 
psychiatric condition (p = . 218) or recent (6 months prior to the study) hospitalisation (p = . 
274) were significantly correlated with  antidepressant adherence rates in this study sample. 
We can therefore conclude that we fail to reject the following study hypotheses: H6, H7, H8, 
H9, and H10.  
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5.3.1.4. Discussion of medication-related variables  
The most common class of all antidepressants prescribed (n=491) to patients in the current 
study was SSRI’s, specifically Escitalopram, comprising of a third (n=74; 31.36%) of all 
SSRI’s prescribed. Recommendations from the South African Society of Psychiatrists 
(SASOP) that apply to the current private health care setting in South Africa (Emsley et al., 
2013) make reference to Fluoxetine as an initial pharmacological treatment modality for the 
treatment of Major Depressive Disorder. The National Department of Health (South African 
Department of Health, 2012) provides treatment guidelines for psychiatric disorders in the 
published Standard Treatment Guidelines and Essential Medicines List for South Africa, 
which typically apply to public health care outpatient settings in South Africa (South African 
Department of Health, 2014), and similarly makes reference to Fluoxetine as first-line 
treatment for moderate to severe depression. Results from the current study suggest that 
Escitalopram is the most commonly prescribed antidepressant as well the most commonly 
prescribed SSRI in this particular sample of psychiatric outpatients. This is somewhat 
incongruent with these treatment guidelines. However, Fluoxetine was observed to be the 
second most common antidepressant (and SSRI specifically) prescribed to patients in the 
current study (n=60; 25.42%). Therefore, there does not seem to be a significant deviation 
from the recommended treatment guidelines in public and private health care services and 
antidepressant prescribing practices.  
A meta-analysis found that Escitalopram and Sertraline were superior to other 
antidepressants when considering both effectiveness and safety (Gartlehner, Thieda, 
Hansen, 2008), which may account for the popular use of this medication observed in the 
current study. It is worth noting that this meta-analysis had several limitations such as 
different measuring instruments used, included studies with low methodological quality, 
different settings (inpatient and outpatient) and clinical profiles (single disorder and comorbid 
diagnoses). However, other analyses (Thaler et al., 2012; AHRQ, 2014), have found that no 
SSRI is more superior to the other. Additionally, an international consumer report noted that 
Escitalopram is more expensive than many other antidepressant drugs, but is now available 
as less-costly generic formulations in some dosage forms (BestBuyDrugs, 2013). Since the 
majority of patients in this sample had financial support to access private medical insurance 
(67.37%; n=254), it would be reasonable to assume that cost may not be a significant 
problem when prescribing antidepressants in this sample. Additionally, the availability of the 
medication in a cheaper generic formulation can only serve to increase the amount of 
patients that can access this particular treatment. This may explain the prevalent use of 
Escitalopram over Fluoxetine in the current study.  
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There were no statistically significant correlations observed between adherence levels and 
the different antidepressant categories. When specific SSRI antidepressants were 
considered for analysis, patients who were prescribed Venlafaxine had on average the 
highest mean MMAQ-8 score (8), and patients who were prescribed Paroxetine had on 
average the lowest mean MMAQ-8 score (5.07). However, there was no statistically 
significant correlation between specific SSRI antidepressant medications and adherence 
scores F(7, 374 = .594, p = .735), or any other antidepressant category in this study. The 
insignificance of this large difference in mean MMAQ-8 scores can be attributed to the low 
number of patients in this study who were prescribed Venlafaxine (n=1; 0.3%), and may be 
considered a statistical outlier. Additionally, the duration (in months) which patients have 
been taking their currently prescribed antidepressant medication was also not significantly 
correlated with adherence levels (r (377) = 1, p = .052). However, the wide range in duration 
(1 - 446 months) which patients were taking their antidepressant medication observed in this 
study may reflect the various phases of treatment (acute, continuation, and maintenance, 
ranging between 1 and 12 months) at which patients are. A third of patients in the current 
study (33.2%; n=125) were on their current antidepressants for less than a year. Many of 
these patients may have volunteered to participate in the study soon after having received a 
psychiatric diagnosis or referred after being discharged from the hospital. However, more 
than half of the study sample (52.2%) was on their current medication between one and ten 
years. This may reflect the chronic nature with which psychiatric conditions present and 
prolonged treatment is often required (Nolen-Hoeksema, 2011). This means that many 
patients may suffer a lifetime of depression with episodes of longer duration and increasing 
severity as time progresses (Keller, Hirschfeld, Demyttenaere, & Baldwin, 2002).  
Additionally, there was no significant correlations observed between other medication-
related variables such as the number of psychotropic medications (p = .52), number of 
antidepressants (p = .81) current experience of medication-related adverse reactions (p = 
.051) or daily dosage (p = .406), and adherence scores.  
Finally, although patients who reported current experience of adverse reactions from 
medications had a lower mean score on the MMAQ-8 (M = 5.35, SD = 2.16) compared to 
patients who did not report current experience of adverse reactions from medications (M = 
5.78, SD = 2), this strong correlation is not considered statistically significant t(375) = 2.536, 
p = 0.51. However, patients who reported that they do not know how to cope with the 
possible medication-related adverse reactions had a significantly lower mean score on the 
MMAQ-8 (M = 5.14, SD = 2.25) compared to patients who reported they did know how to 
cope with the possible medication-related adverse reactions (M = 6.05, SD = 1.76). This may 
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be an area of opportunity for adherence interventions to target, and medication-related 
psycho-education and support may prove beneficial in increasing adherence in this sample.  
Although Zeber and his colleagues (2013) observed that some studies did not report a 
significant correlation with medication-related items and lower adherence levels (Yood, 
Mazor, Andrade SE, et al., 2008; van Geffen, Gardarsdottir, van Hulten, et al., 2009; 
Wamala, Merlo, Bostrom, et al., 2007; Wroth et al., 2006), the majority of studies included in 
their review did observe relationships between poor adherence and various antidepressant 
treatment characteristics such as the use of tricyclic antidepressants (Akincigil, Bowblis, 
Levin, Walkup, Jan & Crystal, 2007; Cooper, Bebbington, King et al, 2007; Keller, Hirschfeld, 
Demyttenaere & Baldwin, 2002), complex treatment regimen (Bucci, Possidente &Talbot , 
2003), and the presence of unpleasant adverse reactions (Nemerhof, 2003; Shigemura, 
Ogawa, Yoshino, Sato, & Nomura, 2010; Zeber et al., 2013).  
In general, the review (Zeber et al., 2013) suggests there is a strong correlation between 
adherence and various aspects of pharmacological treatment. In the current study, only the 
current experience of adverse reactions (showing a strong but statistically insignificant 
correlation) and knowledge of how to cope with adverse reactions were highly correlated 
with adherence levels in this sample of patients. The different findings between the studies 
discussed above and this current investigation, could be explained by the differences in 
health care settings across countries or the prioritisation and availability of medication, 
health literacy and stigma in general of antidepressant medication adherence. In addition to 
this access to services or treatment, in an outpatient setting, can become a barrier to utilising 
services, and mental health literacy and stigma may play a significant role in the 
presentation of patients’ clinical features and profile.  
Finally, differences between study outcome measurements (clinical rating and adherence 
scales) and study design, clinical profile, and sample sizes may also explain the variation 
between observations made involving medication-related variables and antidepressant 
medication adherence.  
Although the majority of medication-related variables such as class of antidepressant (p = 
.289), daily dosage (p = .406), duration of current antidepressant treatment (p = .052) or the 
experience of medication-related adverse reactions (p = .51) were not significantly correlated 
with low adherence in the current study, a statistically significant correlation was observed in 
patients who reported that they do not know how to deal with potential antidepressant 
medication-related adverse reactions (p < 0.001). We can therefore conclude that we fail to 
reject the following study hypotheses: H11, H12, H13, and H14. 
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However, the researcher rejects H15  that states knowledge to cope with adverse reactions is 
not significantly correlated with antidepressant adherence rates in this sample of psychiatric 
outpatients in Gauteng Province of South Africa. Specifically, those who reported they do not 
know how to cope with potential antidepressant medication adverse reactions scored 
significantly lower on the MMAQ-8 compared to patients who reported they know how to 
cope with potential antidepressant medication adverse reactions. This may highlight an area 
of opportunity for adherence interventions to target, and providing appropriate and relevant 
medication-related psycho-education and support may prove beneficial in increasing 
adherence in this population. A brief discussion of recommendations that may be of 
relevance are discussed later in this chapter. 
 
5.3.1.5. Discussion of health system-related variables 
There were no significant correlations observed between adherence levels and various 
health system-related variables such as medical aid or social grant status (p = .648 and p = 
.782 respectively), prescribing practitioner (p = .502), or type of health care system (p = 
.163). However, patients who reported needing additional support from their health care 
system to help them stay adherent to their medication had a significantly lower MMAQ-8 
score (M = 4.24, SD = 2.21) compared to patients who did not need the support (M = 6.1, 
SD = 1.78), t(375) = 13.001, p < 0.001. Lack of social support has also been reported in 
literature to be a predictor of non-adherence to antidepressant medication (Voils et al., 
2005). However, this particular international study only included a small sample (n=85) from 
both in- and outpatients aged 59 years or older. This may indicate a need for interventions to 
increase medication adherence in this sample of psychiatric outpatients, and may be an area 
of opportunity for adherence interventions to target. Psycho-social and educational support 
and treatment-specific information may prove beneficial in increasing adherence to 
antidepressant medication in this sample.  
An international review found that health care system factors such as medication costs and 
co-payments were found to influence adherence rates negatively in chronic illnesses such as 
arthritis and cancer (Mathes, Jaschinski, & Pieper, 2014). Moosa (2007) also cited the 
following health system factors that might impact negatively on psychiatric treatment 
adherence in the local South African context: scarce or poorly developed services; poor staff 
training and lack of capacity to educate patients and to provide continuity of care; inability to 
establish community support, and poor liaison between the hospital setting and the 
outpatient setting. Additionally, Banerjee and Varma (2013) assessed factors that influenced 
adherence to depression treatment in an outpatient setting in India observed that the 
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majority of patients were non-adherent due to health facility-related factors (long distance 
from health care facilities, long waiting hours and unavailability of medication). Although they 
also measured adherence using the MMAQ-8 (Bengali language), this sample only included 
patients with unipolar depression, as defined by the ICD-10, and not the DSM-IV-TR 
classification system used in the current investigation  (WHO, 1992; APA, 2000), as well as 
excluding patients with other comorbid conditions.  
The current study did not investigate other health system-related issues such as staff 
training, the frequency of patient-provider communication, distance from health care 
facilities, waiting hours or medication availability, and this may warrant further study and 
exploration. However, since the majority of this sample is, married (n=143; 37.93%), living 
with their family (n=165; 43.77%), working on a full-time basis (56.5%; n=213), as well as 
having access to medical aid support (67.37%; n=254) through the private health care 
system (75.3%; n=284), it suggests that they may not be so susceptible to these health 
system-related issues. Typically, these patients would have easier access to good quality 
services and treatment, and avoid long waiting queues characteristic of current public health 
services. This may lead to a general greater satisfaction with the health system for these 
patients, and may explain why these variables were not significantly correlated with 
adherence rates in the current study.  
It is not possible to say for certain if the finding of other studies can explain the findings of 
non-adherence in the current study. These reasons include different and additional 
measurements and scales, as well as different operational and conceptual definitions. It is 
not clear whether this is due to differences between populations and health care systems or 
due to differences in the prescribing practitioners; additional studies is needed to verify these 
results. From the observations above it appears that health system related variables such as 
perceived lack of support were significantly associated with adherence levels in patients in 
this particular study, and may warrant further exploration as well as being a possible target 
for intervention.  
Although the majority of health system-related variables such as medical aid benefit (p = 
.648) or social grant status (p = .782), prescribing practitioner (p = .502), or type of health 
care service use (p = .163) were not significantly correlated with low adherence in the 
current study, a statistically significant correlation was observed in patients who reported that 
they do not know how to deal with potential antidepressant medication-related adverse 
reactions (p < 0.001). We can therefore conclude that we fail to reject the following study 
hypotheses: H16, H17, H18, and H19. 
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The researcher however rejects the study null hypothesis H20  that states requiring additional 
support is not significantly correlated with antidepressant adherence rates in this sample of 
psychiatric outpatients in Gauteng Province of South Africa. This finding therefore indicates 
that  those patients who reported that they needed additional support  to help them stay 
adherence to their antidepressant medication scored significantly lower on the MMAQ-8 
compared to patients who reported they do not need additional support  to help them stay 
adherence to their antidepressant medication. This may highlight an area of opportunity for 
adherence interventions to target, and improving access to appropriate psycho-social 
support services to patients and families, may prove beneficial in increasing adherence in 
this population. A brief discussion of recommendations that may be of relevance are 
discussed later in this chapter.  
 
5.3.1.6. Discussion of moderating variables 
Moderating factors that may influence adherence rates refer to socio-economic 
circumstances or settings that affect patients in their particular context. The current 
investigation observed moderating variables such as relationship status (p = .278), living 
arrangements (p = .482), employment status (p = .294) and education level (p = .838).  The 
availability of social support in the form of family, friends, or caregivers to assist or supervise 
treatment and recovery, and higher levels of health literacy and stable living conditions are 
likely to contribute to adherence to treatment in outpatient settings (Moosa, 2007).  
Pampallona and colleagues (2002) summarised literature from 1990 – 1999, and concluded 
that although patient education was commonly assessed for its impact on treatment 
adherence, studies did not show consistent findings. Although lower levels are generally 
associated with poorer treatment adherence, findings have been mixed and suggested that 
education level and its impact on adherence are still not clearly understood (Pampallona et 
al., 2002). More recently, a latent analysis of n=228 participants with depression and 
hypertension found that education level was not significantly correlated with adherence 
levels, whereas relationship status indeed was significantly correlated with adherence levels 
(Bogner & de Vries, 2008).   
Overall, socio-demographic and cultural characteristics do not seem to substantially 
influence patient adherence to antidepressants in the current study. In a study conducted by 
Sirey and associates (2001), they noted that race, marital status, and living arrangements 
(i.e., alone versus with another person) were not significant predictors of adherence to 
treatment in a sample of n=134 patients with MDD. Similarly, a separate study investigated 
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reasons for premature discontinuation of treatment with SSRIs in n=406 patients with MDD, 
and reported that treatment non-adherence was not significantly associated with race, 
marital status, or education (Goethe, Woolley, Cardoni, Woznicki & Pie, 2007). However, in 
the current study, patients who reported that they fear social stigma had a significantly lower 
MMAQ-8 score (M = 5.11, SD = 2.21) compared to patients who did not (M = 6.1, SD = 
1.78), t(375) = 14.911, p < 0.001. Lower perceived stigma was previously found to be 
significantly related (p = .05) to better treatment adherence in patients with MDD (Sirey et 
al., 2001). Stigma related to mental health and its associated treatment was also found to be 
a major barrier to medication adherence for psychiatric patients in later studies (Angermeyer 
& Matschinger, 2003; Gaebel, Zaske & Bauman, 2006; Mitchell, 2006; Adewuya et al., 
2009). The studies cited in this paragraph took place across different social settings, used 
different measurements and study designs and, therefore, make it difficult to draw 
meaningful comparisons between the different investigations. From the observations above 
it appears that perceived stigma specifically, was significantly associated with adherence 
levels in patients in the current study, and may warrant further exploration as well as being a 
possible target for intervention. This may be an area of opportunity for adherence 
interventions to target, and community engagement and advocacy, psycho-social support 
and education may prove beneficial in increasing adherence in this sample. 
In summary, although the majority of moderating variables such as employment status (p = 
.294), level of education (p = .838), relationship status (p = .278) or living arrangements (p = 
.482) were not significantly correlated with antidepressant adherence rates in the current 
study, a statistically significant correlation was observed in patients who reported that they 
had fears of stigma relating to the pharmacological treatment of their psychiatric condition (p 
< 0.001). We can therefore conclude that we fail to reject the following study hypotheses: 
H21, H22, H23, and H24. .  
However, the researcher rejects the study null hypothesis, H25,  that states perceived stigma 
is not significantly correlated with antidepressant adherence rates in this sample of 
psychiatric outpatients in Gauteng Province of South Africa. Specifically, those who reported 
they fear social stigma scored significantly lower on the MMAQ-8 compared to patients who 
reported they do not fear social stigma related to their antidepressant treatment. This may 
highlight an area of opportunity for adherence interventions to target, and improving access 
to appropriate psycho-social and education services to patients and families and may prove 
beneficial in increasing adherence in this population. A brief discussion of recommendations 
that may be of relevance are discussed later in this chapter.  
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5.3.2. Conclusions 
As a result of the chronic and often incapacitating nature of psychiatric conditions, 
adherence to medication is essential to positive treatment response and prevents relapse 
and recurrence of symptoms (Keller et al., 2002). No prior work has been conducted to 
determine antidepressant adherence rates or identified factors that contribute to non-
adherence in psychiatric patients in this region of South Africa. The current study observed 
moderate to high levels of non-adherence to antidepressant medication treatment amongst 
outpatients with various psychiatric disorders in the Gauteng Province of South Africa. This 
suggests that there is substantial opportunity to address a key challenge in antidepressant 
treatment, and the findings of the current study highlights this issue and informs the 
recommendations made here for patients, clinicians, health systems and researchers 
regarding interventions that may promote psychiatric patients’ adherence to antidepressant 
treatment in this population. 
 
5.4. Limitations of the study 
Findings from the current study may be limited because this study collected data through a 
non-random sampling method, and may, therefore represent a biased study sample. 
Although resembling findings from many other international studies, several contradictions 
have also been noted. Due to the heterogeneous methodologies utilised between these 
investigations, the current study cannot draw meaningful comparisons on many variables. 
Although the current study included a relatively small sample of patients in comparison to 
some other international studies, to the best of our knowledge, this is the largest study 
undertaken in South Africa to measure antidepressant medication adherence rates and 
identify factors that may contribute to non-adherence behaviours.  
The aforementioned methodological and conceptual issues between different medication 
adherence measuring instruments signify not only a potential problem for the results of this 
study, it also makes summarising and translating our findings within a consistent and 
universally accepted framework challenging. This means that results are not easily 
comparable to other international or local studies, due to the different conceptual definitions 
and measuring instruments. Varying treatment stages, longitudinal patient medication 
adherence and associated factors following initial prescriptions, as well as accessibility 
issues influencing mental health care use as well as the role of the complementary and 
alternative medicine (CAM) sector were not examined in the current study.  Ongoing work 
can refine, combine and evaluate different study design approaches that measure 
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adherence and its predictors over time for chronic psychiatric conditions. Finally, this study 
was conducted in the English language, and making it available in other South African 
languages may lead to improved response rates among non-English South Africans and a 
more socio-demographically representative sample.  
A key obstacle in measuring adherence stems from the challenge to link the agreement that 
took place in the prescribing practitioner’s office with the patient’s medication-taking 
behaviours outside when they leave. Although, in the near future, this may be overcome with 
the rise of new technologies such as electronic systems that monitor and promote 
medication-taking more efficiently and effectively. Nevertheless, this study demonstrated that 
adherence to antidepressant medication is a complex phenomenon involving various 
mechanisms of behaviours and factors that affect its occurrence. By being cognisant of the 
conceptual, operational and methodological heterogeneity surrounding adherence 
measurements in psychiatry, health care providers, health care systems, researchers and 
policymakers should take note of the potential inconsistencies when evaluating and drawing 
comparisons between studies.  
Despite these limitations, this study has provided valuable insights into adherence 
behaviours in this previously unstudied population of psychiatric outpatients. In addition, the 
current study demonstrated the feasibility of using these methods to assess antidepressant 
medication adherence rates. There is a need for strategies to be developed and 
implemented to address significant variables in order to improve medication adherence in 
psychiatric patients, thereby leading to a better therapeutic outcome. The development and 
implementation of interventions to improve antidepressant treatment adherence, and 
consequently patient health outcomes, may need to be more intensive or tailored for certain 
subgroups of patients with known non-adherence. Patients and prescribing practitioners 
discussing all the information and misconceptions about antidepressant treatment can 
address stigma-related barriers to adherence. Providing continuing education and 
encouragement may strengthen their commitment to taking their antidepressant medication. 
The increased availability of support in the form of family, friends, or caregivers to assist or 
supervise medication may also be an effective strategy to improve adherence rates in this 
sample. Targeted interventions may benefit from focusing on a brief but regular remote 
follow-up through telephone calls or online platforms, as well as family-focused interventions, 
may be a convenient way for patients to obtain additional support within their busy 
schedules. Specialised medication management training for mental health service providers 
may also effective in improving clinical outcomes in people with psychiatric conditions, as 
well as improvement in their own clinical skills and knowledge. These could be explored as 
potential strategies in improving antidepressant adherence rates in psychiatric outpatients in 
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this area. Further research is also needed to assess additional treatment barriers as well as 
the efficacy of current efforts to promote antidepressant adherence. 
 
5.5 Recommendations 
5.5.1. Recommendations for patients 
For patients starting antidepressant treatment for the first time, provision of key psycho-
educational material and messages may be beneficial in improving medication adherence, 
specifically providing information about the possible medication-related adverse reactions, 
how to deal with these reactions and expected benefits from antidepressants. It is important 
for patients to be informed about both the potential risks and therapeutic benefits of 
antidepressant medications in order to make informed decisions about treatment, and not 
become discouraged by unmet expectations. By discussing all the information and 
misconceptions about antidepressant treatment with their prescribing practitioner can 
address stigma-related barriers to adherence. Providing continuing education and 
encouragement may strengthen their commitment to taking their antidepressant medication.  
The increased availability of support in the form of family, friends, or caregivers to assist or 
supervise medication may also be an effective strategy to improve adherence rates in this 
sample. This requires a co-ordinated effort by carers involved with the patient, and recovery 
must be a responsibility shared by clinicians, families and patients.  
It is important that patients understand what is expected of them, and written information 
alone may be insufficient in long-term treatment. Reminder schedules and special 
medication containers may assist in preventing skipped or missed doses of their treatment. 
It's important to keep in mind that antidepressants can help recovery. The American 
Psychiatric Association (American Psychiatric Association, 2000b) recommends that people 
keep taking their medicine at least for four to five months after they recover from a first 
depressive episode in order to reduce the risk of relapse. And for people who have had 
multiple previous episodes, the duration of treatment can be lengthier.  
 
5.5.2. Recommendations for health care providers 
Adhering to a prescribed antidepressant medication regimen may be a complex series of 
behaviours that can have a long-term effect on a patient’s health and well-being. Therefore, 
understanding issues that influence non-adherence behaviour can enable the health care 
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providers to identify targeted interventions during the treatment process, and improve the 
patient’s adherence behaviours and long-term health outcomes. It is thus fundamental that 
relevant health care providers are aware of the magnitude in which patients are non-
adherent to antidepressant medication.  
The level of involvement by health care practitioners in providing educational strategies to 
improve patients’ perceptions of antidepressants, as well as ongoing follow-up may assist 
patients to achieve greater long-term adherence to antidepressants. Thus, to benefit 
patients, providers should attempt to improve patient adherence by facilitating an 
environment in which patients can feel free to discuss their expectations and concerns about 
antidepressants. The possibility of increasing frequency of the contact session with a focus 
on managing expectations of illness and treatment side effects, as well as de-stigmatisation 
should be explored as a way to improve non-adherence.  
By providing training for health care providers on communication skills and facilitating remote 
contact sessions (such as telephone or other online platforms) may increase patient 
satisfaction and provide continuous support for patients with busy schedules. Patients 
should also be orientated on the use of their medication(s), and empowered to not only 
manage illness symptoms, but also potential medication-related adverse reactions, and 
should be provided with tools and trained in monitoring adherence.   
Targeted interventions may focus on a brief but regular remote follow-up through telephone 
calls or online platforms, as well as family-focused interventions, may be a convenient way 
for patients to obtain additional support within their busy schedules. Various ways to 
increase the convenience of care, such as simplified dosing, self- monitoring of medication 
regimen, reminders tailoring treatment to daily habits or routines as well as positive 
reinforcement or rewards for improved adherence may also benefit this type of study 
sample. Early identification of signs of medication or illness related issues that affect 
adherence is also essential, and methods to detect these are of paramount importance in 
addressing non-adherence behaviours.  
 
5.5.3. Recommendations for health care systems 
Poor adherence is a multi-level problem, affected by patient’s knowledge, attitudes, skills 
and the environment of the patient; providers’ practices; and the health care system (Moosa, 
2007). Disclosing one’s mental illness can raise a serious dilemma for many patients. On the 
one hand, they could be subjected to social exclusion and discrimination, but on the other 
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hand, it may lead to a greater sense of personal empowerment, acceptance and higher self-
esteem, as well as enhanced social support. These conflicting issues can provoke 
uncertainty concerning the nature and suitability of disclosure. Addressing the stigma of 
mental illness can be achieved through efforts that target multiple levels of society. Several 
small and large-scale methods of stigma change can be effective (such as patient-specific or 
general public campaigns) and should be informed by the vast research literature on this 
issue.  
The misconceptions associated with taking antidepressant medication can be contested with 
messages that these are no different from taking medications for any other condition such as 
hypertension or diabetes. Prejudice and discrimination toward individuals with any mental 
illness should be opposed with positive messages that people with mental illnesses are able 
to live meaningful lives and make independent life choices like many others who are 
suffering from chronic illnesses. Interventions that include aspects aimed at motivating males 
specifically to access psychiatric health services could also prove beneficial. This may be 
facilitated through the incorporation of gender-appropriate messages or encouragement. 
Finally, addressing medication unavailability, unclear information about drug administration, 
and poor follow-up may improve the extent to which patients take their antidepressants.  
Improvements in adherence can also be achieved by including theoretically informed 
evidence on interventions that promote psychiatric patients’ adherence in psychiatric training 
modules. This can inform, educate and equip health care providers with skills to safely and 
effectively deliver services in outpatient settings. Additionally, by providing training to 
community mental health workers (such as psychiatrists, psychologists, nurses and 
pharmacists) that place an emphasis on adherence to all facets of treatment may also prove 
to be beneficial. Specialised medication management training for mental health service 
providers can be effective in improving clinical outcomes in people with psychiatric 
conditions, as well as improvement in their own clinical skills and knowledge.  
 
5.5.4.  Recommendations for future research 
The current study could be extended and improved upon in several areas. Future research 
in the local context could utilise more scientifically rigorous methodological approaches 
(random sampling) and more objective measures of adherence could facilitate the 
comparison of findings across different studies. Further investigations using clinically 
validated scales measuring various clinical features, medication information, health system 
and socio-economic motivations why patients are non-adherent may also strengthen, 
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support and improve on the current study findings.  Finally, strategies to address issues such 
as specific at-risk groups, targeted psycho-education, self-management strategies and 
ongoing lay support could increase adherence to antidepressant medication in the current 
study sample. Adherence benefits can be framed in terms of improved capacity for individual 
and work/family functioning, reduced hospital visits, reduced financial costs, reduced chance 
of relapse and improved chance of recovery.  
Future research could also explore additional treatment barriers as well as the efficacy of 
current efforts to promote antidepressant adherence. Further research is needed on non-
adherence to antidepressant as well as interventions to promote patients’ adherence to 
treatment, as most of the research identified was only recommended for specific settings, 
illnesses, pharmacological treatments and included small study samples. Results from the 
current study contributed to the existing body of psychological knowledge to stimulate and 
structure further research efforts in the local context. Adherence is a complex phenomenon 
regarding conceptual aspects, accurate assessment and factors affecting its rate. In addition 
to clinical challenges surrounding treatment decisions, researchers and policymakers must 
be aware of the potential inconsistencies in terminology and methodological approaches 
when evaluating non-adherence.  
 
5.6. Summary 
This chapter initially presented the reader with a background of the research. This was 
followed by stating the research objectives, as well as providing a brief overview of the 
research design and methods used in this study. Consequently, a descriptive overview of the 
database was included. The conclusions drawn from the study results were provided by 
discussing the various patient-, illness-, treatment-, health care system- and moderating 
variables that influenced antidepressant medication adherence in this specific sample, as 
well as a discussion relating these findings to the referenced scientific literature. The 
limitations of the research were discussed subsequently. This was supplemented by 
including recommendations for patients, health care providers, health care systems and 
future research that could build upon this study.  
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APPENDIX I: Patient information and consent form 
Dear potential participant, 
 
Before we begin, please take a moment to consider the following information about the 
study. My name is Lian Taljaard. I am currently doing this study to complete my 
Master’s degree in Research Psychology at the University of South Africa (UNISA). I 
have been collaborating with the South African Depression & Anxiety Group 
(SADAG), and we have become aware that many patients experience difficulty in 
sticking to their antidepressant medication.  
We are doing a survey and need your help to see how often people take their 
antidepressant medication, and what some of the reasons may be why they do not. We 
would appreciate your time to answer some questions about you, your diagnosis, and 
medication.  
Ethical clearance to conduct this study was obtained from the UNISA Department of 
Psychology Human Research Ethics Committee (HREC), and SADAG. Any problems, 
concerns or complaints about this study can be directed to this Committee through its 
secretary Cassey Chambers: Tel 011-234 4837; Fax 011-234 4839; email 
operations@anxiety.org.za OR to my supervisor, Louise Henderson: email: 
hendeh@unisa.ac.za  
To take part, you must be 18 years or older, AND, currently prescribed at least 1 
antidepressant medication AND live in Gauteng Province, South Africa. You 
participation would require approximately 10 minutes time to answer some questions 
about you, your diagnosis, and medication. 
 
If you have questions about the study, you can email or call Lian Taljaard at 
research@anxiety.org.za; Tel: 011 234 4837; 079 491 4433 
If you have an emergency, you can call 0800 33 33 77, or SMS 31393. 
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1. Who is SADAG? 
The SADAG is a non-profit, non- governmental organization established 20 years ago to provide 
mental health care advocacy to users across South Africa. SADAG is currently the country’s 
largest and most recognised mental health advocacy initiative. SADAG, for example, routinely 
provides its members with different free telephonic counselling initiatives, such as the: Suicide 
Crisis Line; Trauma Line; Bipolar Helpline; Sleeping Disorder Helpline; Substance Abuse 
Helpline; Mental Health Helpline; and the Support Group Helpline. SADAG aims to: increase 
public awareness of anxiety and mood disorders; disseminate information; and provide support 
to consumers. 
2. What is the study all about? 
People sometimes forget to take their medication for many reasons, and non-adherence to 
antidepressant medications is a remarkably common human experience. This experience and 
its impact on the treatment are enlarged in chronic illnesses such as mental health conditions. 
For these people, non-adherence to treatment substantially adds to the burden of the illness 
and leads to poorer long‐term outcomes in these conditions. Non-adherence to antidepressant 
medication therefore has a profound impact on psychiatric disease course and recovery. In 
addition, there can be significant detriments to the patient’s long-term functioning, including 
social adjustment and academic or vocational performance. The purpose of this investigation is 
to determine levels of adherence to antidepressant medication(s) amongst psychiatric 
outpatients in the Gauteng Province of South Africa, and to identify possible factors that may be 
contribute to the observed medication adherence levels in this specific sample. This information 
could help health care providers better understand the reasons why patients sometimes don’t 
take their antidepressant medication(s), and inform the development of interventions that could 
assist patients.  
3. What will happen during the study? 
When you have considered the information about this investigation and after you have given 
your written consent to participate in the study, you will be asked to complete a questionnaire 
about yourself, what you know and understand about your condition and the antidepressant 
treatment that you are prescribed. We would also like to ask you some questions about sticking 
to your anti-depressant medication. This will not count against you in any way whatsoever and 
no personal information is linked to your answers. You will still be able to see your doctor and 
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receive your medication as always, regardless of your response. For the purpose of this study, it 
is important to answer as honestly as you can. 
4. Are there any risks involved? 
There are no risks involved in taking part in this program. The questions that we ask may be 
personal to you, and you may feel uncomfortable answering them. However, we can assure you 
that no personal information is linked to your responses, and any results published would be 
done anonymously.   
5. Are there any benefits involved? 
There are no direct benefits involved in taking part in this study (financial or otherwise), and can 
in no way guarantee to improve your condition. This programme does not take responsibility for 
the medications you are/ were prescribed. Any adverse effects must be discussed with your 
doctor. However, the programme does offer assistance/ facilitation to this regard. Being 
informed about your condition and treatment reduces stigma and can help you on your road to 
recovery. Additional support structures are also essential in recovery for all those with a mental 
health condition who find it difficult to adjust to their illness. 
6.  Will any personal information be made available in the study? 
The data from the study will be analysed and reported on anonymously and in a manner that will 
make it impossible for individual participants to be identified or recognised. The information from 
this study may be used for publication in professional journals or presented at conferences. 
Confidentiality will be maintained by using a participant code to disguise the identity of 
participants during the entire study process. No names will be linked to the information at any 
point. All data and information will be kept in a protected and locked file in the offices and 
password-protected computer of SADAG to ensure safety. 
 
7. What happens if there is an emergency? 
 
If at any time during the study, for example when you are answering the questions in the 
questionnaires or during a personal or telephone discussion, and it becomes clear that you may 
have to consult a doctor about your condition or treatment, you will be referred for the next 
available appointment at your closest clinic (See contact number for appointments below). If it 
turns out that the problem is more urgent and you may need emergency treatment, you will be 
APPENDIX I: Patient information and consent form 
directed by the investigator who assists you to answer the questionnaire, and standard referral 
processes will be employed. Emergency counselling can be made during 8h00 to 20h00 by 
contacting toll-free 0800 21 22 23, or after hours toll-free 0800 12 13 14. 
 
8. Who can I talk to about the study? 
 
You can contact any of the investigators involved in this study with any question that you may 
have about the investigation or the Reminder and Support Adherence Program. The 
investigators on the research team are: 
Mr. Lian Taljaard (UNISA/ SADAG): 011- 262 6396; 0800 17 18 19; 0800 21 22 23 
Ms Louise Henderson (UNISA) 012- 
Ms. Zane Wilson (SADAG):  011- 262 6396; 080017 18 19; 0800 21 22 23 
 
9. What if I do not want to do this? 
 
Participation in this study is totally voluntary. If you decide not to participate, it will not affect your 
current treatment in any way. Even if after you initially decided to participate and later decide 
that you would rather not continue, you can stop being in the study at any time and your doctor 
will continue to treat you as always. If you don’t want to be in the study please tell the study 
team at any time, and you need to answer only those questions that you understand and are 
comfortable with. The information that is shared will be held in strict confidence and discussed 
only amongst the research team members.  
 
By signing this form below, you are indicating that:  
 
- this study and the form has been explained to you 
- you understand the study, the form and what is expected from you as participant; and 
- any questions that you may have had about it, were sufficiently answered  
 
You are indicating that you understand how the information may be used and how your privacy 
will be protected. By signing this form, you are agreeing to participate in the study. Signing this 
form, however, does not mean that you have waived any of your legal rights. 
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 I have read and understood the information above on the study and what will happen 
during the study. I understand that: 
 
 
(1) participation in this study is voluntary  
(2) I can decline to participate in this study on invitation or at any other time during 
the study without prejudice and that it can or will in no way be used to my 
disadvantage 
(3) I may refuse to answer any questions I would prefer not to 
(4) no information that could identify me will be included in the research report and 
all responses and assessment scores will remain confidential 
(5) in the event of the study results are being published, that my identity and 
responses to questions will remain confidential 
(6) there are no direct risks or benefits involved in participation in this study  
(7) there is no remuneration or reimbursement for participating and there are no 
direct costs to me  
 
 
 All questions about the purpose and process of and reporting on the study were 
answered by the investigator to my satisfaction.  
 I hereby consent to take part in the Research Study by Mr Lian Taljaard 
 
NAME (PRINT)   ___________________________  
 
SIGNATURE       ___________________________  
 
DATE                  ___________________________  
APPENDIX II: Structured questionnaire and adherence rating scale 
 
1.  Information about you 
 
1.1. In what year were you born? (enter 4­digit birth year; for example, 1976) :   
1.2. Are you:     Male       OR     Female  
1.3. What language do you mainly speak at home? 
English Afrikaans Ndebele Northern Sotho Sotho
 Swazi       Tswana  Tsonga Venda  Xhosa Zulu 
 
1.4. What is your relationship status? 
           
     
1.5. Please specify your race 
Asian Black Coloured  Indian White
 Mixed race 
1.6. In which province do you currently live in? 
Eastern Cape Free-State  Gauteng  Kwazulu Natal
 Limpopo  Mpumalanga Northern Cape North West 
 Western Cape 
1.7. Who do you live with at the moment? 
On my own  A Partner  Family (Parents/ siblings) 
 Friends 
Other (please specify)        
1.8. Which of the following categories best describes your employment status? 
Employed, working Full-time  Employed, working Part-time 
Not employed, looking for work  Not employed, NOT looking for work 
Student  Retired  Disabled, not able to work 
 
1.9. Do you have Medical Aid Support?     
1.10. Do you receive a Government/ Social Grant?    
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1.11. What is the highest level of education you have completed? 
Did not attend school  Primary School (7th grade) 
 Some High School (9th Grade) High School (12th Grade) 
 Diploma / Degree   Post-Graduate Degree 
 
2. Information about your ilness 
 
2.1. What is your diagnosis? 
Major Depression (MD)    Bipolar Mood Disorder (BMD)  
Post-Natal Depression (PND)   Generalised Anxiety Disorder (GAD) 
Obsessive-Compulsive Disorder (OCD) Panic Disorder (PD)     
Post-Traumatic Stress Disorder (PTSD) Social Anxiety Disorder (SAD)  
Specific Phobia (SP)    Substance Use - Alcohol (Alc)  
Substance Use -Cannabis (Can)  Substance Use -Cocaine (Coc)   
Brief Psychotic Disorder (BPD)   Schizophrenia (Sch) 
Schizoaffective Disorder (ScD)   Anti-Social Personality Disorder (ASPD) 
Borderline Personality Disorder (BPD) 
If your diagnosis is not on the list, please specify which here:      
 
2.2. Approximately when did you receive your diagnosis? (month & year, e.g. June 2010) 
I       
2.3. Have you been hospitalised in the past 6 months?      
2.4. Do you think or feel your condition makes it difficult for you to do your daily activities? 
             
2.5. Do you think your condition needs to be treated with medication?    
APPENDIX II: Structured questionnaire and adherence rating scale 
3. Information about your medication 
 
3.1. Do you get your anti-depressant(s) prescription from a Psychiatrist OR General 
Practitioner (GP)? 
Psychiatrist General Practitioner (GP) Other     
3.2. Approximately when did you start taking the anti-depressant(s) you are currently 
prescribed? (month & year, e.g. June 2010) 
I       
3.3.     What medication(s) are you currently prescribed? 
(1):       (2):       
(3):       (4):       
(5):       (6):       
(7):       (8):       
 
3.4.   How often do you have to take your medication(s)? 
Once a day   Twice a day  Three times daily   
 More than four times a day 
Other (please specify)        
3.5. Do you know how to deal with potential side-effects of anti-depressants?    
3.6. Are you currently experiencing any side-effects?       
3.7. Do you feel you need more support to help you stick to your medication?    
3.8. Do you think it’s necessary for you to take your anti-depressant medication?   
3.9. Are you afraid of what some people may think about you taking anti-depressant 
medication?           
 
***We would like to ask you some questions about sticking to your anti-depressant 
medication. This will not count against you in any way whatsoever and no personal 
information is linked to your answers. You will still be able to see your doctor and 
receive your medication as always, regardless of your response. For the purpose of 
this study, it is important to answer as honestly as you can.*** 
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4. Information about Adherence 
 
1. Do you sometimes forget to take your antidepressant medication?   Yes No 
 
2. People sometimes miss taking their medicines for reasons other than forgetting. Thinking 
over the past 2 weeks, were there any days when you did not take your antidepressant 
medication?         Yes No 
 
3. Have you ever cut back or stopped taking your antidepressant medication without telling 
your doctor because you felt worse when you took it?    Yes No 
 
4. When you travel or leave home, do you sometimes forget to bring along your antidepressant 
medication?        Yes No 
 
5. Did you take your antidepressant(s) yesterday?    Yes No 
 
6. When you feel like your symptoms are under control, do you sometimes stop taking your 
antidepressant medication?       Yes No 
 
7. Taking antidepressant medicine every day is a real inconvenience for some people. Do you 
ever feel hassled about sticking to your treatment plan?     
 Yes No 
 
8. How often do you have difficulty remembering to take all your antidepressant medicine? 
Never/ Rarely Once in a while   Sometimes          Usually   All the time 
 
Thank you for taking the time to complete this survey! 
 
 
APPENDIX III: Coding Sheet 
Record date  dd-mm-yyy 
Coded identification XXX 
Mode Manual (M); Telephone (T); Online/ electronic (O) 
Date of Birth dd-mm-yyyy 
Age (years) DoB subtracted from current date (i.e., 31-12-2014) 
Age group 18-29 (1); 30-39 (2); 40-49 (3); 50-59 (4); 60+(5) 
Gender Male (M), Female (F) 
Ethnicity Asian (A); Black (B); Colored (C); Indian (I), Mixed race (M); 
White (W) 
Language English (E); Afrikaans (A); Ndebele (ND); Northern Sotho (NS); 
Sotho (S); Swazi (SW); Tswana (TSA); Tsonga (TSO); Venda 
(VE); Xhosa (XHO); Zulu (ZUL) 
Relationship status Married (M); Single (S); Widowed (W); Divorced (D); 
Relationship (R); Engaged (E); 
Residence On my own (OWN); Partner (P); Family (FA); Friends (FR); Other 
(O) 
Employment status Employed, working Full-time (EF); Employed, working Part-time 
(EP); Not employed, looking for work (UL); 
Not employed, NOT looking for work (UN); 
Student (S); Retired (R); Disabled, not able to work (DU) 
Education level Did not attend school (NS); Primary School (7th grade) (SSS); 
Some High School (SHS); High School (12th Grade) (HS); 
Diploma / Degree (D); 
Post-Graduate Degree (PGD); Other (O); 
Province Gauteng Province (G) 
Prescribing practitioner Psychiatrist (PSY); General Practitioner (GP) 
Medical aid status Yes (Y); No (N) 
Social grant status Yes (Y); No (N) 
Health care system Private (PVT); Public (PUB); 
Date of main diagnosis mm-yyy 
Diagnosis AXIS I Mood Disorders (MD); Major Depressive Disorder (MDD); 
Bipolar Mood Disorder I & II (BMD); Dysthemic Disorder 
(DysD);Post-partum onset MDEpisode (PND); Anxiety 
Disorders (ANX); Generalised Anxiety Disorder (GAD); 
Obsessive-Compulsive Disorder (OCD); Panic Disorder w/wo 
agoraphobia (PD); Post-Traumatic Stess Disorder (PTSD); Social 
Anxiety Disorder (SAD); Specific Phobia (SP); Substance use or 
abuse disorders (SUBS); Alcohol (SUBS_Alc); Cannabis 
(SUBS_Can); Cocaine (SUBS_Coc); Schizophrenia & other 
Psychotic Disorders (PSYCH); Brief Psychotic Disorder (BrPD); 
Schizophrenia (Sch); Disorders diagnosed in childhood 
(ADHD); 
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Diagnosis AXIS Id (Differential) As above 
Diagnosis AXIS II Personality disorders (PD); Schizoid Prsonality Disorder 
(ScPD); Anti-Social Personality Disorder (ASPD); Borderline 
Personality Disorder (BPD); 
Diagnosis AXIS III General medical conditions (GMC); Traumatic brain injury 
(TBI); Epilepsy (EPIL); Diabetes mellitus (DIAB); Hypothyroidism 
(HYPOTH); Other (O) 
Previous 6-month hospitalisation Yes (Y); No (N); (from current date e.g., 31-12-2014) 
Illness severity requires pharmacological 
treatment  
Yes (Y); No (N); 
Illness perceived as difficult/ intrusive by 
patient 
Yes (Y); No (N); 
Start date of current pharmacotherapy  mm-yyyy 
 Central Nervous System Stimulants (CNSS); Respiratory 
Stimulants (RS); Methylphenidate (METHYL); Sedative 
Hypnotics (SH); Benzodiazepines (BENZO); Temazepam 
(TAMAZ); Epilizine (EPILI); Loprazolam (LOPRAZ); Flurazepam 
(FLURAZ); Others (O); Zolpidem (ZOLPI); Zopiclone (ZOPIC); 
Anxiolytics (ANXIO); Benzodiazepines (BENZO); Alprazolam 
(ALPRAZ); Diazepam (DIAZ); Clobazam (CLOBA); Lorazepam 
(LORAZ); Oxazepam (OXAZE); Etifoxine (ETIFO); Others (O); 
Buspirone (BUSPI); Antidepressants (AD); Tricyclic 
(TRIC); Amitriptyline (AMYTR); Mianserin (MIANS); Imipramine 
(IMIPR); Mono-Amine Oxidase inhibitors (MOAi) 
[INCL.SELECTIVE & NON_SELECTIVE]; Tranylcypromine 
(TRANY); Moclobemide (MOCLO); Selective serotonin re-
uptake inhibitors (SSRI); Fluoxetine (FLUOX); Citalopram 
(CITAL); Escitalopram (ESCIT); Sertraline (SERTR); Paroxetine 
(PAROX); Serotonin & noradrenaline re-uptake inhibitors 
(SNRI); Venlafaxine (VENLA); Duloxetine (DULOX); Vortioxetine 
(VORTI); Noradrenaline & dopamine re-uptake inhibitors 
(NDRI); Bupropion (BUPRO); Reboxetine (REBOX); Tetracyclic 
(TETRA); Mirtazapine (MIRTA); Melatonergic Specific 
(MELOT);Agomelatine (AGOME); Lithium (LITHI); Lithium 
Carbonate (LITH); Others (O); Trazodone (TRAZO); Anti-
psychotics (ANTIP); Butyrophenones (BUTYR); Olanzapine 
(OLANZ); Haloperidol (HALOP); Atypical anti-psychotics 
(AT_ANTIP); Olanzapine; (OLANZ); Quetiapine (QUETI); 
Risperidone (RISPE); Clonazepam (CLONA); Ziprasidone 
(ZIPRA); Aripiprazole (ARIPI); Flupenthixol (FLUPE); Others (O); 
Sulpiride (SULPI); Anticholinergics (ANCHOL); Orphenadrine 
(ORPHE); Anti-epileptics (ANEPIL); Others (O); Lamotrigine 
(LAMOT); Clonazepam (CLONA); Sodium Valproate (SODIV); 
Carbamazepine (CARBA); Pregabalin (PREGA); Topiramate 
(TOPIR); 
DailyDosage 1nce a day (1); 2ce a day (2); 3ce a day (3); 4 Or More (4) 
Cope with Side Effects  Yes (Y); No (N); 
Currently Experiencing Side Effects Yes (Y); No (N); 
Requires Adherence Support  Yes (Y); No (N); 
Medication Perceived As Necessary Yes (Y); No (N); 
Currently experiencing stigma Yes (Y); No (N); 
 
 
Ethical Clearance for M/D students: Research on human participants 
 
The Ethics Committee of the Department of Psychology at Unisa has evaluated this research proposal 
for a Higher Degree in Psychology in light of appropriate ethical requirements, with special reference 
to the requirements of the Code of Conduct for Psychologists of the HPCSA and the Unisa Policy on 
Research Ethics. 
 
Student Name: Lian Taljaard        Student no.  47175427      
        
Supervisor:   Ms L Henderson                Affiliation: Dept. of Psychology, Unisa      
          
Title of project: 
 
Adherence to Anti-Depressant Medications among Psychiatric Out-Patients in Gauteng: A 
Descriptive Multi-Mode Survey 
 
The proposal was evaluated for adherence to appropriate ethical standards as required by 
the Psychology Department of Unisa.  
 
Because of the sensitivity of the information being sought and the fact that the participants 
come from a vulnerable group, the application was approved by the Ethics Committee of the 
Department of Psychology on the understanding that –  
 
 All ethical requirements regarding informed consent, the right to withdraw from the 
study, the protection of participants’ privacy and confidentiality of the information 
should be made clear to the participants and adhered to, to the satisfaction of the 
supervisor;  
 If access to participants or data relating to them is gained through institutions acting 
as intermediaries, all conditions and procedures regarding access to patient data for 
research purposes that may be required by these  institutions are to be met; 
 If further counseling is required in some cases, the participants will be referred to 
appropriate counseling services.   
 
Signed: 
                                         Date: 2014-09-11 
[For the Ethics Committee                ] 
[ Department of Psychology, Unisa ] 
  
 
 
 
The proposed research may now commence with the proviso that: 
 
1) The researcher/s will ensure that the research project adheres to the values and 
principles expressed in the UNISA Policy on Research Ethics.  
2) Any adverse circumstance arising in the undertaking of the research project that is 
relevant to the ethicality of the study, as well as changes in the methodology, should 
be communicated in writing to the Psychology Department Ethics Review Committee.  
An amended application could be requested if there are substantial changes from the 
existing proposal, especially if those changes affect any of the study-related risks for 
the research participants.                   
3) The researcher will ensure that the research project adheres to any applicable 
national legislation, professional codes of conduct, institutional guidelines and 
scientific standards relevant to the specific field of study. 
 
 
 
 
 
          26 April 2014 
The Registrar 
Professional Board of Psychology 
HPCSA 
PO Box 205 
Pretoria 0001 
 
Dear Sir/ Madam 
We hereby declare that we are willing to provide supervision for Mr. Lian Taljaard, and look forward to 
accommodate him for his study entitled  ADHERENCE TO ANTIDEPRESSANTS IN PSYCHIATRY: A 
DESCRIPTIVE SURVEY OF OUTPATIENTS IN JOHANNESBURG, GAUTENG from January, 2014 to December, 
2014 Mr. Taljaard will be working under close supervision with myself and executive staff to assist with the 
implementation of the project. We will ensure that the necessary support services are available to 
complete the study successfully and according to the ethical guidelines prescribed by the relevant health 
research ethics committee.  
 
 
Yours sincerely 
 
____________________________ 
Ms ZaneWilson 
Founder/ Director 
The south African Depression & Anxiety Group  
SADAG 
Email: zane1@medport.zo.za 

